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Abstract 
Numerous studies have investigated how bulk lipid metabolism is influenced in obesity and in 
particular how the composition of triglycerides found in the cytosol change with increased 
adipocyte expansion. However, in part reflecting the analytical challenge the composition of 
cell membranes, and in particular glycerophospholipids, an important membrane component, 
have been seldom investigated. Cell membrane components contribute to a variety of cellular 
processes including maintaining organelle functionality, providing an optimized environment 
for numerous proteins and providing important pools for metabolites, such as choline for one-
carbon metabolism and S-adenosylmethionine for DNA methylation. Here, I have conducted a 
comprehensive lipidomic and transcriptomic study of white adipose tissue in mice that become 
obese either through genetic modification (ob/ob genotype), diet (high-fat diet) or a 
combination of the two across the life course. Specifically, I demonstrated that the changes in 
triglyceride metabolism that dominate the overall lipid composition of white adipose tissue 
were distinct from the compositional changes of glycerophospholipids. These latter lipids 
became more unsaturated to maintain the fluidity and normal function of the membrane in the 
initiation of obesity but then turned saturated after long-term administration of HFD and aging. 
This suggests that while triglycerides within the adipose tissue may be a relatively inert store 
of lipids, the compositional changes occur in cell membranes with more far-reaching functional 
consequences in both obesity and aging. The two-phase change of phospholipids can be 
correlated well with transcriptional and one-carbon metabolic changes within the adipocytes. 
The transcriptomic study demonstrated that the lipid metabolic pathways regulated by the 
peroxisome, AMPK, insulin and PPARγ signaling were activated in the initiation of obesity 
but inhibited in the adipose tissue of old ob/ob mice along with up-regulated inflammation 
pathways. The brown and white adipose tissue of PPARα-knock-out mice were also studied by 
lipidomic tools to get a deeper understanding of the effect of the peroxisome and PPAR system 
on adipose tissue and lipid metabolism during obesity. Most of the lipids were increased and 
became more saturated and shorter in adipose tissues of PPARα null mice, which is in good 
accordance with the results of the former animal study. In conclusion, my work using different 
rodent models and multi-omics techniques demonstrated a protective metabolic mechanism 
activated in the initiation but impaired at the end of the processes of obesity and aging, which 
could be an explanation of the similarity of obesity and aging in terms of high incidence of the 
metabolic syndrome and related diseases. 
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Chapter 1 Introduction 
1.1 Obesity and Lipid Metabolism 
1.1.1 Obesity, Energy Homeostasis, and Metabolic Syndrome 
The prevalence of obesity has become a serious worldwide health problem, with the number 
of individuals classed as being obese (body mass index, BMI ≥30 kg/m2) doubling since 1980. 
In 2014, nearly 2,000,000,000 adults worldwide were estimated as being overweight and, of 
these, more than 500,000,000 were classed as obese according to the World Health 
Organisation (WHO) [1]. The fundamental cause of obesity is a positive energy balance where 
energy intake is greater than energy expenditure. All living organisms depend on the 
homeostasis of a variety of internal conditions, such as body temperature, cell number and size, 
acidity and alkalinity, blood glucose concentration, water and ion concentrations. Metabolic 
control mechanisms are required for the maintenance of energy homeostasis within an 
organism depending on the needs of the cell and the availability of substrates. Anabolic and 
catabolic pathways of basic substrates (amino acids, carbohydrates, lipids, and nucleic acids) 
are interconnected by intermediates which flow in cycles as both products of one reaction and 
substrates for subsequent reactions. For example, the Randle cycle describes the dynamic 
interactions between glucose and fatty acid pools [2].  
 
After long-term intake of high-calorie foods, either high-carbohydrate or high-fat, fats 
accumulate in the adipose tissue (obesity) and at some point, the storage capacity of adipose 
tissue is exceeded and ectopic fat deposition rises followed by dysfunctions in the whole 
metabolism system. Obesity is a major risk factor for a number of diseases and a component in 
all definitions of metabolic syndrome, which is a clustering of interrelated factors that increase 
the risk of developing cardiovascular disease and Type 2 diabetes mellitus (T2DM) [3]. 
Diabetes occurs when the islets of Langerhans of the pancreas fail to produce enough insulin 
(type I) and/or metabolic tissues are unresponsive (resistant) to insulin (type II, T2DM). There 
are multiple definitions for metabolic syndrome arising from variations in the emphasis of the 
components of this disorder. For example, the WHO focuses on the risk factors associated with 
developing T2DM while the International Diabetes Foundation (IDF) emphasizes the effects 
of increased visceral adiposity. The principal contributing factors can be grouped in four main 
categories: abdominal (visceral) obesity, insulin resistance (hyperglycemia and 
hyperinsulinemia), atherogenic dyslipidemia (high serum triacylglycerol (TAG) and decreased 
high-density lipoproteins (HDL) concentration) and endothelial dysfunctions 
(microalbuminuria and hypertension). Insulin resistance, T2DM, and cardiovascular diseases 
have been strongly associated with obesity-caused excess fat deposition and disturbed lipid 
metabolism.  
 
While many factors in terms of genetics and the environment are involved in energy balance, 
diet, physical inactivity, and the intrauterine environment have been highlighted as major 
causes [4]. The extra energy intake in the diet is manifested primarily as an excess accumulation 
of fat of adipose tissues. At the beginning of this process, the organism remains healthy as 
excess energy is predominantly stored as triacylglycerides in the adipose tissue without 
disturbing any of the function of this tissue or other tissues across the body. During progression 
to ectopic fat storage, fat accumulates in the circulation system, liver, heart, and other non-
adipose tissues. The accumulated fat mass and increased number of fat cells are associated with 
an increase in the risk for developing T2DM, cardiovascular diseases (CVD), chronic kidney 
disease (CKD), non-alcoholic fatty liver disease (NAFLD) [5] and several types of cancer [6], 
and as a result has been found to reduce life expectancy. However, the detailed 
pathophysiological mechanisms behind the development and maintenance of obesity and how 
‘benign obesity’ turns into morbidity and mortality have not been fully defined. Although a 
few genes have been identified that fundamentally influence BMI [7, 8], the communal genetic 
factors of obesity are still largely unknown, and currently thought to be able to only explain a 
proportion of the risk of how obesity proceeds to disease. 
1.1.2 Sources of Fats and Lipid Synthesis 
Neutral fats, also referred to as triglycerides (TG), are a subgroup of lipids which are esters of 
three fatty acid (FA) chains and the alcohol glycerol. 95% of the lipids obtained from the food 
are TGs, with phospholipids (4.5%) and other lipids as the remainder. The major sources of 
FAs for TG storage are: food-derived FAs through the digestive system, de novo lipogenesis 
(DNL) in the liver and adipose tissue, and modifications (desaturation and elongation) of the 
existing FAs.  
 
Feeding behavior is mainly controlled by the hypothalamus and pituitary. Appetite is a complex 
process resulting from the integration of numerous signals by the hypothalamus [9-12]. Neural 
signals, hormonal signals such as leptin, cholecystokinin (CCK) and ghrelin, and nutrient 
signals such as glucose, free FAs, and amino acids are integrated by the hypothalamus. A 
specific sequence of neurotransmitters transported through the orexigenic or anorexigenic 
neurons in the hypothalamus alter food intake. The liver and gastrointestinal tract also cause 
meal termination by signaling through the vagus nerve to the nucleus of the solitary tract (NTS) 
[13-15]. Other mechanisms determining the absorption of dietary lipids through the intestine 
include food agitation action in stomach, solubilisation (emulsification) by bile salts, and 
digestion of lipids via various lipases in the gastrointestinal tract, all of which transform dietary 
TGs into free FAs and a mixture of mono- and diglycerides (MG and DG) [16]. The re-
synthesis of TGs then occurs in the body, followed by solubilisation in lipoprotein complexes, 
chylomicrons in intestinal mucosal cells and very low-density lipoproteins (VLDLs) in the liver, 
which are released into the circulation system (blood or lymph) for delivery to the various 
tissues for energy production or storage [17, 18]. 
 
Lipogenic enzymes, desaturases and other enzymes indirectly involved in the de novo 
lipogenesis (DNL) can control long-term levels of particular TGs through changes in gene 
expression following hormonal or nutritional stimuli (substrate adaptive changes) [19-22]. 
Acetyl-CoA generated in the mitochondria from pyruvate dehydrogenase (PDH) and fatty acid 
oxidation is transported to the cytoplasm via the tricarboxylate transport system. Then acetyl-
CoA is activated by the synthesis of malonyl-CoA, which is the first committed step of the 
fatty acid synthesis. Acetyl-CoA Carboxylase (ACC) catalyzes the synthesis of malonyl-CoA 
and is the major site of regulation of fatty acid synthesis [23-27]. This rate-limiting enzyme is 
allosterically activated by citrate and inhibited by palmitoyl-CoA and other short- and long-
chain fatty acyl-CoAs. Glutamate and other dicarboxylic acids can also allosterically activate 
the ACC. The activation effect of insulin and the inhibition effect of α-adrenergic receptors on 
the ACC activity might be partly through regulating the phosphorylation of ACC [28, 29]. The 
synthesis of FAs from acetyl-CoA and malonyl-CoA is carried out by fatty acid synthase (FAS) 
[30-32]. The primary FA synthesized by FAS is palmitic acid in most tissues in mammals, 
which is then released from the enzyme. Palmitate may undergo separate elongation and/or 
unsaturation to yield other FA molecules. Insulin can stimulate both ACC and FAS synthesis 
while starvation inhibits the synthesis of these enzymes [30, 33, 34]. Moreover, sterol 
regulatory element-binding protein (SREBP1) and leptin have activating and inhibitory effects 
on the expression of lipogenic genes, respectively [35]. In turn, elongation and desaturation of 
FAs are controlled by essential enzymes such as long-chain fatty acid elongase 6 (ELOVL6) 
and stearoyl-CoA desaturase-1 (SCD-1, Δ9 desaturase), both of which are also SREBP-1c 
targets [36]. A change in the set point control of insulin-induced gene 1 (Insig1) / SREBP1 
facilitates lipogenesis and availability of appropriate levels of fatty acid unsaturation through 
SCD-1 expression [37, 38].  
 
The observed increase in fatty acid unsaturation may also be a response of ‘overloaded’ adipose 
tissue in obese animals, and a mechanism to cope with the large intake of fats by improving 
membrane receptor functionality [37, 39-41]. Specific FAs of different degrees of unsaturation 
can have an impact on these desaturases’ activity. For instance, saturated FFAs activate the 
expression of SCD-1 [42, 43]. Polyunsaturated fatty acids (PUFAs) play a key role in the 
regulation of three classes of desaturase, i.e. Δ9, Δ6, and Δ5, which are present in humans [19, 
44-48]. Interestingly, monounsaturated fatty acids (MUFAs) don’t exhibit such kind of effects 
on the expression of either SCD-1 or other desaturases. Other transcription factors involved in 
the control of lipogenesis and modifications include proliferator-activated receptors (PPARα, 
γ, δ), carbohydrate response element binding protein (ChREBP), and liver X receptor alpha 
(LXR) [49, 50]. High insulin and carbohydrate concentrations can activate SREPB1c and 
ChREBP transcription factors [51] inducing lipid remodeling. 
 
The FAs are activated to acyl-CoAs through various acyl-CoA synthetases and incorporated 
into TGs stored for future use. In virtually all cells except adipocytes and intestinal enterocytes, 
TG synthesis begins with glycerol phosphorylated by glycerol kinase to generate glycerol-3-
phosphate. Two activated FAs are successively added resulting in the production of 
lysophosphatidic acids (LPA) and phosphatidic acid (PAs), respectively. The phosphate group 
of the phosphatidic acid is then replaced by a fatty acid by phosphatidic acid phosphatase 
(PAP1) and a TG is formed. There is no expression of glycerol kinase in adipose tissue so the 
building block for TG is the glycolytic intermediate, dihydroxyacetone phosphate (DHAP) 
which is reduced to glycerol-3-phosphate by a cytosolic glycerol-3-phosphate dehydrogenase. 
In the intestinal enterocytes, monoacylglycerides (MAGs) undergoes acylation with two fatty 
acyl-CoA yielding TGs which can then be incorporated into chylomicrons. [52, 53] 
 
Another structurally and functionally important lipid class synthesized from phosphatidic acid 
is the phospholipids (PL). Phospholipids are in part synthesized by esterification of alcohol 
(serine, ethanolamine, choline, etc.) to the phosphate of phosphatidic acid. Another mechanism 
for the synthesis of PLs is to utilize cytidine diphosphate (CDP) - activated 1, 2-diacylglycerol 
and an inactivated polar head group. Among these phospholipids, phosphatidylcholines (PC) 
are a major component of biological membranes. Length and saturation of the hydrocarbon 
tails of PCs are important in characterizing the cell membrane and also determines specific 
processes such as signal transduction. They contain primarily palmitic or stearic acid (saturated 
FAs) at carbon 1 and primarily oleic, linoleic or linolenic acid (unsaturated FAs) at carbon 2. 
A third pathway to generate PC involves the conversion of either phosphatidylserine (PS) or 
phosphatidylethanolamine (PE) to PC. The conversion of PE to PC requires a series of three 
methylation reactions using S-adenosylmethionine (SAM) as a methyl group donor, while the 
decarboxylation of PS leads to PE generation. The phospholipids in membranes are undergoing 
continuous degradation and remodeling and the FA distribution at the C-1 and C-2 positions 
of glycerol are continually in flux. Thus, the FA pool which originates from either dietary lipids 
or DNL plays a vital role not only in energy homeostasis by remodeling TGs but also in 
maintaining cell membrane functionality and lipid signaling. [54-56] 
1.1.3 Lipolysis and Oxidation of Fats 
The TG components of VLDL and chylomicrons are hydrolyzed to free FAs and glycerol in 
the capillaries of various tissues by lipoprotein lipase (LPL) or hepatic triglyceride lipase 
(HTGL) [57-60]. The glycerol is returned to the liver and kidney via the blood and can be 
converted to DHAP or glycerol-3-phosphate for reuse in TG synthesis. The free FAs are 
absorbed by most cells for oxidation to generate energy or storage in the form of TGs, with the 
majority of storage occurring in adipose tissue. The fatty acid receptors include fatty acid 
translocase (FAT/CD36), plasma membrane-associated fatty acid-binding protein (FABPpm), 
and fatty acid transport proteins (FATPs). The expression of lipoprotein lipases are increased 
by insulin and decreased by fasting in adipose tissue. In response to energy demands, the FAs 
stored in TGs are mobilized for use by other tissues. This process uses a variety of lipases to 
control the direction of energy flux. The intravascular lipases are mostly LPL and HTGL, while 
the primary intracellular lipases are adipose triglyceride lipase (ATGL), hormone-sensitive 
lipase (HSL), monoglyceride lipase (MGL), and lipase A (LIPA). ATGL and HSL are involved 
in hydrolyzing TGs to DGs and MGs in lipid droplets (LDs), while MGL releases the final FA 
chain and glycerol from MG in the cytosol. LIPA is the central lipase for lysosomal lipid 
metabolism, in particular, cholesteryl ester metabolism. All the lipases are controlled by a 
complex series of interrelated signaling cascades determining the storage or release of 
metabolic energy in the form of FAs. For example, epinephrine and glucagon stimulate FA 
release from TGs in lipid droplets, whereas insulin inhibits release and induces storage of fats 
through inhibiting HSL. This is a cAMP-dependent pathway in which protein kinase A (PKA) 
regulates the activity of ATGL and HSL. The LD-associated proteins, such as caveolin and 
perilipin-1, play an important role in this signaling pathway to control lipid release. FAs 
released from adipose tissue are bound to albumin in the blood for transport to peripheral 
tissues. Then the FAs released from FA-albumin complexes or lipoproteins are taken into cells 
via fatty acid translocase FAT/CD36, fatty acid binding protein (FABPpm), or fatty acid 
transport proteins (FATPs). In the cytosol, the intracellular lipid-binding proteins like FABPs 
reversibly bind these FAs to transport them throughout the various cellular compartments, 
including the mitochondria, peroxisomes, endoplasmic reticulum, and nucleus. [61-64] 
 
Oxidation of FAs occurs primarily in the mitochondria and the peroxisomes, playing a 
profound role in overall lipid homeostasis. Short- (4-8 carbon atoms) and medium-chain (6-12 
carbon atoms) fatty acids (SCFAs and MCFAs) are oxidized exclusively in the mitochondria. 
Long-chain fatty acids (10-16 carbons, LCFAs) are oxidized in both the mitochondria and the 
peroxisomes. Very-long-chain fatty acids (17-26 carbons, VLCFAs) are preferentially oxidized 
in peroxisomes. The FAs are activated by the fatty acyl-CoA synthetases to form fatty acyl-
CoA. The acyl-CoA molecules are transported into the mitochondria by the carnitine-
acylcarnitine translocase (CAT) in the form of acyl-carnitine intermediate by the exchange 
actions of carnitine palmitoyltransferase 1 (CPT-1) and CPT-2. CPT-1 can be rapidly inhibited 
by the malonyl-CoA produced by ACC, which serves to prevent de novo synthesized FAs from 
entering the mitochondria and being oxidized. Finally, the re-generated fatty acyl-CoA 
molecules in the mitochondrial matrix undergo β-oxidation catalyzed by FAD-dependent acyl-
CoA dehydrogenases and the mitochondrial trifunctional protein (MTP), resulting in the 
sequential removal of 2-carbon units in the form of acetyl-CoA. The acetyl-CoA generated in 
each round of β-oxidation enters the TCA cycle following conjugation with CoA for feeding 
the respiratory pathway with reducing potential (oxidative phosphorylation) to generate the end 
products CO2 and ATP. The energy production of FA oxidation is significantly more than 
oxidation of carbohydrates (about 106 and 30 moles of ATP for complete oxidation of 
palmitate [65] and glucose [66], respectively).  
 
The peroxisomal β-oxidation pathway [67-70] is similar to mitochondrial β-oxidation except 
that in the first oxidation step it is catalyzed by acyl-CoA oxidases rather than acyl-CoA 
dehydrogenases. This is coupled with the reduction of O2 to hydrogen peroxide (H2O2) which 
is degraded back to O2 by the enzyme catalase. When catalase is not expressed highly enough 
for the clearance of the H2O2, the increased release of reactive oxygen species (ROS) can result 
in damaged cell function and inflammation. For example, the damage to the pancreatic β-cell 
by ROS contributes to progressive insulin deficiency in obesity. There are as well other minor 
pathways of overall FA oxidation that may provide an effective means for the elimination of 
toxic levels of FAs in certain pathophysiological states, such as the microsomal ω-oxidation 
reactions [71-74].  
 
1.1.4 Transport of Fats and Cholesterols 
In circulation, a small proportion of free fatty acids (FFA) are bound to albumin, while most 
of the fats are transformed and emulsified within lipoproteins which have exterior amphiphilic 
proteins and lipids to be water-soluble and allow fats to move through the water inside and 
outside cells. Plasma lipoprotein particles include, from larger and less dense to smaller and 
denser (fat to protein ratio decreases): chylomicrons, very low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL) and high-density 
lipoproteins (HDL) [75-77]. These particles are synthesized in the small intestine (exogenous) 
or the liver (endogenous). In the exogenous pathway, dietary TGs are emulsified by bile and 
cleaved by pancreatic lipase into two FAs and one 2-monoacylglycerol and absorbed by 
enterocytes. In enterocytes, these lipids are transformed back into TGs and assembled with 
apolipoproteins B-48 (Apo B48) along with cholesterols and phospholipids (PLs) to form 
nascent chylomicrons. The nascent chylomicrons circulate to the bloodstream through 
lymphatic vessels and form the mature chylomicrons after combining with Apo C -II and E 
which are obtained from interacting with HDL particles. The chylomicrons can activate 
lipoprotein lipase (LPL) to hydrolyze TGs and release glycerol and FAs into peripheral tissues, 
especially adipose and muscle. The hydrolyzed chylomicrons (chylomicron remnants) then 
circulate to the liver and interact with chylomicron remnant receptors via Apo E, followed by 
endocytosis by hepatocytes and hydrolysis by lysosomes. In the endogenous pathway, 
hepatocytes create FAs and TGs mainly via de novo lipogenesis (DNL). Bile is also produced 
in the liver from cholesterol. TGs and cholesteryl esters are assembled with Apo B-100 to form 
nascent VLDL particles. Like chylomicrons, nascent VLDL particles are released into the 
blood circulation and obtain Apo C-II and Apo E from HDL particles to form mature VLDL, 
from which triglycerides would be removed by LPL and absorbed into peripheral tissues. The 
VLDL remnants are now called IDLs which can interact with the remnant receptors of 
hepatocytes and be re-absorbed by the liver. In the alternative, TGs of IDLs are removed by 
hepatic lipase producing LDLs (IDL remnants) which also circulate into liver and peripheral 
cells and are hydrolyzed by lysosomes. A residual fraction of LDLs is phagocytized by 
macrophages and turned into foam cells and deposit in atherosclerotic plaques (atherosclerosis) 
[78], which can lead to serious cardiovascular problems, including coronary heart disease 
(angina or heart attack) [79], carotid artery disease (stroke) [80, 81], chronic kidney disease 
[82] and chronic inflammatory disease [83]. All of these are common complications of obesity 
and diabetes [84, 85].  
 
Animal fats are composed of mostly TGs, with lesser amounts of cholesterol and phospholipids. 
As mentioned above, cholesterol (or in form of cholesterol ester) is transported within 
lipoproteins along with TGs. Cholesterol is another important component (about 30%) of 
animal cell membranes, interacting with phospholipids and sphingolipids to maintain 
membrane integrity and alter membrane fluidity [86], and it also functions in intracellular 
transport and cell signaling processes [87, 88]. Just like other lipids, cholesterol is either from 
dietary sources or synthesized from acetyl CoA in a complex 37-step process beginning with 
the mevalonate pathway [89, 90]. Biosynthesis and absorption of cholesterol, which mostly 
occurs in the liver and the intestines, is regulated by cholesterol levels present through 
mechanisms that are only partly understood. SREBP is an important protein for the sense of 
intracellular cholesterol, which will be detailed in Section 1.3.2. So, it is clear that different 
lipids including TGs, PLs, and cholesterol are correlated and regulated through many 
homeostatic mechanisms. In addition, cholesterol is not only transported along with TGs within 
the lipoprotein, but also recycled by being excreted by the liver in a non-esterified form via 
bile into the digestive tract, and 95% is reabsorbed by the small intestine back into the 
bloodstream [91-93].  
1.1.5 Diseases and Ectopic Fat Storage 
Apart from cardiovascular diseases directly caused by atherosclerosis such as hypertension and 
coronary artery disease, the diabetic heart can also develop an abnormality in diastolic function 
and be at high risk of heart failure, an entity termed as diabetic cardiomyopathy [94, 95]. The 
structural changes in diabetic cardiomyopathy are often accompanied by fat droplet deposition. 
The heart obtains FAs from the circulation in the form of albumin-FFAs, chylomicron-TAGs, 
and VLDL-TAGs, and the uptake rate is dependent on the FFA concentration in plasma. The 
FAs released from these lipoproteins can be absorbed passively by diffusion or actively by the 
fatty acid receptors (FAT/CD36, FABPpm, and FATPs). In the cytosol, long-chain FAs are 
esterified to long-chain fatty acyl coenzyme A (CoA) by fatty acyl-CoA synthase (FACS). 
Fatty acyl CoA is mainly used in mitochondria for β-oxidation to supply energy for the heart, 
whereas some fatty acyl CoA is incorporated into TG by glycerolphosphate acyltransferase for 
storage. The TG synthesis increases when the plasma FA level is elevated in obesity. The 
excess TG deposition then can contribute to myocardial hypertrophy and fibrosis, and results 
in damage to the diastolic function of the heart. There have been many putative factors studied 
so far to explain the functional disorders in diabetic cardiomyopathies, such as deregulation of 
the renin-angiotensin system (RAS), intracellular Ca2+ homeostasis, increased cell death, and 
advanced glycosylation end-products. Another major etiological factor is metabolic 
derangement, especially disturbed lipid oxidation. In our previous study [95], a persistent 
increase in FA oxidation is observed in the heart of both type 1 (NOD mouse) and type 2 (high-
fat diet (HFD)-fed ob/ob mouse), diabetic models. Increased oxygen consumption by FA 
oxidation led to a reduction in the efficiency of cardiac energy production and increased 
mitochondrial uncoupling through elevated levels of uncoupling protein 2/3 (UCP2/3). 
Production of reactive oxygen species (ROS) accumulated, accompanied by the damaged 
complex I of the electron transport chain. These processes finally resulted in myocardial 
mitochondrial dysfunction. Moreover, when FA uptake and oxidation is enhanced, the PPAR 
signaling pathway is activated. This pathway increases fatty acid uptake and oxidation and up-
regulates the expression and PDK4 while inhibiting GLUT-4 expression, resulting in decreased 
glycolysis and oxidative phosphorylation through the Randle cycle. Amino acid metabolism is 
also disturbed in the obese/diabetic heart. Increased circulating branched-chain amino acids 
(BCAAs, leucine, isoleucine, and valine) and higher protein degradation and turnover rates are 
observed in diabetic hearts. All of these lead to reduced respiratory capacity and a decrease in 
energy production for a contractile function of the heart. [96-98] 
 
Ectopic fat storage also results in pathology in other tissues besides the cardiovascular system; 
for example, the most common liver disorder in developed countries, non-alcoholic fatty liver 
disease (NAFLD), is linked to insulin resistance and diabetes [99]. The disease begins as fat 
accumulation in the liver (hepatic steatosis), and sometimes it will progress to become non-
alcoholic steatohepatitis (NASH) characterized by lobular inflammation and ballooning 
degeneration. Up to 9% of patients with NASH will develop cirrhosis through fibrosis 
(thickening and scarring of connective tissue), and 40%-62% of patients with NASH-related 
cirrhosis will suffer complications including hepatocellular carcinoma (HCC) [100]. The liver 
is central to regulating storage, mobilization, and metabolism of macronutrients across the body. 
It is also notable that some advanced liver disease might be missed in this progression; for 
example, there are some cases of HCC progression in NASH without cirrhosis. In a previous 
study in our group, Chu and colleagues [99] identified many metabolic dysfunctions in livers 
of three animal models of steatosis, including increased activity of the urea cycle, fatty acid β-
oxidation, total fatty acid content, total palmitoleic acid, total oleic acid, stearoyl-CoA 
desaturase (SCD, Δ9) activity and free fatty acids; and decreased choline metabolism, purine 
metabolism, omega-3 polyunsaturated fatty acids, phosphatidylcholines and short-chain 
acylcarnitines. 
1.2 Adipose Tissue 
Adipose tissue is a type of loose connective tissue principally comprised of adipocytes, but also 
containing macrophages, leukocytes, fibroblasts, adipocyte progenitor cells, and endothelial 
cells. There are two morphologically and functionally different adipose tissue forms: brown 
adipose tissue (BAT) and white adipose tissue (WAT). The development of these two forms 
involves the concerted cooperation of various transcription factors together with their 
coactivators and corepressors [101]. WAT comprises large lipid droplets which occupy no less 
than 90% of the cell in volume for the storage of fat, a thin peripheral cytoplasm, and the 
nucleus. The major functional role of WAT is as a reservoir of fat and insulation of the visceral 
organs, but it also participates in the regulation of glucose homeostasis, inflammation, 
angiogenesis, and hemostasis (blood coagulation). A variety of growth factors, cytokines, 
enzymes, and hormones are synthesized and secreted by mature adipocytes functioning as an 
endocrine and immune organ. On the other hand, BAT stores fats in numerous small lipid 
droplets which contains an abundance of mitochondria primarily tasked with oxidation of free 
fatty acids for non-shivering thermogenesis, especially in the neonate [102]. Molecular 
characteristics of BAT include expression of uncoupling protein 1 (UCP1) but no expression 
of leptin (UCP1+ and leptin-), while WAT shows the opposite expression pattern (UCP1- and 
leptin+). Both WAT and BAT are highly vascularized and innervated [103, 104]. 
 
As the storage capacity of adipose tissue is exceeded at some point in obesity, TAGs and FFAs 
are released into the circulation and this leads to lipid accumulation in non-adipose tissues 
(ectopic fat storage) [105]. Ectopic fat is defined as the deposition of TGs within cells of non-
adipose tissue that normally contain only a small amount of fats [106]. Both lipodystrophic 
patients and those with hypertrophic adipocytes exhibit insufficient storage capacity of adipose 
tissue and ectopic fat storage, resulting in insulin resistance [107, 108]. The detailed 
mechanism of how insulin resistance interacts with adipose tissue dysfunction has not been 
fully revealed, and there appears to be a number of mechanisms responsible. It is possible that 
the dynamic interactions of inflammatory, neural, endocrine and cell-intrinsic pathways lie 
beneath the etiology of insulin resistance [109].  
 
The balance of some adipose tissue secretory proteins (adipokines) is also perturbed in obesity 
[110-113]. Disturbance of adipokine secretion and alteration of lipogenesis and lipolysis have 
been related to the occurrence and development of insulin resistance [114-117]. For example, 
leptin, the “satiety hormone” is secreted almost exclusively by adipocytes. Leptin regulates the 
amount of fats storage through directly affecting on food intake and energy expenditure, and 
also plays a critical role in the regulation of reproductive and immune function in humans [118] 
as discussed in Section 1.6.1. Increased adiposity also triggers innate immune receptors in 
adipose tissue and results in systemic inflammation, which combined with ectopic fat storage 
and disturbed adipokine production leads to dysfunction in the liver, skeletal muscle, gut, 
pancreas, and other organs. [119-121].  
 
Thus, adipose tissue has an important impact on metabolic health across the whole body. There 
are far more underlying pathways for the physiopathology of adipose tissue dysfunction which 
remain to be determined, which is of vital for us to understand the mechanism of and develop 
new treatment and diagnostic methods for obesity, MBS, T2DM, NAFLD, and cardiovascular 
diseases. 
1.2.1 Regulation of Adipogenesis 
The storage capacity of adipose tissue in part depends on the extent of adipocyte differentiation, 
expandability, and remodeling in obesity [50]. The pre-adipocyte which is the precursor of 
adipocyte differentiation is derived from the mesenchymal stem cells (MSCs) following 
receiving extracellular cues. CCAAT/enhancer binding protein alpha (C/EBPα) and 
peroxisome proliferator-activated receptor gamma (PPARγ) is the key transcription factors for 
the initial growth arrest of pre-adipocytes [122-124]. PPARγ is the only factor without which 
the adipocyte differentiation cannot occur and no other factor has been identified that can 
rescue adipogenesis in the absence of PPARγ. It is also involved in the regulation of a variety 
of key metabolic pathways such as lipid metabolism and glucose homeostasis. The C/EBP 
family of transcription factors also contain C/EBPβ and C/EBPδ, which in part regulate the 
actions of C/EBPα and PPARγ in mature adipocytes. The activation of C/EBPα enhances 
insulin sensitivity of adipose tissue. The general activation model of adipogenesis is AP-1, 
STAT5, KLF4, and KLF5 → C/EBPβ and C/EBPδ → SREBP-1 and KLF15 → PPARγ and 
C/EBPα → adipogenesis. The functions of SREBP-1 and PPARγ will be discussed in more 
detail in Section 1.3. Adipogenesis can be controlled by transcription factor-mediated 
inhibition by members of the Krϋppel-like factor family KLF2 and KLF3, GATA2 and GATA3, 
and members of interferon regulatory factor family IRF3 and IRF4. [122-124] Moreover, 
chromatin dynamics such as histone protein methylation and DNA methylation have important 
impacts on adipogenesis, which will be further discussed in Section 1.4. 
1.2.2 Lipid Metabolism in Adipocytes 
TG flux in adipose tissue is regulated by the dietary state (food intake/fasting), pancreatic and 
adrenal hormones, inflammatory processes and other pathophysiology processes. As discussed 
above, under ordinary conditions of positive energy input such as in the postprandial period, 
plasma TGs in VLDL and chylomicrons are released and hydrolyzed to free fatty acids (FFA) 
and glycerol via lipolysis catalyzed by LPL. Glycerol and FFAs are then taken up into the 
adipocytes by FAT/CD36, FABPpm, and FATPs. In the cytoplasm, monoacylglycerides 
(MAGs) and FFAs are transformed to acyl-CoA by acyl-CoA synthase (ACS). This process is 
then reversed in the cell resulting in TG storage in adipose tissue [114]. During negative energy 
input, the stored TGs are hydrolyzed by ATGL, HSL, and MGL back to FFAs (lipolysis), which 
are transported out of adipose tissue into the circulation, and taken up by other tissues and then 
go through β-oxidation to produce energy in the mitochondria [125] or peroxisome [126]. HSL 
is the only DG lipase identified currently but also has moderate hydrolytic activity on TG and 
CE, and it has the greatest activity against FAs in the sn-1/3 position. ATGL is a TG specific 
lipase expressed predominantly in adipose tissue. Other HSL-independent TG lipases include 
triacylglycerol hydrolase (TGH)/carboxylesterase 3 (predominantly expressed in the liver, also 
in mature adipocytes) [127, 128] and adiponectin. MGL is a specific MG lipase which has no 
catalytic activity towards TG, DG or CE [129, 130]. TG uptake via FFAs and glycerol and 
synthesis occurs in multiple tissues, while lipolysis (release) takes place predominantly in 
adipose tissue. LPL and HSL are the rate-limiting enzymes in lipid uptake and lipolysis 
processes of adipose tissue, respectively. Moreover, there are some lipid droplet (LD) 
associated proteins involved in fat storage capacity of adipose tissue, such as perilipins which 
restrict access of TG lipases to substrates, acid-binding protein (aP2/FABP4/aFABP) that carry 
FFAs from the LD to the plasma membrane, caveolin-1 binding various classes of signaling 
molecules (e.g. PKA), lipotropin that shuttles HSL from the cytosol to the LD, and aquaporin 
(AQP7), a water and glycerol transport protein for glycerol export.  
 
Many hormones are involved in the stimulation of adipose tissue TG hydrolysis via activating 
ATGL, HSL and other lipolysis events, including epinephrine, norepinephrine, and glucagon, 
but only insulin has been shown to inhibit FA release from adipose tissue. Insulin stimulates 
the synthesis and storage of TGs while inhibiting lipolysis in adipose tissue, acting by impeding 
HSL and stimulating LPL, which is vital for the regulation of fat content in adipocytes [131]. 
It also increases the rate of glucose uptake into adipose tissue and skeletal muscle through 
recruitment of GLUT 4 transporter, followed by transformation to fatty acids in adipose tissue 
via DNL. In obesity adipose tissue becomes refractory in terms of either the suppression effect 
of insulin on fat mobilization or its stimulatory effect on fat uptake and storage [132], resulting 
in augmented FFAs and TGs in blood. This gives rise to a positive feedback loop between 
circulating TGs and insulin resistance and makes the adipose tissue dysfunction worsen 
gradually [133, 134]. What’s more, the expression of HSL is up-regulated by saturated FAs 
(stearate and palmitate) rather than unsaturated fatty acids (oleate and linoleate) [135], 
suggesting that lipolysis and release of FFA from adipose tissue would increase when saturated 
FAs are released from the dietary lipids or DNL. This contributes to further positive feedback 
regulation of insulin resistance and obesity and results in the development of lipotoxicity and 
MBS across the body. 
 
Whitening (loss of mitochondria) and browning (mitochondrial biogenesis) of adipose tissue 
is another important way for the body to maintain energy balance in response to environmental 
challenges [136]. BAT was thought to be active only in the neonatal period for humans. 
Recently, it has been found that adults still retain some metabolically active BAT deposits 
which can be activated by cold and the sympathetic nervous system. The most studied regulator 
of the action of BAT is norepinephrine [137]. Cold exposure produces norepinephrine which 
binds to β3-adrenergic receptors, resulting in activation of Gs type proteins. The Gs proteins 
stimulate phosphorylation and activation of HSL and release of FFAs via the adenylate cyclase 
→ cAMP → PKA pathway. The released FFAs are used for oxidation in mitochondria or 
activating the uncoupling protein 1 (UCP1/thermogenin) to uncouple the proton gradient in 
mitochondria leading to a release of energy as heat. Norepinephrine can promote the 
proliferation of brown preadipocytes and the differentiation of mature brown adipocytes, and 
prevent brown adipocytes from undergoing apoptosis. The expression of the UCP1 gene is also 
under the control of the norepinephrine. It has not been fully determined how the balance 
between stimulatory and inhibitory actions of norepinephrine on heat generation is determined. 
Furthermore, like WAT, BAT also secretes certain adipokines as an 
endocrine/autocrine/paracrine organ, but this role is not as well established as for WAT. 
Identified signaling factors produced by BAT include FGF2, IGF-1, NGF, VEGF, NO, adipsin, 
prostaglandins, and adenosine. [138-140] 
1.2.3 Adipose Tissue Hormones and Cytokines 
J.M. Friedman’s discovery of the “satiety factor” leptin initiated the discovery of many 
hormonal mechanisms that regulate food intake and energy storage, including ghrelin, orexin, 
and adiponectin, as well as adipokines. Adipokines are a variety of bioactive peptides secreted 
by adipose tissue, including leptin, agouti, angiotensin II, tumor necrosis factor-alpha (TNFα), 
prostaglandins, adiponectin, plasminogen activator inhibitor-1 (PAI 1) and interleukin 6 (IL-
6), and act both locally and distally through autocrine, paracrine and endocrine effects. In 
obesity, the production of most adipokines are associated with changes to maintain normal 
metabolic pathways in terms of appetite and energy balance, lipid metabolism, insulin 
sensitivity, immunity, blood pressure, angiogenesis, and haemostasis, all of which are linked 
with cardiovascular diseases when regulation is no longer controlled [116, 117]. In morbid 
obesity the endocrine functions of adipose tissue can be impaired, resulting in reduced 
adipokine production necessary for maintaining normal biological homeostasis. [110, 141-144] 
1.2.4 Adipose Tissue and Inflammation 
The increase in secretion of adipose tissue-derived cytokines in obesity is associated with a 
number of inflammatory responses. The infiltration of macrophages into adipose tissue is 
significantly increased during obesity and is regulated by the monocyte chemotactic protein-1 
(MCP-1). The macrophages are a primary source of pro-inflammatory cytokines. [145] 
 The two pro-inflammatory cytokines mostly studied in adipose tissue during obesity are TNF-
α and IL-6. Their increase in circulation in obesity is directly correlated with insulin resistance 
and T2DM. Both IL-6 and TNF-α stimulate the release of pro-inflammatory cytokines such as 
JUN N-terminal kinase (JNK) and nuclear factor kappa B (NFκB). The activation of JNK 
increases the serine phosphorylation of the insulin receptor and insulin receptor substrate (IRS), 
leading to impaired insulin signaling [146, 147]. JNK and NFκB also activate pro-
inflammatory genes which result in a self-perpetuating cycle of increased inflammatory 
cytokine release. Moreover, TNF-α can stimulate the expression of endothelial nitric oxide 
synthase (eNOS) leading to an accumulation of ROS and increased oxidative stress and 
endoplasmic reticulum (ER) stress [148]. Oxidative stress, in turn, triggers the cell to release 
more NFκB. The anti-inflammatory adipose tissue-derived hormone, adiponectin, suppresses 
the production of TNF-α and IL-6 but also results in suppression of adiponectin production and 
secretion. In addition, the increased acute phase proteins from the liver following IL-6 secretion 
may contribute to the promotion of sepsis. 
 
There are 2-way paracrine interactions between adipose and lymph tissues, with the latter 
surrounded by pericapsular adipose tissue. Firstly, leptin secreted by the adipocytes protects T-
Cells from apoptosis and enhances the switching of T-cells to a Th1 response, resulting in an 
increase of pro-inflammatory cytokine production and release. Leptin is involved in many 
signal transduction pathways in the immune and endothelial cell [149, 150]. It stimulates the 
expression of adhesion molecules when binding its receptor on endothelial cells. This increases 
the ability of neutrophils and other leukocytes to adhere to the endothelium, resulting in local 
inflammatory processes.  
 
In addition, it has been reported that palmitoleate (C16:1) might act like adipokines to suppress 
inflammation and inhibit apoptosis of cells induced by glucose and saturated FAs [151]. 
Moreover, the interaction of ω-6 with ω-3 fatty acids together determines the production and 
subsequent action of eicosanoid precursors, which is important for the regulation of 
inflammation [152]. Conversely, depletion of ω-3 long-chain PUFAs are associated with 
hepatic insulin resistance, enhanced sterol regulatory element-binding protein 1c (SREBP-1c) 
and decreased peroxisome proliferator-activated receptor alpha (PPAR-α) activity, favoring 
lipogenesis over FA oxidation [153]. 
1.3 Regulation of Lipid Acyl Composition 
Interestingly, it is not only the total amount of fat storage which has an impact on adipose tissue 
health, but also the lipid composition; in particular, the chain length and unsaturation of fatty 
acyl chains of specific lipids have important effects on energy balance and pathophysiology of 
MBS, T2DM and cardiovascular diseases [154]. There have been a number of metabolomics 
studies [155-160] aimed at finding potential lipid biomarkers in plasma or urine for diagnosing 
insulin resistance and T2DM, but evidence that either support or contradict their effectiveness 
is conflicting, particularly in terms of whether lipid changes are associated with fatty acid 
consumption direct from the diet or synthesized from glucose as a result of DNL. It is necessary 
to elucidate the mechanism of how these lipids are formed, control normal cell functions and 
their relationships with disease progression before considering them as biomarkers.  
 
One of the major reasons for controlling in vivo lipid composition is to maintain proper physio-
chemical properties of the membrane bilayer. The average chain length of a biological 
membrane for eukaryotic cells from vertebrate species is strictly maintained around 18 carbon 
atoms, and the relative distribution between SFAs and UFAs typically follows a ratio of 2:3 
[161]. The membrane pacemaker hypotheses of aging and metabolism [162] suggest that both 
decreasing longevity and increasing metabolic rate are correlated with increases in unsaturation 
of lipids within membranes. The membrane pacemaker hypothesis of aging postulates that 
PUFAs are more easily oxidized than saturated fatty acids or MUFAs because of the 
susceptibility of the bis-allylic hydrogens (attached on the single carbon separating two double 
bonds) to lipid peroxidation (the oxidative degradation of lipids whose electrons are “stolen” 
by free radicals [163]). This is a particular problem in mitochondrial membranes as the 
peroxidized lipids can induce oxidation of macromolecules, in particular, mitochondrial DNA, 
leading to cellular dysfunction and decline in tissue function [164-167]. 
 
Another reason for the tight regulation of membrane composition is that differences in protein 
activity are caused by the differences in membrane fluidity. Generally, saturated fatty acids 
make the membrane bilayer less fluid and inactive, which in turn has consequences for protein 
function and membrane transport [168], whereas unsaturated fatty acids result in a more plastic 
membrane and improve the function of membrane receptors and sensitivity to hormones [169, 
170]. The geometry of the cis-double bond induces a bend in the molecule, thereby precluding 
rigid lipid bilayers. One process of high relevance to T2DM is glucose transport across the 
membrane which may be influenced by membrane fluidity [171]. There have been studies 
reporting the relationship between membrane fluidity of erythrocytes and insulin sensitivity in 
hypertensive subjects [172], and also changes in the composition of membrane lipids associated 
with increased insulin sensitivity in skeletal muscles after physical training [173]. However, a 
study in rat brown adipose tissue [174] showed that the increase of mitochondrial activity in 
this tissue was related to phospholipid composition changes rather than to membrane fluidity. 
PUFAs result in an even greater increase in plasticity of membranes [40, 175], and have been 
associated with improved cardiac function following arrhythmias.  
 
However, changes in membrane fluidity do not explain the effects of some highly unsaturated 
fatty acids (HUFAs, >2 double bonds), such as DHA, on protein activity as the overall 
membrane fluidity is only significantly increased by the first two double bonds added to a 
saturated acyl chain, with each subsequent double bond having less effect on membrane fluidity 
[166, 176]. One mechanism invoked recently is that some form of energy transfer between the 
flexible PUFAs and the membrane-bound proteins occur through collisions [177-181]. One 
piece of evidence put forward is that the lateral pressure of membrane phospholipids, which is 
presumed to be related to both the unsaturation of the membrane and the number of molecular 
collisions in the membrane, was found to be correlated with the activity of Na+/K+-ATPase 
[180]. This presumed mechanism relied somewhat on the assumption that membranes are 
homogeneous environments where collisions happen in equal likelihood between proteins and 
any lipid molecules. However, there is increasing evidence that membranes are composed of 
different lipid/protein domains, including lipid rafts [182-184] mainly composed of 
phospholipids, sphingolipids, and cholesterol with saturated fatty acyl chains. Some proteins 
are resident in the lipid rafts and some move between rafts and non-raft areas of the membrane, 
e.g. Na+/K+-ATPase, so there could be additional mechanisms for the effects of increasing the 
PUFA content of cell membranes on activities of enzymes such as the Na+/K+-ATPase. The 
addition of HUFAs, especially DHA, to the membrane increases the formation and stability of 
lipid raft domains, which could be an alternative mechanism explaining the interactions 
between membrane lipid unsaturation and protein activity [183, 185, 186]. It is found that the 
steric incompatibility of DHA and cholesterol leads to more cholesterol incorporated into 
ordered lipid rafts while driving phospholipids with DHA into disordered non-raft domains. 
This suggests that the segregation of particular types of proteins into raft or non-raft domains 
might control their activity accordingly [187-189], providing an explanation for the control of 
Na+/K+-ATPase activity by PUFA-mediated lipid domain formation. However, this idea still 
needs to be tested. In addition, increases in the unsaturation of membranes could affect 
membrane structure and phase behavior, increasing the propensity of membranes to form 
hexagonal (HII) phases [190-192]. The HII phase propensity stimulates recruitment of certain 
signaling proteins into membranes and increases their activity, such as the G protein-coupled 
receptors and protein kinase C [191, 193-195]. The lateral surface pressure which is 
proportional to Na+/K+-ATPase activity [180] is also related to lipid phase behavior [196]. 
However, the relationship between FA unsaturation and HII phase propensity is not linear and 
oleic acid has a disproportionally large effect compared with DHA [192]. 
 
In summary, there are both supporting [167, 197, 198] and conflicting [199, 200] views to the 
validity of the membrane pacemaker hypotheses of metabolism and aging. The key point to 
address is the mechanistic gaps in our understanding, which is further complicated by the fact 
that the fatty acyl composition of different lipid classes in different organs/tissues/sub-cellular 
membranes are not the same and need to be separated out. Furthermore, it is not only the 
number of double bonds, but also other elements of fatty acyl composition, such as n-3/n-6 
ratio and carbon length [200-202], which play important roles in relating membrane 
composition to metabolic rate, disease, and longevity. 
 
1.3.1 Elongases and Desaturases 
The diversity of lipids needed in cell membranes requires complex metabolic and regulatory 
pathways to maintain the normal structure and functions of an organism. Eukaryotic cells invest 
around 5% of their genes to adjust lipid synthesis and to monitor membrane lipid composition 
[203]. The elongation and desaturation activities of fatty acid synthase (FAS) in DNL appears 
to be regulated primarily at the transcriptional level, thus the relevant transcription factors, 
ligands, and cofactors play a vital role in the regulation of fatty acid composition. At the same 
time, hormones, substrate availability, circadian rhythms, and many other factors have been 
reported to control FA homeostasis. Then synthesized fatty acids, termed non-essential fatty 
acids including saturated and ω-10, ω-7 and ω-9 unsaturated FAs can be synthesized from 
palmitic acid (C16:0) by DNL, as shown in Fig 1.1, while the precursors of ω-6 and ω-3 FAs, 
linoleic acid (Δ9,12-C18:2) and α-linolenic acid (Δ9,12,15-C18:3), can only be obtained from 
dietary sources, and are termed essential FAs. Carbon chains are elongated and double bonds 
are introduced into substrate FAs through a variety of desaturases and elongases localized in 
the endoplasmic reticulum (ER), as well as the peroxisomal β-oxidation pathway, to form long-
chain (16C, 18C) and very-long-chain fatty acids (VLCFAs) (≥20C) of different degrees of 
unsaturation [204] (Fig 1.1). The generated FAs can be primed by an acyl-CoA synthetase and 
added to a phospholipid by an acyltransferase, or transferred between two phospholipids using 
a transacylase [205]. 
 
The elongation process in the ER is similar to the two-carbon-addition reactions performed by 
cytosolic FAS, but the initial and rate-controlling condensation reaction of the microsomal FA 
elongation is catalyzed by the elongase enzymes referred to as Elongation of very-long-chain 
fatty acids (ELOVLs). To date, there are seven ELOVL proteins (ELOVL1-7) identified which 
are highly conserved in mice, rats, and humans [206-213]. ELOVL1, ELOVL3, ELOVL6, and 
ELOVL7 are selective for SFAs and MUFAs while ELOVL2, ELOVL4, and ELOVL5 prefer 
PUFAs as substrates. The Elovl1, Elovl5 and Elovl6 genes are expressed ubiquitously, while 
others exhibit different tissue-specific levels of expression. Moreover, these ELOVL proteins 
exhibit different chain-length specificities [214, 215] and vary in activity according to tissue 
and physiological state.  
 
The most common pathway from palmitic acid is ELOVL6-catalyzed elongation followed by 
Δ9-desaturation by SCDs, resulting in the production of stearic acid (C18:0) and oleic acid (Δ9-
C18:1), respectively. Oleic acid is the precursor substrate of the ω-9 family FAs. Another 
pathway from palmitic acid is to be directly Δ9-desaturated to palmitoleic acid (Δ9-C16:1) 
which can be further elongated and/or desaturated to form other ω-7 FAs. These saturated and 
mono-unsaturated VLCFAs not only constitute most of the acyl chains of TGs stored in adipose 
tissue but also serve as essential barrier components of the plasma membrane, and some of 
them even act as lipokines (e.g. palmitoleic acid) and second messengers in the control of 
specific transcription factors and membrane proteins [216, 217].  
 
The key elongase in the generation of stearic acid (C18:0) is the ELOVL6 enzyme which is 
under the control of the sterol regulatory element binding proteins (SREBPs) [218]. The 
deletion of the Elovl6 gene in the mouse is related to improvement in insulin resistance without 
amelioration of obesity or hepatosteatosis [219] but has also been associated with partial 
embryonic lethality. Further elongation of SFAs and MUFAs is primarily catalyzed by the 
ELOVL1 and ELOVL3 enzymes. ELOVL1 is believed to catalyze the formation of SFAs 
containing as many as 26-carbons [211, 213], while ELOVL 3 is involved in the synthesis of 
both SFAs and MUFAs with as many as 24-carbons [207, 220]. ELOVL7 [206] is also involved 
in the elongation of SFAs with as many as 24-carbon atoms. In addition, although ELOVL4 
was thought to catalyze elongation of C28-38 PUFAs in the ω-6 and ω-3 pathways, it has also 
been shown to be involved in the synthesis of saturated C28 and C30 VLCFA [208]. 
 
Acyl-coenzyme A (CoA) desaturases in mammalian cells include Δ9, Δ6, and Δ5-desaturases 
which introduce double bonds at different positions of the acyl chain counting from the 
carboxylic acid moiety. At the same time, these desaturases can be divided into two families 
referred to as stearoyl-CoA desaturases (SCDs) and fatty acid desaturases (FADS). SCDs are 
Δ9-desaturases for saturated FAs, and include four isoforms (SCD-1, -2, -3 and -4) identified 
in the mouse to date [221-225][27, 33, 36-38]. SCD-1 is abundant in adipose tissue and liver. 
SCD-2 is expressed at high levels in the brain and neuronal tissues. SCD-3 is identified 
specifically in sebocytes in the skin and harderain and preputial glands, while SCD-4 is 
expressed only in the heart. In humans, only a gene highly homologous to Scd-1 is ubiquitously 
expressed [226], but there is a novel form, HSCD5, expressed highly in the brain and pancreas 
[227]. The Δ6 and Δ5-desaturases have been shown to belong to the same cluster of genes 
[228], referred to as FADS after being cloned. Marquardt et al. suggested the names FADS1 
and FADS2 for Δ5-desaturase and Δ6-desaturase, respectively, while there is a third putative 
desaturase FADS3 for which no activity has been described [229]. There are clear phylogenic 
differences between SCDs and FADS families of desaturases despite sharing certain common 
structural features [230, 231]. 
 
All of the four SCD isoforms can be used to desaturate palmitic acid (C16:0) and stearic acid 
(C18:0) with a preference for stearic acid, except for SCD-3 which can only desaturate palmitic 
acid rather than stearic acid. The SCDs are also associated with the control of energy 
homeostasis and Scd-1-/- mice appear to have reduced rates of lipid synthesis [232] and 
enhanced lipid oxidation [233], thermogenesis [234] and/or insulin sensitivity [235, 236] in the 
liver, skeletal muscle, and adipose tissue. Moreover, mice lacking SCD-1 in their skin [237] 
exhibit a similar hypermetabolic phenotype and are resistant to obesity. Moreover, there is a 
minor pathway that converts palmitic acid to ω-10 FAs (Δ6-C16:1) by FADS2, which to date 
has only been identified in sebocytes, such as in the preputial gland of Scd-1-/- mice [238].  
 
In the essential PUFA synthesis pathways, both linoleic acid (Δ9,12-C18:2) and α-linolenic acid 
(Δ9,12,15-C18:3) begin with sequential Δ6-desaturation, elongation, and Δ5-desaturation, leading 
to the synthesis of arachidonic acid (Δ5,8,11,14-C20:4) and eicosapentaenoic acid (EPA, 
Δ5,8,11,14,17-C20:5), respectively. FADS2 catalyzes the initial and rate-limiting Δ6-desaturation 
procedure [231, 239], followed by the ELOVL5-catalyzed elongation and Δ5-desaturation by 
FADS1. In an alternative route for the synthesis of arachidonic acid and EPA, the Δ8-
desaturation activity of FADS2 may be evoked, although it is considerably lower than Δ6-
desaturation activity so this pathway may be viewed as a minor component [240, 241]. 
ELOVL5 has been suggested to be involved in the elongation of 18-carbon and 20-carbon 
PUFAs [209]. In further elongations of arachidonic acid and EPA to 24-carbon PUFAs, both 
ELOVL5 and ELOVL2 [207, 210, 211] play a role. The C24:4 (ω-6) and C24:5 (ω-3) are then 
used as substrates for Δ6-desaturation by FADS2 again, followed by production of C22:5 (ω-
6) and C22:6 (ω-3) through peroxisomal β-oxidation or further elongation by ELOVL2 and 
ELOVL4 as shown in Fig. 1.1. 
  
 Fig. 1.1 Long chain and very long-chain fatty acid biosynthesis in mammals (modified from [204]). 
The saturated fatty acids (FAs) and ω-10, ω-7, and ω-9 unsaturated FAs can be synthesized from 
palmitic acid (C16:0) produced by de novo lipogenesis (DNL). The ω-6 and ω-3 unsaturated FAs can 
only be synthesized from precursors obtained from the diet. The elongases (ELOVLs) and desaturases 
(SCDs and FADSs) for steps studied to date are indicated. 
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1.3.2 Sterol Regulatory Element-binding Proteins (SREBPs) 
The Sterol regulatory element-binding proteins (SREBPs) are membrane-bound transcription 
factors that bind to the sterol regulatory element (SRE) DNA sequence TCACNCCAC and 
regulate intracellular sterol content as well as the biosynthesis of fatty acids, triacylglycerols 
and phospholipids [242-244]. Humans express two distinct SREBP genes: sterol regulatory 
element binding transcription factor 1 (SREBF1) and sterol regulatory element binding 
transcription factor 2 (SREBF2). The SREBF1 gene encodes two proteins referred to as 
SREBP-1a and SREBP-1c/ adipocyte differentiation-1 (ADD-1). SREBP-1a is identified 
primarily in the spleen and intestines and regulates both the cholesterol and fatty acid 
biosynthetic pathways, while SREBP-1c predominates in liver, adipose tissue, and muscle and 
controls SREBP-responsive genes involved in the fatty acid synthesis and differentiation of 
adipocytes. SREBP-1c is also a transcription factor downstream of insulin in carbohydrate and 
lipid metabolism. SREBP-2 predominates in the liver and controls the expression of genes in 
sterol biosynthesis and the LDL receptor (LDLR) gene. SREBP-1c is the predominant isoform 
expressed in most animal tissues and significantly elevated in livers from ob/ob mice [245, 
246]. 
 
The expression of SREBPs is regulated in complex pathways involving different substrates, 
hormones, and transcription factors. SREBPs are embedded in the membrane of the 
endoplasmic reticulum (ER) with their C-terminal domain exposed to the cytosolic side 
interacting with a protein called SREBP cleavage-activating protein (SCAP). SREBP activity 
is controlled by the interaction of SCAP with insulin-induced protein-1 and -2 (Insig-1 and 
Insig-2) [247, 248]. INSIG1 gene expression is highest in the liver while INSIG2 is expressed 
ubiquitously. Both Insig-1 and Insig-2 can cause ER retention of the SREBP/SCAP complex 
[249]. High sterols activate expression of the SREBP-1 gene via the action of the liver X 
receptors (LXRs) but do not affect the SREBP-2 gene. Interestingly, the expression of Insig-1 
can also be regulated by SREBPs with the SRE upstream of the transcriptional start site of the 
INSIG-1 gene. Moreover, expression of Insig-1 can be regulated by PPARδ, pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR). The Insig-2 promoter is controlled 
by insulin receptor activation and nuclear receptors such as the two farnesoid X receptor (FXR) 
response elements. In addition, both Insig proteins activate the sterol-dependent degradation of 
HMG-CoA reductase (HMGR).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 
When SCAP no longer interacts with either of the Insights in situations like decreased PUFA 
intake, during the anabolic effects of insulin, or following excess SFA, the SREBP-SCAP 
complex migrates to the Golgi and SREBP is subjected to proteolysis sequentially by site-1 
protease (S1P) and site-2 protease (S2P), generating a soluble and transcriptionally active 
SREBP mature protein [249]. The SREBPs has been implicated in insulin resistance [250], β 
cell dysfunction [251], T2DM [252], and CVD [253]. SREBP1 has been shown to occupy the 
promoters of 1,141 target genes involved in diverse biological pathways, particularly lipid 
metabolism and insulin signaling pathways [254]. Demonstrated targets include genes involved 
in DNL (e.g., Acc and Fas) [255-257], FA desaturation (e.g., Scd1) [256, 258] and elongation 
(e.g., Elovl6) [210, 218], FA re-esterification (e.g., mitochondrial glycerol-3-phosphate 
acyltransferase [Gpat1]) [259], and PL synthesis (e.g., CTP: phosphocholine 
cytidylyltransferase α [Cctα]) [260, 261].  
 
There is a complex feedback regulatory system between PPARγ, insulin, Insig1, and SREBP1. 
Firstly, PPARγ agonists can induce Insig1 expression in vitro and in vivo in WAT [262, 263] 
to limit the promotion of adipocyte differentiation by PPARγ itself. Insulin can also activate 
SREBP1 to promote lipogenesis, while, at the same time inducing the expression of Insig1 for 
restricting the production of too much active SREBP1 [262, 264-266]. This autoregulatory 
feedback loop has not only been suggested as a control mechanism for cholesterol synthesis in 
the liver [264, 267] but also reported to be involved in the pathophysiological dysregulation of 
WAT for in vivo and in vitro obesity models [37]. In the insulin-resistant (IR) state, this 
negative Insig1/SREBP1 regulatory feedback is suggested to be reset for the downregulation 
of Insig1 and maintenance of active SREBP1 levels for maintaining lipid homeostasis. Active 
SREBP1 ensures enough supply of specialized FAs used for the maintenance of membrane 
lipid homeostasis, effectors of intracellular signaling, and lipid modification of proteins [254]. 
The concept that SREBP1 needs to be activated to restore the biosynthesis of 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) has been suggested both in 
Caenorhabditis elegans and mammalian cells [39] and Drosophila heart [41]. This regulatory 
feedback can compensate lipid perturbations in membranes and specific signaling pathways in 
obesity and IR, but, simultaneously, increases lipogenesis [37, 41] and may aggravate 
associated pathology. 
1.4 Epigenetics and One-carbon metabolism 
Mendelian genetics cannot completely clarify the rapid worldwide increase in the prevalence 
of obesity over the past years along with its underlying inherited susceptibility [268]. 
Epigenetics, which refers to the heritable changes in gene expression resulting from 
modifications to DNA or histones rather than changes in the nucleotide sequence, has attracted 
extensive attention in recent years as an alternative mechanism for pathologies associated with 
metabolic disorders [269, 270]. In particular, DNA methylation (e.g. cytosine → 5-
methylcytosine) is a major epigenetic modification of the genome that regulates gene 
expression [271]. Although the DNA sequence is comparatively stable, epigenetic patterns can 
be greatly influenced by external factors, and remain dynamic all the way through the life 
course [272], providing an important interface between environmental factors and genetics.  
 
Besides being influenced by hormones and adipokines, lipid metabolism can also be influenced 
by interactions with epigenetic mechanisms. For example, epigenetic and chromatin-modifying 
proteins have been found to contribute to adipogenesis and maintenance of mature adipocytes 
through the PPARγ gene [273]. The fat mass and obesity associated gene (FTO) has been found 
to be associated with a type of demethylase [274]. Furthermore, there is evidence that high-fat 
diets can affect the methylation of the main anorexigenic neurohormone pro-opiomelanocortin 
(POMC) and leptin-related genes, having an impact on appetite [275, 276]. Methylation of the 
genes encoding PPARα and the glucocorticoid receptor (GR) have been shown to be decreased 
when maternal protein is restricted which have a long-term impact on systemic metabolism 
[277], and methylation of the melanocortin-r receptor (MC4R) is associated with exposure to 
long-term exposure to a high-fat diet [278].  
 
Diet can change gene expression through epigenetic modifications as well as by the 
transcriptional regulation of metabolic pathways. For example, the epigenetic profile of the 
genome was suggested to be altered after a carbohydrate-based diet was replaced by a high-fat 
diet, which resulted in insulin resistance and T2DM [279, 280]. Moreover, some metabolites 
have been found to be used by epigenetic enzymes as necessary co-factors, such as S-
adenosylmethionine (SAM) which is used as a chief methyl donor cofactor by both DNA and 
histone methyltransferases [281]. There are good mechanistic reasons to link changes in a high-
fat diet with epigenetic modifications of DNA. SAM is mainly derived from methionine via 
the enzyme methionine adenosyltransferase, which is part of the choline and one-carbon (1-C) 
pathway [282-284] (Fig. 1.2). Choline is the head group of phosphatidylcholines (PCs), which 
are the major building blocks of the lipid bilayer of cell membranes. A sufficient SAM 
concentration is also required to establish the normal ratio of phosphatidylethanolamine (PE) 
to PC [285]. 
 
Fig. 1.2 Interconnection between the 1-carbon cycle, Methylation pathway, Transsulfuration 
pathway and Kennedy pathway (modified from references [286, 287]). DHF, Dihydrofolate; 
THF, tetrahydrofolate; SAM, S-adenosyl methionine; SAH, S-adenosyl homocysteine; GSH, 
glutathione. 
 
1.5 Mass Spectrometry in Metabolomics and Lipidomics 
The small molecules of interest in metabolome and lipidome vary significantly in terms of their 
concentrations, molecular weights, solubility, polarity, and volatility. Therefore, the analytical 
platform suitable for lipidomics must have maximum coverage of metabolites detected in a 
sample. Mass spectrometry (MS) is a commonly used technique providing structural 
information of chemicals in a wide range of structures and concentrations and has strongly 
influenced the field of metabolomics and lipidomics [288-290]. MS broadly consists of three 
components: an ion source, a mass analyzer, and a detector with a data processing system [291]. 
Analytes are ionized when admitted to the ion source, then transported to the mass analyzer by 
magnetic or electrical fields and separated out depend on their mass-to-charge ratio (m/z). The 
m/z signals of charged molecules (or fragments) obtained by the detector are transmitted to the 
data processing system producing a plot of ion abundance against m/z defined as a mass 
spectrum, which gives information about structures and quantities of the analytes. Different 
configurations of the ion source and mass analyzer (or two or more mass analyzers for a tandem 
mass spectrometry) are actively used in research, chosen depending on their strengths and 
weaknesses. The use of a combination of these MS techniques allows the identification and 
quantification of a large number of metabolites, with a wide range of chemical properties and 
concentrations [292]. Due to its high sensitivity and versatility, MS is used extensively in 
metabolomic studies. Besides the identification of metabolites, MS easily determines the 
relative quantification of low-concentration and low-weight metabolites [293-295]. Moreover, 
absolute quantification can be achieved by MS with particular reference compounds. 
1.5.1 Generating Ions: Ionisation 
Many different ionisation techniques have been used to generate gas phase ions, including 
electron ionisation (EI), chemical ionisation (CI), electrospray ionisation (ESI), and matrix-
assisted laser desorption/ionisation (MALDI), depending on the states of samples 
(gas/liquid/solid) and also the internal energy transferring during ionization [296]. EI, formerly 
known as electron impact, is the ionization technique for mass spectrometry that is only used 
for ionization of analytes in the gas phase. EI is very energetic that the resultant ions are mostly 
fragmented. The fragments generate a reproducible pattern of m/z signals, which can be 
matched to spectral databases for identification. However, EI requires the analyte to be a gas 
phase or volatile to bombard high energy electrons and is used almost exclusively combined 
with GC. Molecules are introduced from GC into the ion source and collided with ESI, one of 
the so-called “soft” ionization techniques, do not require chemical derivatization (except for 
enhancing or enabling ionization [297]) and minimize the fragmentation of analytes, so it can 
assist in the analytical interpretation of complex mixtures. In ESI, the analyte is eluted and 
charged by spraying it through a highly charged needle tip, followed by extensive solvent 
evaporation and entry into the mass separation unit. The analyte is dissolved in a polar or 
volatile solvent is pumped into a fine capillary with a flow rate ranging from 1 μl/min to 1 
ml/min [298]. The range of the diameter of the capillary is typically 75-150 μm [298]. A voltage 
(normally 2-3 kV for methanol/acetonitrile and 4 kV for water) is applied to the tip of the 
capillary and results in the production of an electric double layer through charge migration 
from the solution species to the solution/capillary interface [299]. The electrostatic forces from 
the pre-organisation of charges in the electric double layer of the capillary counterbalance the 
surface tension to produce a Taylor cone at the needle tip [300]. When the voltage increases to 
some extent, the Taylor cone will be destabilized and the sample will be dispersed as a fine 
spray of charged droplets from the capillary with co-axial nebulizing gas (typically nitrogen) 
flowing around the capillary. Then evaporation of solvent increases the concentration of charge 
on the droplet surface. “Coulombic explosion” [301, 302] occurs when the Rayleigh limit is 
reached and the droplets explode resulting in the formation of a number of smaller droplets of 
a lesser charge. The solvent becomes less and less as the evaporation and Coulombic explosion 
continues, creating the spray of charged solvent free analyte ions. Two competing theories 
[303], known as the charge residual model and the ion evaporation model, disagree at whether 
the ions in the gas phase are formed prior to total droplet fissions or after successive droplet 
fissions. The spray of the analyte ions is then introduced into a sampling cone and an 
intermediate sampling vacuum followed by entering the mass analyzer, where they are 
analyzed for m/z. Differently charged ions will be detected under certain conditions as the 
charges are distributed among many sites on the analyte. 
 
ESI has the capacity of ionizing non-volatile and high mass analytes, such as intact lipids, 
peptides or proteins, and allows the mass spectrometric detection of the vast majority of 
biological molecules among all the ionization techniques [304, 305]. ESI is especially suitable 
for the analysis of polar and ionic metabolites [306, 307]. ESI is by far the most frequently 
used ionization technique in lipidomics studies, partially due to the ease of combining the 
separation power of an analytical LC experiment with the interpretation power of a mass 
spectrometer, and the analysis of polar metabolites by LC-ESI-MS is also experiencing a rapid 
period of growth [293, 295]. However, ESI can suffer from some disadvantages, of which the 
most prominent is the strong ion suppression effect when investigating complex molecular 
mixtures [308, 309].  
1.5.2 Mass Analyser and Direct Infusion-Mass Spectrometry 
In direct infusion-MS (DI-MS), the analyte mixture is directly introduced into the mass 
spectrometer by ESI. A large number of lipid species can be measured in different ionization 
modes, so this method is also dubbed “shotgun” [310]. Anionic lipid species are easily ionized 
in negative mode, especially after the addition of ammonium acetate, formic acid or lithium 
hydroxide, while neutral and polar lipids could be detected in positive mode [311, 312]. Ionized 
molecules are separated according to their mass-to-charge ratio (m/z) in a variety of mass 
analyzers including quadrupole, ion trap, time-of-flight (TOF), magnetic and/or electric sectors, 
and Fourier transform ion cyclotron resonance [313, 314]. The analyzers vary in terms of their 
mass accuracy, dynamic range, mass resolution, and suitability for tandem MS (MS/MS), and 
an extensive range of instruments are utilized in metabolomic studies.  
 
In a quadrupole mass analyzer, ions generated at the source are accelerated and focussed by a 
lens, which functions as an ion guide and collisional dampening cell into the quadrupole [315-
317]. A quadrupole consists of four parallel metal rods. Any opposing rods have the same 
applied potential, (U+Vcos(ϖt)) for one pair and -(U+Vcos(ϖt)) for the other. U and Vcos(ϖt) 
is a direct and an alternating current voltage respectively, used to control the course of ions 
through the quadrupole filter. By altering Vcos(ϖt) ions of a particular m/z (resonant ions) are 
allowed as they move along the ion flight path at the center of the four rods. Therefore, the 
quadrupole is widely used not only in the radio-frequency only mode as a single mass 
spectrometry but also functions as a mass filter accelerating the ions of interest into a collision 
cell in MS/MS mode. [318] 
 
The separation and identification of analytes by m/z signals can be improved by instruments 
with higher resolution and mass accuracy. A high-resolution mass analyzer such as a TOF 
analyzer can be a powerful tool for identification works in an open profiling metabolomic study 
[319]. In the TOF analyzer, ions that are accelerated by an electric field are separated according 
to their velocities while they drift in a free-field region in flight tube. Firstly, a pulsed electric 
field pushes the ions into the accelerating column from where the ions enter the field-free space. 
Then the kinetic energy distribution of the ions is corrected by a reflectron: the ion beam is 
reflected towards the detector by an electrostatic field. The depth an ion penetrates the 
electrostatic field and the length of its flight path to the detector depend on the ion’s kinetic 
energy. With this corrected energy distribution, ions of identical m/z would simultaneously 
arrive at the detector, referred to as time-of-flight focus. In the end, ions are detected by two 
microchannel plates with mass spectra recorded by a time-to-digital converter [319]. 
 
However, an increase in the resolution of an instrument is often correlated with relative cost. 
Lower resolution and mass accuracy can be compensated for by tandem MS (MS/MS) 
capability to a degree [320, 321]. MS/MS can isolate and select molecular ions with specific 
m/z ratios in the first mass analyzer for fragmentation in a collision cell, and then separated in 
the second mass analyzer to obtain the fragments information to aid the identification of these 
analytes [322-324]. There are many methods can be used to fragment ions, producing different 
types of fragments and information about the structure and composition of analytes. In one 
process known as collision-induced dissociation (CID), the selected molecular ions are 
accelerated by an electrical potential and collide with neutral gas molecules within a collision 
cell, resulting in fragmentation of the ions [325]. The fragments are then separated and 
measured by their m/z value, giving more information about the original molecular ions. For 
example, the fragment signal in the form of a neutral loss or a characteristic signal at m/z value 
74 often indicates the phospholipid headgroups in lipidomics [326].  
 
There are different ways to combine two or more mass analyzers to perform a tandem mass 
spectrometry, such as triple quadrupole (QqQ), quadrupole-TOF (Q-TOF) and quadrupole 
linear ion trap (Q-IT) mass spectrometer. A tandem MS system of QqQ mass spectrometry 
(QqQ-MS) contains two quadrupole MS in series, with a radio frequency only quadrupole 
between them as a collision cell for CID. Multiple reaction monitoring (MRM) in QqQ-MS 
has shown high sensitivity, specificity, and excellent quantitation ability. Therefore, a QqQ-
MS system is ideal for targeted metabolomics studies, which normally focus on the 
identification and quantification of specifically selected metabolites. For example, QqQ-MS 
has been used in the identification of drug metabolites [327]. An MRM scan mode method was 
used in the quantification of one-carbon metabolites of this study, in which by having three 
quadrupoles in series, a compound of a given mass can be selected by the first quadrupole, 
fragmented in the second (which acts as a collision cell), and a particular fragment then detected 
in the third. Three characteristics (retention time, parent ion m/z, product ion m/z) will be 
applied simultaneously to determine a certain compound in the TIC, which improves the 
sensitivity and selectivity of the quantitative method to a large extent. A diagram illustrating 
how to determine 5-methyltetrahydrofolate using the MRM scan mode is shown in Fig. 1.3. 
This selective LC-MS/MS method can be a highly sensitive tool for the measurement of 
specific metabolites. In this project, the UPLC-MRM-MS/MS method will be modified for 
aqueous extracts from white adipose tissue, and more fragmentation ion pairs will be chosen 
to measure more methyl donors. 
 Fig. 1.3 Multiple reaction monitoring (MRM) scan mode of a triple quadrupole mass 
spectrometer (A), and an example to determine 5-methyltetrahydrofolate (5-MeTHF) using this 
mode according to its product ion spectra of [M+H]+ (B) [328] 
 
Another mass spectrometer that is often used for MS/MS is the quadrupole linear ion trap (Q-
IT) mass spectrometer which consists of an ESI source, a heated capillary, and two successive 
rod arrays, a quadrupole and an ion trap [317, 318]. There is a lens gating entry of ions into the 
ion trap by pulsing from negative to positive voltages to attract and repel the ions into the 
aperture. This control of entry time not only maximizes signal but also diminishes the space-
charge effects of an excessive quantity of ions in the trap. The ion trap is composed of three 
hyperbolic quadrupole rod arrays which radially restrained ions in the center by a two-
dimensional radio frequency trapping field. Meanwhile, the front and rear end electrodes 
confine the ions axially through applying direct current potentials, and helium-filled in the ion 
trap (~1 mtorr) collide with ions and contract their trajectories to the center of the trap (kinetic 
cooling). When auxiliary alternating current voltages on the X-rods alter the field in the ion 
trap by dipole excitation, the trapped ions leave the trapping field in order of successive m/z 
ratio and strike a detector (such as electron multiplier and conversion diode) offering structural 
information [329]. Ion traps can perform MS/MS to the nth degree by confining 90% of isolated 
ions and fragments in the trap, and as a consequence, many mass selective operations are 
capable of being performed. 
 
DI-MS is a high-throughput and easily optimized technique widely used in identification and 
relative quantification of lipids [330] and metabolic “fingerprinting” studies [331], but also has 
a number of disadvantages. Ion suppression effects can be a considerable problem when 
analyzing complex mixtures of metabolites [332]. Ion suppression occurs when analytes 
compete for the charge during the ionization process, resulting in a change in the intensity of a 
5-MeTHF               460.4      313.2
(A) (B)
particular ion [333]. This problem can be avoided, to an extent, by using chromatographic 
techniques to separate the analytes prior to injection into the mass spectrometer for analysis 
[334]. 
1.5.3 Gas Chromatography-Mass Spectrometry 
MS becomes a particularly powerful metabolic profiling tool in identification and 
quantification of the metabolomes in combination with prior separation, usually by 
chromatography [335], therefore providing higher sensitivity in terms of the size of 
metabolome detected. Chromatography utilizes a column which varies in length, diameter and 
chemical property (stationary phases) to provide separation of different chemicals [336-338]. 
A mixture of metabolites is separated out depending on their different chemical properties as 
they travel through the column. The metabolites eluted at different time are then subject to 
mass spectrometry (MS) analysis for both identification and the further separation of co-eluting 
peaks.  
 
Gas-chromatography (GC) was first projected in 1941 by Martin and Synge [339], suggesting 
that the mobile phase in a liquid-liquid chromatography system could be substituted with a 
vapor. After significant developments in technology, it has eventually become possible to 
couple the chromatography to mass spectrometry. The GC-MS technique finally came into 
shape when Gohlke and McLafferty [340] combined a gas chromatography to a TOF mass 
spectrometer During the 1950s. GC-MS has since become an important technique in a wide 
range of fields, especially in lipid biochemistry, lipidomics and metabolomics due to its high 
chromatographic resolution. GC consists of a carrier gas mobile phase and column coated with 
a solid stationary phase. It is usually a separation method more robust than liquid 
chromatography (LC). It can separate and analyze volatile (i.e. with a low m/z) and thermally 
stable gaseous or aqueous phase metabolites following derivatization prior to analysis.  
 
Since GC-MS requires the analytes to be volatile and thermally stable, derivatization can be 
used to introduce volatility to complicate metabolites or remove the polar functional group, so 
it is required for identification of much low volatility and unstable metabolites. In general, the 
most useful derivatives are trimethylsilyl ethers (TMS) for hydroxyl groups, methyl esters for 
carboxyl groups, and alkyl oximes for carbonyl groups. A 2-step protocol using methoxyamine 
hydrochloride followed by N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) is 
commonly used in the aqueous metabolomic analysis to increase the volatility of the 
metabolites such as monosaccharides [341, 342]. The derivatization most commonly used for 
fatty acids is hydrolysis of complex lipids and methylation of the released free fatty acids to 
form fatty acid methyl esters (FAMEs) to increase the volatility and mask the polar carboxyl 
group [343]. Some research used boron trifluoride and methanol for acidic esterification of the 
fatty acids.  
 
The GC system consists of the GC column as the stationary phase and the carrier gas 
functioning as the mobile phase [344, 345]. The sample is injected, vaporized and pushed by 
the carrier gas through the heated GC column. The velocity that different compounds move 
through the column depends on their partition between the mobile and stationary phases. The 
separation is dependent on analyte chemistry, column dimensions, stationary phase type, 
carrier gas flow rate, and the temperature of the column [346, 347]. A programmed temperature 
gradient can be adjusted and applied to control the velocity for better separation. The stationary 
phase also has a significant impact on the identification of analytes. Different columns could 
be used to separate fatty acid methyl esters based on molecular weight, unsaturation, or 
cis/trans isomers. Provisional identifications can also be made using commercially available 
standards, but this kind of tentative identifications had better be further verified by 
spectrometric techniques. [346, 348] 
 
After separation in the column, compounds are eluted through a heated transfer line to the ion 
source, which commonly uses EI as the ionization technique [349, 350]. In EI an energetic 
beam of electrons generated from a filament impact the analyte to produce a radical cation that 
loses an electron. The Ionised analytes undergo further fragmentations removing the excess 
internal energy gained from ionization. The ions and fragments enter a mass analyzer, typically 
quadrupole mass analyzers to generate a mass spectrum, amplified by the detector and sent to 
a computer to convert the signal into a visual display. Since the fragmentation in EI is extremely 
reproducible with the same ionization energy (typically 70 eV), standardization of 
fragmentation libraries could be compared with the fragments to provide structural information 
for analyte identification. One of the most famous commercially available databases is the 
National Institute of Standards and Technology (NIST)/ Environmental Protection Agency 
(EPA)/ National Institutes of Health (NIH) mass spectral library. [351] 
 
GC-MS overall is a robust analytical approach with high sensitivity and good resolution. 
However, the additional derivatization step must be used for many samples to make them 
thermally stable and volatile, but this process may introduce variability, contamination and 
recovery losses into the samples and can mask metabolite structural information [352, 353]. 
What is more important, the range of analytes that can be analyzed is limited by its m/z range, 
preventing applying to larger metabolite species. The large and polar metabolites cannot be 
analyzed by GC because they are neither volatile nor able to be made volatile by derivatization. 
These difficulties can be overcome by a combination of GC-MS with other analytical 
techniques such as DI-MS and LC-MS so that the metabolome coverage can be increased to a 
large extent.  
1.5.4 Liquid Chromatography-Mass Spectrometry 
The atmospheric pressure interface between a liquid chromatography (LC) and a mass 
spectrometer (MS) became possible after development of the Atmospheric Pressure Ionisation 
(API) ionisation interface, including ESI and Atmospheric Pressure Chemical Ionisation 
(APCI), and nano-spray technique in the 1980s from original work of John Fenn’s group [354]. 
LC-MS has a number of advantages and has become a popular technique for metabolomic 
analysis [355]. In contrast to GC-MS, LC-MS can not only apply to measure volatile samples. 
It is a high throughput method that is suitable for a good dynamic range of species (including 
intact lipids, peptides, and other macromolecules) and has the potential for analyte 
identification from the spectral data. Even with a low-resolution chromatography, the mass 
spectrometer can operate in both negative and positive ion mode to broad the screening 
coverage of analytes. LC-MS can also be very sensitive with good resolution and mass 
accuracy. 
 
DI-MS often suffers from a matrix effect named “ion suppression” [332], which means co-
eluting compounds including prominent phospholipids, especially when using positive 
ionization, can compete for a charge during ionization and decrease the ionization of certain 
analytes of interest. The ionization efficiencies individual analytes are based on their chemical 
characteristics, so that the observed count for a specific ion depends on not only itself but also 
other analytes and contaminants co-eluted and co-ionised [333]. What makes the problem more 
complicated is that the interfering compounds may not be seen in the mass spectrum and both 
low and high concentration analytes are affected [356]. The use of an initial, either offline or 
online, liquid chromatography (LC) separation [357], especially the high-resolution high-
performance liquid chromatography (HPLC) and ultra-performance liquid chromatography 
(UPLC), prior to MS analysis can significantly reduce the detrimental ionization properties, so 
UPLC-MS can be more accurate with good resolution [355]. HPLC is a widely used technique 
for separating lipid classes by normal phase chromatography and often coupled to detectors 
including ultra-violet detection [358] and evaporative light scattering detection [359, 360]. 
However, ESI-MS detector is much better than these detectors in terms of selectivity and choice 
of mobile phase [357], although identification of metabolite species is still a considerable 
challenge and some analyses can be low-throughput because of relatively long chromatography 
runs. 
 
Although most thermally labile, polar or high molecular mass compounds can be directly 
analyzed by LC-MS, there may be some problems in ionization of some labile compounds and 
those without enough innate polarity. Ammonium adducts can be produced by adding 
ammonium acetate or formic acid to the mobile phase to aid the ionization of metabolites before 
injecting them into the HPLC or UPLC columns [361]. The column has a narrow tube packed 
with chemically modified silica which interacts with the analytes in the mobile phase (the 
solvent) to separate chemical classes of the analyte. The column chemistries include normal 
phase, ion exchange, partition, displacement, size exclusion and reversed phase 
chromatography (RPC). This study used some type of RPC columns which have a non-polar 
stationary phase and rely on the principles of hydrophobic and electrostatic forces [362, 363]. 
An aqueous and moderately polar mobile phase is commonly selected for an RPC column. 
 
Retention of analyte molecules by the stationary phase relies on the solvophobic theory and the 
contact surface area around the non-polar segment of the molecules with the stationary phase 
within the aqueous eluent [362, 364]. The binding of analytes to the RPC stationary phase can 
be decreased and analytes eluted from the column by reducing the polarity and surface tension 
of the mobile phase. The larger non-polar molecules are eluted after polar molecules in RPC 
[365]. Higher resolutions and faster separations can be achieved by using a sub-2 μm particle 
size column and elevated column temperature [366]. Both flow rates and pressure increase with 
smaller column packing particles, while effective pressure is reduced by increasing the 
temperature. The separated analyte molecules are then introduced into a mass spectrometer via 
an ESI or APCI. 
 
In contrast to GC-MS, libraries for sample identification for LC-MS data are limited, because 
ESI-MS spectra and fragmentation patterns are affected by many factors including the 
instrument type, ion source, and mobile phases [353]. However, there are a lot of resources 
available providing pertinent reference material, structural information and MS/MS patterns of 
lipids, such as the LIPID MAPS (http://www.lipidmaps.org/) [367], Cyber Lipid Center 
(http://www.cyberlipid.org/), and LipidBank (http://lipidbank.jp/). 
 
1.6 Obese mouse models 
Animal models are widely used as a strategy to study how obesity and metabolic syndrome 
results in different diseases. They offer more logistic advantages over human tissue studies, 
such as ease of drug interventions and selective genetic manipulation and better tissue and 
organ availability alongside disease developmental progress [368]. The metabolic syndrome 
can be induced in several well-established obese mouse strains with high-fat feeding or other 
diets. These models are generally classified into three categories: (1) genetic models, such as 
ob/ob mice, db/db mice, PPARα  knockout mice, SREBP-1c transgenic mice, and acyl-
coenzyme A oxidase (AOX) null mice; (2) nutritional models, such as mice fed on high-fat diet 
(HFD), choline-deficient (CD) diet, fructose, cholesterol and cholate diet; (3) combinational 
models of genetic and nutritional models. Actually, in humans, obesity is also commonly 
caused by excessive food intake along with a lack of physical activity [369, 370] and genetic 
susceptibility [371]. The lipid composition of the white adipose tissue of diet-induced obesity 
depends on the food consumed. High carbohydrate diet leads to excessive DNL in the liver and 
adipose tissue and the newly synthesized lipids (such as C16:0 and C18:1) will dominate. HFD 
results in reduced DNL and the WAT is filled with TAGs composed of the FAs directly from 
the diet. The expression of genes associated with DNL is activated by a high carbohydrate diet, 
inhibited by HFD [268, 372]. To date, membrane lipids have not fully been examined and will 
be the focus of this study. The composition of WAT of genetic-induced obese humans is 
decided by the pathways the gene is in control of. For example, PPARδ activation results in 
more oxidative catabolism of FAs and TCA cycle intermediates, while the PPARγ activation 
was distinguished by the sequestration of lipids into WAT [373, 374]. The WAT of ob/ob 
mouse is dominated by DNL-lipids resulting from mutations in the gene responsible for the 
production of leptin, which will be discussed in details below. 
 
Rodents are by far the most commonly used pre-clinical model of human obesity. While the 
literature supports the notion that many similarities exist between rodents and humans, notable 
differences emerge related to fat deposition and the function of adipose tissue. In humans, 
adipose tissue is found in specific locations (adipose depots), such as around internal organs 
(visceral fat, including mesenteric, epididymal and perirenal adipose tissues), beneath the skin 
(subcutaneous fat), intermuscular (muscular system), in bone marrow (yellow bone marrow), 
around the heart (epicardial adipose tissue), and in the breast tissue [375, 376]. Adipose depots 
in different parts have different physical and biochemical profiles [377-379]. The visceral fat 
in the abdomen is mostly semi-fluid while the subcutaneous and intramuscular fat is not 
consistently spaced. The visceral fat is more linked to obesity-related diseases than the 
subcutaneous fat does. Mice have in total of eight major adipose depots [380]. The largest is 
the paired gonadal depots which are attached to the testes and epididymis in males and the 
ovaries and uterus in females and enclose the inguinal group of lymph nodes [381]. The gonadal 
depots comprise about 30% of the dissectible fat [381]. The other two adipose depots in the 
abdominal cavity are the paired retroperitoneal depots surrounding the kidney. These adipose 
depots extend into the pelvis when they reach a particular size. The omental depot which 
originates near the spleen and stomach and can extend into the ventral abdomen and the 
mesenteric depot which forms a glue-like web supporting the intestines include many lymphoid 
tissues [382]. The two superficial depots are the paired inguinal depots (anterior to the upper 
segment of the hind limbs) and the subscapular depots (under the skin between the dorsal crests 
of the scapulae) which are paired medial mixtures of BAT adjacent to regions of WAT and 
also often covered by a "frosting" of WAT [383]. Besides these eight major depots, there are 
also some minor depots in mice such as the paired popliteal depots (between the major muscles 
behind the knees, each containing one large lymph node) [384] and the pericardial (surrounds 
the heart) [385, 386]. 
1.6.1 The ob/ob mouse model 
One of the commonly used and well-characterized models of obesity is the ob/ob mouse, a 
strain with mutations in the leptin gene. Mutant mice are indistinguishable from the littermates 
at birth, but they become heavier rapidly within 2 weeks and gain weight throughout their lives, 
reaching about three times the weight of their unaffected littermates [387]. 
 
Leptin is a hormone yielded in adipocytes, which regulates adipose mass through controlling 
food intake [388], which provides a link between nutritional state and several important 
physiological progressions [389-391]. Mice with mutations in leptin (ob/ob) or the receptors 
(db/db) exhibited noticeable obesity phenotypes [392, 393], e.g. increased appetite, 
hyperglycemia, and hyperinsulinemia [394-396]. Interestingly, ob/ob mice gained extra fat and 
weight even after restricted to a diet which was adequate for the maintenance of lean mice. 
However, these mice significantly reduced their food intake and body mass and raised the 
energy expenditure back after the administration of leptin [397-399].  
 
Microarray comparisons showed that gene expression of adipose tissue of ob/ob mice are 
significantly different from wild-type mice [400], which indicated that leptin deficiency (or 
obesity) not only influence the phenotype of adipose tissue but also have an effect on the 
expression of genes associated with lipid biosynthesis and/or immune systems [389, 401]. In 
ob/ob adipose tissue, expression of SREBP-1c and its target genes are reduced than in wild-
type, but the opposite happens in the liver [402]. Alteration of SREBP-1c also has an global 
effect on other genes necessary for fatty acid synthesis, including SCD-1 [403], ACC [404], 
FAS [405], elongase [406], Δ5 and Δ6 desaturase [407]. Insulin motivates SREBP-1c gene 
transcription [408, 409], synthesis and secretion of which could also be inhibited by leptin. 
Leptin deficiency leads to increase of insulin content and expression of SREBP-1c [410, 411], 
which results in increased FAs and TAGs biosynthesis, and also the occurrence of diseases like 
diabetes and fatty liver [412]. 
1.6.2 The PPARα null mouse model 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors controlling the 
expression of genes associated with organogenesis, cell differentiation, proliferation, 
inflammation, carbohydrate, and lipid metabolism and energy homeostasis [373, 374, 413, 414]. 
The PPAR family of nuclear receptors is composed of three members: PPARα, PPARβ/δ 
(commonly referred to as PPARδ), and PPARγ. The different functional properties of the 
PPAR subtypes result from subtle differences in binding site preference, tissue distribution and 
their ability to bind different co-repressors and coactivators [415]. PPARα reportedly activates 
the proliferation of peroxisomes [416], while the activation of PPARδ and PPARγ cannot lead 
to peroxisome proliferation.  
 
PPARs form permissive heterodimers with the retinoid X receptors (RXRs) which bind to 
PPAR-responsive elements (PPREs) in target DNA through the DNA-binding domain (DBD) 
[417]. The function of PPARs is dependent on the precise shape of their ligand-binding domain 
(LBD) modification [418]. Upon ligand binding, to PPARs the complex of the PPAR/RXR 
heterodimer with co-repressors is exchanged for the formation of the co-activator complex 
which leads to transcriptional activation of target genes [419, 420]. The LBD of the PPARs is 
large and can accommodate a variety of lipids including endogenous FAs, derivatives of 
linoleic acid, eicosanoids, and oxidized and nitrated FAs, linking lipidomics with 
transcriptomics. However, the concentration required for these FAs to bind to PPARs is higher 
than would be encountered in vivo, and as such, it is still yet to be conclusively determined 
whether any of the various lipid ligands represent the ‘true’ physiological ligand. One of the 
primary co-activators of the PPARs is peroxisome proliferator-activated receptor-γ 
coactivator-1α (PGC-1α) [421]. The primary function of PGC-1α is to stimulate mitochondrial 
biogenesis and oxidative metabolism and as such is most abundant in tissues that have a high 
demand for energy production, such as brown adipose tissue (BAT), skeletal muscle, heart, 
brain, and kidney. The endogenous ligands PPARα include certain members of the metabolites 
of arachidonic acid such as leukotriene B4 and 15-Hydroxyicosatetraenoic acid family. 
Activation of PPAR in 3T3-L1 preadipocytes increase expression of enzymes of the β-
oxidation pathway when co-expressed with PGC-1 [422]. The widely prescribed lipid-lowering 
drugs of the fibrate (phenoxyisobutyrate) class reportedly increase FA oxidation [423] and 
decrease VLDL particles and circulating TAGs [424] through activation of PPAR. Fibrates 
also increase HDL cholesterols in a similar way through the activated expression of lipoprotein 
lipase and apolipoprotein A-V, and increased macrophage cholesterol efflux helps to alleviate 
inflammation and atherosclerotic plaque formation in the vasculature, reducing the risk of 
cardiovascular disease [425]. Other factors that influence the expression and activity of PPAR 
include stress, insulin, leptin, growth hormone, hepatocyte nuclear factor 4 (HNF4), and 
COUP-TFII. 
 
PPAR is important for the lipid homeostasis through the activation of peroxisomal and 
mitochondrial β-oxidation, microsomal ω-hydroxylation/oxidation, lipogenesis, ketogenesis, 
lipid binding and transport/lipoproteins, and cholesterol metabolism, and has anti-
inflammatory and anti-atherogenic effects. Mice lacking the PPAR gene, which is susceptible 
to adipocyte hypertrophy, hypercholesterolemia but normal triglycerides, are used as models 
of spontaneous late-onset obesity with stable caloric intake and a marked sexual dimorphism 
[426]. Females have higher serum triglycerides and gain more fat than males, while the males 
show a delayed occurrence of obesity and original centrilobular-restricted steatosis. Hepatic 
peroxisomal proliferation is inhibited along with decreased expression of some hepatic target 
genes in these transgenic mice [426]. Interestingly, genes associated with the peroxisome were 
changed significantly in the obese and old wild-type mice [427]. , Li et al. [428] demonstrated 
that the expression of PPARγ increased significantly in PPARα null mice along with a profound 
perturbation induced by these changes in terms of metabolism in adipose tissues. Fat cells from 
the liver of the PPARα null mice expressed substantial levels of PPARg2 transcripts when 
compared with lean cells.  
  
PPAR is highly expressed in tissues that oxidize fatty acids at a rapid rate, such as liver, BAT, 
heart, intestines, muscle, and kidney [429], where it promotes FA β-oxidation and transport, 
and decreases glycolysis [216, 429, 430]. Uptake of FAs into the liver can be increased by 
activation of PPAR, followed by the activation of peroxisomal β-oxidation and mitochondrial 
β-oxidation. Thus, PPAR is thought to have a profound effect on systemic metabolism and in 
particular the handling of lipids across the organism. On the other hand, it appears that PPAR 
plays a limited role in adipogenesis due to the low levels of expression, as the obese PPAR 
null mice appear to have normal WAT. The metabolomics study conducted by Atherton et al. 
[431] demonstrated a decrease in the hepatic concentration of glucose and glycogen of PPAR 
null mice which increased in an age-dependent manner. This suggested the important role 
PPAR plays in gluconeogenesis and its interaction with the aging process. It also 
demonstrated that white adipose tissue changes with the low expression of PPAR in this 
particular tissue. This was hypothesized to be a consequence of overall changes in systemic 
metabolism altering the lipids that are stored in white adipose tissue.  
 
 
1.7 Project Aims 
This thesis aims to investigate how the metabolic composition (lipidome and metabolome) of 
adipose tissue is influenced by both diet and genetic-induced models of obesity, and in 
particular how the composition of phospholipids, the major component of sub-cellular 
membranes, vary. In addition, the 1-C metabolism pool of methylation donors was investigated 
and in turn, the methylation of key genes in white adipose tissue (WAT) was measured to 
understand the link between the metabolome and altered gene expression and the pathways 
behind these alterations. To achieve this, I conducted: 
 
(1) In Chapter 3, a lipidomic study of aging examining the metabolome of white adipose tissue 
from wild-type and ob/ob mice on a regular chow diet (RCD) or high-fat diet (HFD) to better 
define how diet influences the lipidome. It was hypothesized that a high-fat diet, a genotype 
associated with leptin deficiency, and aging, all-cause characteristic variations in lipid profiles 
but would exhibit differences mirroring the pathways of different lipid metabolism and 
signaling. Especially, the composition of membrane lipids (PCs, lysoPCs, Pes and PSs) would 
be changed by diet/genotype/age in a different way compared with the neutral lipids (FAs, DGs 
and TGs).  
 
(2) In Chapter 4, a microarray study was performed on adipose tissues from 2- and 10-month 
animals, to examine the gene expression of essential enzymes involved in lipid metabolism in 
adipose tissue. It was hypothesized that there be a correlation between the transcriptomic 
patterns of obesity and aging, especially in inflammatory, metabolic and transcriptional 
pathways. 
 
(3) In Chapter 5, an LC-MS quantitative method was established to profile methyl donors in 
adipose tissue to understand how high-fat diet and leptin deficiency influences the turnover of 
1-C methyl donors. It was hypothesized that changes in phospholipids may correlate with 1-C 
metabolism, as choline was involved in not only lipid metabolism but also 1-C cycle as shown 
in Section 1.4. In addition, four genes associated with obesity and diabetes were chosen from 
the literature to determine their methylation status for validation of the suggested mechanism 
of a PC/1-C/epigenetics regulation system. 
 
(4) In Chapter 6, the lipid changes in BAT, visceral (epididymal) WAT, and subcutaneous 
(inguinal) WAT of PPARα null mice were profiled and compared with wild-type controls to 
understand how the lipidome changes under the regulation of important transcriptional factors. 
It was hypothesized that PPARα null mice might have more “bad fat” (saturated and shorter 
lipids) in store as some of the key transcription factors in PPARα related pathways might not 
be activated, such as SREBP-1c and PPARγ. 
Chapter 2 Materials and methods 
2.1 Chemicals and Reagents 
The FAME standard mix (Supelco 37 Component FAME Mix, certified reference material, 
TraceCERT®, in dichloromethane (varied conc.), ampule of 1 mL) was purchased from Sigma 
Aldrich (Gillingham, Dorset, UK) with analytes detailed in Table 2.1. All other chemicals used 
in the experiment (mentioned in sections 2.3 – 2.9) were of analytical grade. 
Analyte Concentration 
Methyl butyrate   400 μg/mL 
Methyl hexanoate   400 μg/mL 
Methyl octanoate   400 μg/mL 
Methyl decanoate   400 μg/mL 
Methyl undecanoate   200 μg/mL 
Methyl laurate   400 μg/mL 
Methyl tridecanoate   200 μg/mL 
Methyl myristate   400 μg/mL 
Methyl myristoleate   200 μg/mL 
Methyl pentadecanoate   200 μg/mL 
Methyl cis-10-pentadecenoate   200 μg/mL 
Methyl palmitate   600 μg/mL 
Methyl palmitoleate   200 μg/mL 
Methyl heptadecanoate   200 μg/mL 
the cis-10-Heptadecanoic acid methyl ester 200 μg/mL 
Methyl stearate   400 μg/mL 
trans-9-Elaidic acid methyl ester 200 μg/mL 
the cis-9-Oleic acid methyl ester 400 μg/mL 
Methyl linolelaidate   200 μg/mL 
Methyl linoleate   200 μg/mL 
Methyl arachidate   400 μg/mL 
Methyl γ-linolenate   200 μg/mL 
Methyl cis-11-eicosenoate ≤  200 μg/mL 
Methyl linolenate   200 μg/mL 
Methyl heneicosanoate   200 μg/mL 
cis-11,14-Eicosadienoic acid methyl ester 200 μg/mL 
Methyl behenate   400 μg/mL 
cis-8,11,14-Eicosatrienoic acid methyl ester 200 μg/mL 
Methyl erucate   200 μg/mL 
cis-11,14,17-Eicosatrienoic acid methyl ester 200 μg/mL 
cis-5,8,11,14-Eicosatetraenoic acid methyl ester 200 μg/mL 
Methyl tricosanoate   200 μg/mL 
cis-13,16-Docosadienoic acid methyl ester 200 μg/mL 
Methyl lignocerate   400 μg/mL 
cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 200 μg/mL 
Methyl nervonate   200 μg/mL 
cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 200 μg/mL 
 
Table 2.1 The analytes present in the FAME standard mix (Supelco 37 Component FAME 
Mix, certified reference material, TraceCERT®, in dichloromethane (varied conc.), 
ampule of 1 mL) used in GC-MS experiments. 
2.2 Animals and diets 
Five-week-old male ob/ob mice and their wild-type (C57B1/6J, WT) controls were purchased 
from a commercial breeder (Harlan UK). This study focussed on tissues from male offspring, 
as female offspring are more sensitive to pubertal parameters, such as cycling, estrus and 
vaginal opening, which were all reported [432] to be changed by leptin, and may add 
uncertainty to our metabolism study. Therefore, I controlled for sex differences but did not 
address them in the present study. Mice were housed in a temperature–controlled (24 °C) and 
humidity-controlled (55%) facility, with a 12h:12h (06:00-18:00, 18:00-06:00) light-dark cycle 
and access to water ad libitum. Mice (n=10/age group/genotype) fed a regular chow diet (RCD, 
caloric content: 11.5% fat, 26.9% protein, 61.6% carbohydrate) (RM1, special diet services 
UK) were sacrificed at the age of 2-, 4-, 10- and 14-months. A separate group of mice was 
switched to a custom-produced high-fat diet (HFD, caloric content: 55% fat, 29% protein, 16% 
carbohydrate; fatty acid composition: 27% saturated fatty acid, 48% monounsaturated fatty 
acid, and 25% polyunsaturated fatty acid) (diet code: 829197; special diet services, UK) at 
different stages for various lengths of time and were sacrificed at the age of 2-months (3-week 
high-fat feeding) 4-months (12-week high-fat feeding) and 10 months (12-week high-fat 
feeding). This HFD diet has been previously described [433]. The study also examined the 
effects of obesity and aging on epigenetic profiles, therefore the time points were spread over 
a long period. 4-months was chosen because mice were switched to the HFD only after the 
weaning period (5 weeks) and the initial HFD was shorter for the 2-month old group (only 3 
weeks). 14-months was initially chosen to maximize the influence of aging, but many 14-
month-old mice died during the HFD feeding. At each time point, animals (after overnight 
fasting) were killed by CO2 asphyxiation, and white adipose tissue (from paired gonadal depots 
within the abdominal cavity attached to the epididymis and testes) was rapidly dissected, snap 
frozen in liquid nitrogen and stored at -80C until further analysis. Three ob/ob and three 
control mice at post-mortem were measured by dual-energy X-ray absorptiometry (DEXA, 
PIXImus, Lunar, Madison, WI) to determine body lean and fat mass ([94] conducted by Dr. 
Xinzhu Wang, University of Cambridge.). All animal procedures were approved by the UK 
Home Office and the University of Cambridge and carried out under the supervision of a 
project or personal license holder. 
 
No. Genotype 
Age  
(months) 
Diet No. Genotype 
Age  
(months) 
Diet 
wt 01-10 WT 2 RCD ob 01-10 ob/ob 2 RCD 
wt 11-20 WT 4 RCD ob 11-20 ob/ob 4 RCD 
wt 21-30 WT 10 RCD ob 21-30 ob/ob 10 RCD 
wt 31-40 WT 14 RCD ob 31-40 ob/ob 14 RCD 
wt 41-50 WT 2 HFD ob 41-50 ob/ob 2 HFD 
wt 51-60 WT 4 HFD ob 51-60 ob/ob 4 HFD 
wt 61-70 WT 10 HFD ob 61-70 ob/ob 10 HFD 
 
Table 2.2 Schematic of the study design of the ob/ob and wild-type (C57B1/6J, WT) mice of 
different ages fed with high-fat (HFD) or regular chow diet (RCD).  
 
 
2.3 Lipid Extraction  
2.3.1 Fatty Acids (FAs) and Triacylglycerols (TGs) 
Tissues were extracted using a chloroform-methanol Folch method [434]. ~20 mg frozen 
tissues were pulverized in chloroform-methanol (400 µl; 2:1 v/v) using a TissueLyser (Qiagen), 
then the mixture was sonicated for 10 minutes. Water (80 µl) was added and samples were then 
centrifuged (13,200 rpm, 10 min). The resulting aqueous and organic layers were collected in 
separate glass tubes. The remaining liquid and pellet were separated two further times 
following the same procedure of chloroform-methanol (2:1) addition, sonication, water 
addition, and centrifugation to create a ‘triple extraction’ procedure. The two phases were 
separated, and the aqueous and organic layers from each step of the extraction were collected 
in new glass tubes and combined respectively. Organic extracts were dried overnight in a fume 
hood, and aqueous extracts were evaporated to dryness using an evacuated centrifuge 
(Eppendorf, Hamburg, Germany). Extracts were stored at -20ºC until analysis. 
 
2.3.2 Glycerophospholipids (PCs) and 1-carbon metabolites 
Intact lipids were extracted by a modified Bligh and Dyer (BD) method [435] from adipose 
tissue to separate aqueous-soluble metabolites from lipids. Approximately ~50 mg frozen 
tissue was pulverized in methanol-chloroform (300 µl, 2:1 v/v) using a TissueLyser (Qiagen, 
West Sussex, UK). Then the mixture was sonicated for 10 min. Chloroform-water (1:1) was 
added (100 µl of each component) and samples were then centrifuged (16,600 refs, 20 min). 
The resulting aqueous and organic layers were collected in separate tubes. The remaining liquid 
and tissue pellet were extracted again following the same procedure of methanol-chloroform 
(2:1) addition, sonication, chloroform-water (1:1) addition, and centrifugation. The two phases 
were separated, and the aqueous and organic layers from each step of the extraction were 
combined respectively in tubes to create a ‘double extract’. Organic extracts were dried 
overnight in a fume hood under a stream of nitrogen gas, and aqueous extracts were evaporated 
to dryness using an evacuated centrifuge (Eppendorf, Hamburg, Germany). Extracts were 
stored at -20C until use.  
 
Different solid phase extraction (SPE) methods were tested as a preliminary experiment to 
further separate different fractions of lipids from organic extracts obtained using the method 
above and improve their detection. The optimized pre-treatment method finally chosen is: The 
CHROMABOND® NH2 (3 ml, 500 mg) column was washed by using 10 ml methanol and 
then conditioned using 10 ml hexane before the sample application. The dried organic extract 
was reconstituted in 1 ml n-hexane and slowly aspirated through the column. The fraction of 
cholesteryl esters was firstly eluted with 1 ml hexane. Then all TAGs were eluted from the 
column using 2 ml hexane-ethyl acetate (85:15, v/v). Finally, the column was continuously 
eluted using 1 ml chloroform-methanol (2:1, v/v) and 2 ml methanol to obtain the fractions of 
monoacylglycerides and phospholipids. Each fraction was dried under the flow of nitrogen in 
a fume hood. Dried extracts were stored at -20C until injection. 
 
2.4 GC-MS analysis for total Fatty Acids 
Organic-phase metabolites were derivatized by acid-catalyzed esterification [140]. 
Chloroform-methanol (1:1 v/v;400 µl) and BF3 –methanol (10%; 125µl) (Sigma-Aldrich, 
Dorset, UK) were added to the dried organic phase and incubated at 80 °C for 90 min. Once 
cool, water (500 µl; milliQ) and hexane (1000 µl) were added and samples were vortex-mixed 
for 1 min. The aqueous layer was discarded and the remaining organic layer was evaporated to 
dryness in a fume hood, then reconstituted in hexane (1000 µl) for GC-MS analysis. GC-MS 
analyses were made using a Trace GC Ultra coupled to a DSQ single-quadrupole mass 
spectrometer (ThermoScientific). The derivatized organic samples were injected with a split 
ratio of 50:1 onto a 30 m x 0.25 mm 70 % cyanopropyl polyphenylene-siloxane 0.25 µm TR-
FAME stationary phase column (ThermoScientific). The injector temperature was set to 230 °C 
and helium carrier gas was at a flow rate of 1.2 ml/min. The initial column temperature was 
60 °C for 2 min, increased by 15 °C/min to 150 °C and then increased at a rate of 4 °C /min to 
230 °C (transfer line =240 °C; ion source=250 °C; electron ionization =70 eV). The detector 
was turned on after 240 s, and full-scan spectra were collected using three scans/s over a range 
of 50 to 650 m/z. 
 
GC-MS chromatograms were processed using Xcalibur (version 2.1; Thermo Scientific). Data 
were extracted by the Quan Browser in the Xcalibur and the peaks were integrated and 
normalized so that the total sum of peaks in a chromatogram was set to 10000. Overlapping 
peaks were separated using traces of single ions. Peak assignment was based on mass 
fragmentation patterns matched to the National Institute of Standards and Technology (NIST) 
database of mass spectra (NIST Standard Reference Database 1A. www.nist.gov/srd/). 
Identification of metabolites from organic phase GC-MS analysis was supported by 
comparison with a FAME standard mix (Supelco 37 Component FAME Mix; Sigma Aldrich, 
Gillingham, Dorset, UK) as detailed in Table 2.1, which was injected after every 10 samples. 
For example, a lot of structural information was generated for saturated fatty acids including a 
characteristic McLafferty rearrangement ion at m/z 74, a molecular ion and many other 
fragment ions. PUFAs typically has little or no molecular ion abundance but multiple sites of 
radical cation formation [326]. 
2.5 DI-MS/MS analysis for neutral lipids 
The dried organic phase in part 2.2.1 was reconstituted in methanol/chloroform (1:1,300 µl), 
then an internal standard mix (400 μl, diluted in 1:1 methanol/chloroform; contained 5 μM 1,2-
di-O-octadecyl-sn-glycerol-3-phosphocholine, 10 μM 1,2-di-O-phytanyl-sn-glycerol-3-
phosphoethanolamine, 5 μM N-heptadecanoyl-D-erythro-sphingosylphosphorylcholine, 5 μM 
C8-ceramide, 50 μM undecanoic acid, 5 μM trilaurin and 10 μM β-sitosterol acetate) was added 
and the solution was sonicated for 10 min. 40 µl of the solution was transferred to the 
appropriate well on a glass coated 240 µl low well plate (Plate+ TM, Esslab, Hadleigh, UK) 
with 160 µl of MS-mix (7.5 mm NH4AC IPA: MeOH (2:1)), after which the plate was sealed 
for analysis. 
 
Samples were infused into a Thermo Exactive benchtop Orbitrap (Hemel Hampstead UK), 
using an Advion Triversa Nanomate (Ithaca US). The Nanomate infusion mandrel was used to 
pierce the seal of each well before analysis, after which with a fresh tip, 5 µl of sample was 
aspirated followed by an air gap (1.5 µl). The tip was pressed against a fresh nozzle and the 
sample was dispensed using a 0.2 psi nitrogen pressure. Ionization was achieved by a 1.2 kV 
voltage. The Exactive started acquiring data 20 s after the aspiration of the sample began. Then 
the analysis was stopped and the tip was discarded before a new sample was analyzed. 
Throughout the analysis, the sample plate was kept at 15ºC. The Exactive acquired data from 
185 to 2000 m/z, with a resolution of 100,000, with automatic gain control sat at 3,000,000 – 
initially in positive mode (1.2 kV, 0–1.2 minutes), then in negative mode (-1.5 kV, 1.2–2.3 minutes). 
The maximum filling time of the trap was set at 10.00 ms in positive mode and set at 250 ms 
in negative mode. 
 
A selected subset of samples was infused into a Thermo LTQ Velos Orbitrap Elite (Hemel 
Hempstead UK), using an Advion Triversa Nanomate (Ithaca US) for lipid identification. The 
LTQ-Orbitrap Velos was controlled either manually or set-up using the data-dependent 
precursor selection. Generally, the selected masses were isolated with a 1.5 m/z width in the 
linear ion trap and then fragmented using either the linear ion trap with 35% relative collision 
energy or in the higher–energy Collision-induced Dissociation (HCD) collision cell, with a 
range of collision energies from 5% to 75% relative collision energy. All spectra were recorded 
in the Orbitrap set at 100,000 resolution. 
 
DI-MS chromatograms were processed using Xcalibur (version 2.1; Thermo Scientific). The 
mass data were averaged from the chromatogram for the period of sample injection and the 
“exact masses” were exported; the data points summed between M and M+1, to give variables 
which corresponded to individual peaks, normalized to the total spectral area across all TG 
types and integrated. The average carbon number per chain and average unsaturation were 
computed after identification of the TGs by matching the “exact masses” and MS/MS data to 
those in the LIPID MAPS (http://www.lipidmaps.org/) [367]. ESI generates abundant 
[M+NH4]
+ molecular ions for TGs when ammonium ions are present in the solvent system. 
The side chains were identified by three “diglyceride type ions” in MS/MS spectra ([M+H-
R1CH2COOH-NH3]
+, ([M+H-R1CH2COOH-NH3]
+ and ([M+H-R1CH2COOH-NH3]
+ 
correspond to loss of one esterified fatty acyl group at the sn-1, sn-2, or sn-3 position of glycerol 
as the free carboxylic acid with ammonia). These diglyceride ions can be further decomposed 
by CID to create “monoglyceride” ions (([R2CH2CO]+ or ([R3CH2CO+74]+ ) and the neutral 
loss (difference in mass between the diglyceride ion” and the “monoglyceride ion”) reveals the 
third FA group. 
2.6 UPLC-MS analysis for phospholipids 
Chromatography was performed on an ACQUITY UPLC System (Waters Corporation, Elstree, 
Hertfordshire, UK) equipped with an Acquity UPLC 1.8 μm HSS T3 column (2.1 × 100 mm; 
Waters Corporation) coupled to a Waters Q-Tof Xevo mass spectrometer (Waters MS 
Technologies, Ltd., Manchester, UK). The column temperature was kept at 55°C.  
 
For the analysis of TAGs, the desolvation gas temperature was 3 kV and the cone voltage was 
50 V. The binary solvents were 10 mM ammonium acetate, 0.1% formic acid (Solvent A) and 
analytical grade acetonitrile/isopropanol (1:9) with 10 mM ammonium acetate, 0.1% formic 
acid (Solvent B). The temperature of the sample organizer was set at 4ºC. Mass spectrometric 
data were collected in centroid mode over the mass range of m/z 50-1200 with a scan duration 
of 0.2 s. As lock mass, a solution of 2ng/ µl (50:50 acetonitrile: water) leucine enkephaline 
(m/z 556.2771) was infused into the instrument at 3 µl/min. Dried organic phase samples were 
reconstituted in methanol-chloroform (1:1,100 µl), then diluted 20-fold further prior to 
injection onto the column. The gradient started from 60% A/40%B, reached 100% B in 10 min, 
returned to the initial conditions in 0.1 min and remained there for the following 2 min; the 
eluent flow rate was 0.400ml/min.  
 
The phospholipids extracts (fractions D) described in section 2.3.2 were reconstituted in 200 
µl initial mobile phase (isopropanol/acetonitrile/water, 2:1:1) prior to injection of 3 µl onto the 
column, respectively. A lyso-phosphocholine C17:0 internal standards (in initial mobile phase) 
was spiked into each sample to give a final concentration of 20 μM. The binary solvent system 
used was HPLC-grade acetonitrile: water 60:40, 10 mM ammonium formate (solvent A) and 
HPLC-grade acetonitrile: isopropanol 10:90, 10 mM ammonium formate (solvent B). The 
gradient used was: 0 min, 40% B, 2 min, 43% B, 2.1 min, 50% B, 12 min 54% B, 12.1 min, 
70% B, 18 min, 99% B. The eluent flow rate was 0.400 ml/min. The temperature of the sample 
organizer was set at 4°C. The electrospray source was operated in positive ion mode with the 
source temperature set at 120°C and a cone gas flow of 50 L/h. The desolvation gas temperature 
was 550°C and the nebulizer gas flow rate was set at 900 L/h. The capillary voltage was 2 kV 
and the cone voltage was 30 V. Mass spectrometry data was collected in centroid mode over 
the mass range of m/z 200–1200 with a scan duration of 0.2 s. As lockmass, a solution of 2 
ng/μl leucine enkephaline (m/z 556.2771) in 50:50 acetonitrile: water was infused into the 
instrument at 3 μl/min.  
 
Tandem mass spectrometry was performed as an additional function for data collection to allow 
fragmentation data to be collected. The MS/MS method was operated with a collision energy 
ramp starting at 20 eV and finishing at 40 eV. The data dependent acquisition method was 
performed on a pooled sample, in which the most abundant 5 peaks from a survey scan were 
selected, and the corresponding ions were subjected to MS/MS analysis. 
 
UPLC-MS data were processed using the Micromass Markerlynx Applications Manager 
(Waters Corporation). Peaks were detected, deconvoluted, noise-reduced and integrated, 
and then matched, and retention time aligned across the samples. The ion-intensities for 
each peak were detected and normalized to the total response across all phospholipid types. 
Individual peaks were normalized to the total integrated area of the sample. Lipid species 
were identified using exact mass, tandem mass spectrometry data, and data-dependent 
acquisition (DDA) data. ESI generates both [M+H]+ and [M-H]- ions for PLs, but the polar 
head group typically drives a preference for formation of either positive ion (PC) or 
negative ion (PS, PI, PA, and PG). PE yields both positive and negative molecular ions by 
either the ionization method. The fragment ions observed in positive mode are mostly from 
the neutral losses of the phospho-headgroups or formation of the headgroups ions. For 
example, the [M-NH3CH2CH2HPO4]
+ ([M-140]+) ions were observed in MS/MS spectra 
of PEs due to the neutral losses, while phosphocholine ions with m/z 184 were observed 
for PCs in positive ion mode. 
2.7 Determination of 1-carbon metabolites by UHPLC-SRM-MS 
The aqueous component of the extract described in section 2.3.2 was thoroughly dried under 
nitrogen and reconstituted in 25 µl aqueous 100 mM dithiothreitol (Sigma Aldrich, Haverhill, 
Suffolk, UK) containing the following internal standards at a concentration of 50 µM: [U13C, 
U15N] L-glutamic acid and L-proline (Cambridge Isotope Laboratories, Tewkesbury, MA, UK); 
L-leucine-d10, L-phenyl-d5-alanine and DL-homocysteine-3, 3, 4, 4-d4 (CDN Isotopes, Pointe-
Claire, QC, Canada); L-valine-d8 (Sigma Aldrich).  This mixture was thoroughly vortexed and 
sonicated for 15 mins. at room temperature after which a further 100 µl 10 mM ammonium 
acetate (Sigma Aldrich) was added and the resulting solution transferred into 300 µl liquid 
chromatography vials (Chromacol, Welwyn Garden City, Herts., UK) and capped with PTFE 
screw caps with silicone septa (Agilent Ltd., Stockport, Cheshire, UK). One-carbon cycle 
metabolites were analyzed via a targeted assay using a Thermo Quantiva triple quadrupole 
mass spectrometer coupled to an Ultimate 3000 UHPLC liquid chromatography system 
(Thermo Fisher, Hemel Hempstead, Herts., UK).  A C18PFP column (150×2.1mm, 3µm; 
Advanced Chromatography Technologies, Aberdeen, UK) was used to separate the compounds. 
Mobile phase A consisted of aqueous 0.1% formic acid, and mobile phase B consisted of 0.1 % 
formic acid in acetonitrile. The following gradient was used to separate the compounds: 100% 
A was held for 1.5 mins, followed by a linear increase of B from 0% to 100% over 3 mins with 
a further re-equilibration for 1.5 mins to give a total run time of 6 mins. The flow rate was 400 
µl/min and the injection volume was 2.5 µl. The mass spectrometer was operated in positive 
ion mode with the following parameters: a spray voltage of 3.5 kV, sheath gas 50 arb. units 
auxiliary gas 15 arb., sweep gas 2 arb., ion transfer tube temperature 350°C and a vaporizer 
temperature of 400°C. Compound dependent parameters are listed in Table 2.3 and were 
established by infusion of a 100 nM standard of the relevant compound prepared in a solution 
of 4:1 acetonitrile: water with 0.1% formic acid at a flow rate of 15 µl/min using the automatic 
optimisation protocol available through the Xcalibur software (ThermoScientific, Hemel 
Hempstead, UK). 
 
Compound Precursor 
(m/z) 
Product (m/z) Collision 
Energy (V) 
RF Lens (V) 
Glycine 76.07 48.20 6 30 
Serine 106.08 60.20 10 39 
Cytosine 112.10 95.11 18 84 
Betaine 118.15 58.23 26 67 
Cysteine 122.03 59.14 24 34 
Valine-d8 126.20 80.20 10 41 
Methylcytosine 126.13 109.16 19 78 
Homocysteine 136.18 90.12 10 52 
Homocysteine-
d5 
141.20 95.12 10 52 
Leucine-d10 142.23 96.24 8 35 
Methionine 150.05 61.16 23 36 
Glutamaticacid 
13C515N1 
154.13 89.09 15 47 
Phenylalanine-
d5 
171.12 125.15 13 41 
S-Adenosyl 
Homocysteine 
385.15 136.13 20 73 
S-Adenosyl 
Methionine 
399.44 250.15 16 79 
 
Table 2.3 SRMs and detection parameters for 1-carbon metabolism pathway intermediates and 
relevant internal standards. 
 
UHPLC -MS chromatograms were processed using Xcalibur (version 2.1; Thermo Scientific). 
The mass data were averaged from the chromatogram for the period of sample injection; the 
data points summed between M and M+1, to give variables which corresponded to individual 
peaks. The ion-intensities for peaks of Cysteine and Homocysteine were normalized to the area 
of the internal standard Homocysteine-d5. Ion-intensities for all the other one-carbon 
metabolites were normalized to the area of the internal standard Glutamate acid 13C5
15N1. 
 
2.8 Measurement of DNA Percent Methylation 
DNA was extracted using the QIAamp DNA Mini Kit (Cat. no. 51304) except with some 
modifications:  ~50 mg frozen adipose tissue was pulverized in 180 µl Buffer ATL using a 
TissueLyser (Qiagen, West Sussex, UK) with 5 mm stainless steel beads for 20 s at 30 Hz. The 
sample was centrifuged briefly to ensure that all the tissue debris was at the bottom of the tube. 
20 μl proteinase K was then added to the tube which was incubated for 56°C for 1 h in a shaker 
incubator. Briefly, the 2 ml microtube was centrifuged to remove drops from inside the lid 
before 200 μl Buffer AL was added to the sample, then the solution was mixed again by pulse-
vortexing for 15 s, and incubated at 70°C for 10 min. The 2 ml microtube was briefly 
centrifuged to remove drops from inside the lid. Then the Tissue Protocol in the QIAamp DNA 
Mini Kit (Cat. no. 51304) and QIAamp DNA Blood Mini Kit Handbooks was conducted from 
step 4. 
 
The concentration of DNA was measured by absorbance at 260 nm using a Thermo Scientific 
NanoDrop 2000c UV-Vis spectrophotometer and then diluted to 4 ng/μl using water. OneStep 
qMethyl™ Kit (Catalog No. D5310) was used to determine the methylation status of four genes 
(Lhfpl2, Rgs3, ACSL1, and AKT2). OneStep qMethyl™ Kit was performed on a 
StepOnePlusTM (Cat. No. 4376600, ThermoFisher, Hemel Hempstead, UK) using a Real-Time 
PCR System. The kit contains Human Methylated DNA & Non-methylated DNA Standards 
with an MGMT primer set for validating the effectiveness of the OneStep qMethyl™ system. 
 
Information about these five genes: 
(1) Acsl1: acyl-CoA synthetase long-chain family member 1 [ Mus musculus (house mouse) ] 
 NCBI Gene ID: 14081 
 NCBI Reference Sequence: NC_000074.6 
Base pair size: 65015 bp 
Forward: 5′ - TGC GGC CGC GAC TCC TTA AATA- 3′ 
Reverse: 5′ -AGG GAA ACG AGG CCG TGG AG - 3′ 
(2) Akt2: thymoma viral proto-oncogene 2 [ Mus musculus (house mouse) ] 
 NCBI Gene ID: 11652 
 NCBI Reference Sequence: NC_000073.6 
Base pair size: 47897 bp 
Forward: 5′ - CGT TGC TGC CGC CAG TTC ATA AAT- 3′ 
Reverse: 5′ - GAG CCT CCA GGT CCG TGG TC- 3′ 
(3) Lhfpl2: lipoma HMGIC fusion partner-like 2 [ Mus musculus (house mouse) ] 
 NCBI Gene ID: 218454 
 NCBI Reference Sequence: NC_000079.6 
Base pair size: 137757 bp 
Forward: 5′ - ACC GGA CTG AGC GAC CCT C- 3′ 
Reverse: 5′ - GGC AGG TGA CAA TGA CAT GAC ACA TAT T- 3′ 
(4) Rgs3: the regulator of G-protein signaling 3 [ Mus musculus (house mouse) ] 
 NCBI Gene ID: 50780 
 NCBI Reference Sequence: NC_000070.6 
Base pair size: 143185 bp 
Forward: 5′ - AGC CAA GTC AGG TGG AAA TCT- 3′ 
Reverse: 5′ - CTC CAT GGC GTC CCT GTT- 3′ 
(5) MGMT: O-6-methylguanine-DNA methyltransferase [ Homo sapiens (human)] 
NCBI Gene ID: 4255 
 NCBI Reference Sequence: NC_000010.11 
Base pair size: 303800 bp 
Forward: 5′ - GGT GTG AAA ACT TTG AAG GA - 3′  
Reverse: 5′ - CAC TAT TCA AAT TCC AAC CC - 3′ 
2.9 Microarray analysis of mouse adipose tissue 
RNA was extracted using the RNeasy lipid tissue kit (Qiagen GmbH, Hilden, Germany). 
Approximately 100mg of tissue was used per sample for RNA isolation and procedures were 
carried out according to the manufacturer’s instructions. Extracted RNA was quantified by 
ribogreen and its purity assessed by evaluating absorbance ratios using a Fluostar microplate 
reader (BMG Labtech). The level of degradation of each sample was assessed using a 
bioanalyzer (Agilent, UK). Illumina Bead Station 500 (Illumina Inc., San Diego, CA, USA) 
was used to perform transcriptomics. Approximately 25,600 transcripts were interrogated using 
the MouseRef-8 v2.0 Expression Bead Chip, which was chosen for  mouse whole-genome 
expression profiling The Bead Chip content was derived from the National Center for 
Biotechnology Information Reference Sequence (NCBI RefSeq) database (Build 36, Release 
22), supplemented with probes derived from the Mouse Exonic Evidence Based 
Oligonucleotide (MEEBO) set, as well as exemplary protein-coding sequences described in the 
RIKEN FANTOM2 database.  
2.10 Data analysis methods 
Multivariate statistical analysis was performed within SIMCA 14 (Umetrics, Umea, Sweden). 
The supervised pattern recognition tool partial least squares discriminate analysis (PLS-DA) 
was used. PLS-DA is a regression extension of the unsupervised pattern recognition tool 
principal components analysis (PCA) and finds the maximum covariance between predefined 
classes [436, 437]. The dataset is commonly visualized using scatter plots, which summarise 
the observations by revealing clusters and outliers in the data along the new latent dimensions 
in the data. Loading plots for these models display the variables (metabolites in this thesis) 
responsible for the clustering of the observations. The contribution of each variable to the 
clustering was ranked using the coefficient plot. The robustness of the multivariate model 
generated was assessed by R2 and Q2. R2 shows the percentage of variation explained in the 
model, whereas Q2 indicates the predictive power of the model, which is considered to be 
significant when Q2 > 40%. 
 
The PLS-DA method was also used to link different factors like genotype, age, and diet with 
the profiles of total FAs, TGs, PCs, 1-C metabolites, transcriptomics, and DNA methylation 
data sets. A separate model was built treating genotype, age, and diet as a factor (response 
variable) and lipidomics, 1-C metabolites and transcriptomics data set as a factor (predictor 
variables). For each of the data types (for example total FAs, TGs) we selected variables based 
on variable importance in projection (VIP) scores that estimate the importance of each variable 
in the projection used in a PLS model and is often used for variable selection. A variable with 
a VIP Score close to or greater than 1 can be considered important in the given model. The 
selection of variables was done for genotype, diet, and age and further Venn diagram 
representation was performed to find out which variables were unique to a factor and which 
overlap between the genotype, age and diet factors. Further to correlate between two data sets 
(e.g. FAs vs. TGs; FAs vs. 1 Carbon metabolites data etc), two-way orthogonal PLS (O2PLS) 
was used. O2PLS is a generalization of PLS and in contrast to PLS and OPLS, it is bidirectional 
(i.e. X ↔ Y) [438].  
 
Gene Set Enrichment Analysis (GSEA) is a computational analysis that determines whether a 
priori selected set of genes shows statistically significant, concordant differences between two 
biological states. GSEA was performed using this website 
http://amp.pharm.mssm.edu/Enrichr/. 
  
Chapter 3 Lipidomics of High-fat-diet and ob/ob mouse models of 
obesity 
3.1 Introduction 
Animal models are widely used as a strategy to study the mechanisms of metabolic syndrome 
and how obesity results in different diseases. The metabolic syndrome can be induced in several 
well-established obese mouse strains with high-fat feeding in part caused by ectopic fat 
deposition in animals where the storage of fat is close to its maximum. One of the commonly 
used and well-characterized models of obesity is the ob/ob mouse, a strain of mouse with a 
mutation in the gene for the production of leptin [439-441].  
 
Leptin is a hormone produced in adipocytes, which regulates adipose mass through controlling 
food intake [388], and provides a link between nutritional state and several important 
physiological progressions [389-391]. Mice with mutations in the gene leptin (ob/ob) or its 
receptors (db/db) exhibit noticeable obesity phenotypes [392, 393], increased appetite, 
hyperglycemia, and hyperinsulinemia [394-396]. Moreover, ob/ob mice significantly reduce 
their food intake and body mass and raise energy expenditure back to control levels after the 
administration of leptin [397-399]. Interestingly, ob/ob mice gain extra fat and body mass even 
after being restricted to a diet which is an adequate amount for the maintenance of lean mice, 
indicating that obesity arises because of mechanisms in addition to increased appetite. 
 
Microarray comparisons have demonstrated that gene expression of adipose tissue of ob/ob 
mice are dramatically different from wild-type mice [400], which indicates that leptin 
deficiency not only influences the phenotype of adipose tissue but also has an effect on the 
expression of genes associated with lipid biosynthesis and/or immune system [389, 401]. In 
ob/ob adipose tissue, expression of SREBP-1c and its target genes are reduced compared with 
wild-type animals, but the opposite situation is found in the liver. These alterations in the 
expression of SREBP-1c also have global effects on other genes necessary for fatty acid 
synthesis, including SCD-1 [403], ACC [404], FAS [405], elongase [406], Δ5 and Δ6 
desaturase [407]. Insulin induces SREBP-1c gene transcription [408, 409], synthesis and 
secretion while this process is in part inhibited by leptin. In this manner, leptin deficiency leads 
to an increase in insulin content and expression of SREBP-1c [410, 411], which results in 
increased FAs and TAGs biosynthesis, and also increased the occurrence of diseases such as 
diabetes and fatty liver disease [412].  
 
Previous lipidomic studies only focused on FAs and TGs in adipose tissue. The neutral lipid 
act as an energy reservoir in adipose tissue so it should be most affected by the composition of 
diet and the DNL process in the liver and adipose tissue, while the cell membrane and some 
membrane-bounded cellular components such as the peroxisome and the mitochondria play a 
key role in regulating the energy homeostasis. The compositional differences may reflect in the 
compositions of the lipid building blocks.  
 
3.2 Aims and Objectives 
In this Chapter I aim to: 
i. Profile the lipid changes associated with diet-induced obesity. 
ii. Profile the lipid changes associated with genetic-induced obesity resulting from a failure 
to produce leptin in the ob/ob mouse. 
iii. Compare and contrast the two mouse models 
 
3.3 Materials and Methods 
3.3.1 Animals and diets 
All animals and samples described in Chapter 2 (section 2.2) were used for the lipidomic study 
in this Chapter. The WAT from paired gonadal depots within the abdominal cavity attached to 
the epididymis and testes in male mice was examined in this study not only because of the 
abundance and availability of the WAT, but due to the signaling functions of the WAT (e.g. 
through producing leptin and adipokines) relative to the BAT which seems to mainly respond 
to signals and generates body heat [174, 235, 442]. Further, the visceral adipose tissue is linked 
to insulin resistance [443], type 2 diabetes [444], inflammatory diseases [445], and other 
obesity-related diseases[446]. 
 
3.3.2 Lipid Extraction 
Lipid extraction from mouse adipose tissue was performed according to Chapter 2 (section 2.3).  
 
3.3.3 GC-MS analysis for total Fatty Acids 
GC-MS analysis for total fatty acids from mouse adipose tissue was performed according to 
Chapter 2 (section 2.4). 
 
3.3.4 DI-MS/MS analysis for neutral lipids 
DI-MS/MS analysis for neutral lipids from mouse adipose tissue was performed according to 
Chapter 2 (section 2.5). 
 
3.3.5 UPLC-MS analysis for phospholipids 
UPLC-MS analysis for phospholipids from mouse adipose tissue was performed according to 
Chapter 2 (section 2.6). 
 
3.3.5 Data analysis 
Data analysis were performed according to Chapter 2 (section 2.10). 
 
3.4 Results 
3.4.1 Physiological characteristics 
Physiological characteristics of the mice used in the present study were measured previously 
[94, 95] conducted by Dr. Xinzhu Wang, University of Cambridge. Body weight was increased 
by both ob/ob genotype and high-fat diet in all age groups, while the genotype was dominant 
(Fig 3.1, >70% of the total variation by two-way ANOVA). Body fat composition of the 10-
month (10M) old group was determined by DEXA (Fig 3.2). The lean weights remained stable 
in mice of any genotype fed on any diet, while fat mass significantly increased in ob/ob mice 
fed on an RCD, and wild-type mice fed on HFD compared with the wild-type mice fed on an 
RCD. Interestingly, HFD did not induce further fat weight gain in ob/ob mice (10M-OB-HFD 
= 48 ± 3.1 g, 10M-OB-RCD = 43.5 ± 2.6 g). Hyperglycemia and hyperinsulinemia were 
observed in all ob/ob mice compared with age-matched WT controls as shown in Table 3.1. 
Further, glucose tolerance was impaired in 10M-OB-RCD mice (Fig 3.3A). The ob/ob mice 
fed on an HFD exhibited high levels of glycosylated hemoglobin (HbA1C) as shown in Fig 
3.3B, indicating the long-term effect of a high blood glucose level. 
 
Fig 3.1 Body weight of ob/ob and wild-type (WT) mice on either a regular chow diet (RCD) or a high-
fat diet (HFD) (n=6-10/group). All data are mean ± SEM. Statistical significance with two-way 
ANOVA is indicated by a: genotype-dependent, b: diet-dependent, and c: interaction between genotype 
and diet. # P<0.05, ## P<0.01, ### P<0.001 compared with WT animals on RCD. †P<0.05, ††P<0.01, 
†††P<0.001, compared with ob/ob mice on HFD using Bonferroni’s post-hoc analysis. * P<0.05, 
***P<0.001, compared with WT animals on the same diet using Student’s t-test. This figure was 
redrawn from a previous study [94]. 
 
 
Fig 3.2 Body fat composition determined by dual-energy x-ray absorptiometry (DEXA) (n=3-4/group). 
A: body fat composition of 10-month old animals fed on a regular chow diet (RCD) or a high-fat diet 
(HFD). All data are mean ± SEM. Statistical significance with two-way ANOVA is indicated by a: 
genotype-dependent, b: diet-dependent, and c: interaction between genotype and diet. # P<0.05, ## 
P<0.01, ### P<0.001 compared with WT animals on RCD. †P<0.05, ††P<0.01, †††P<0.001, compared 
with ob/ob mice on HFD using Bonferroni’s post-hoc analysis. * P<0.05, ***P<0.001, compared with 
WT animals on the same diet using Student’s t-test. B: representative scanning images of DEXA of 10-
month old animals fed on either RCD or HFD. [94] 
 
 
Table 3.1 Plasma insulin and glucose levels in ob/ob and wild-type mice. All data are mean ± SEM. * 
P<0.05, **P<0.01, ***P<0.001 compared with WT animals on RCD or HFD using t-test. The data 
was tabulated from a previous study [94, 95]. 
 
 
Fig 3.3A: Glucose tolerance test performed on 10-month old mice fed on a regular chow diet (RCD) 
after overnight fasting (n=5/group). B: HbA1C levels of ob/ob and WT controls on a high-fat diet (HFD) 
(n=5/group). [94] 
3.4.2 Increase of oleic acid in adipose tissue is the key feature of both obesity and aging 
Total FA compositions of the two diets (RCD and HFD) were analyzed by GC-MS (Fig 3.4). 
The percentage of each FA species (relative to the sum of all the FAs) were semi-quantified 
and calculated as shown in Fig 3.5 RCD diet contains much less fat (11.5%) than HFD (55%), 
and is dominated by C18:2ω6 (51.59%) which accounts for more than a half of total fatty acids 
detected. The content of C16:0 (16.35%) and C18:3ω3 are also of a higher percentage 
compared with HFD diet. The HFD diet comprises a relatively diversified distribution of fatty 
acids: C18:2ω6 and C16:0 drop to 34.91% and 12.80% of the total, respectively, while other 
FAs, especially C18:1ω9 (29.38%), account for higher percentages in the HFD diet. I then 
compared the total FA composition in adipose tissues of all the mice with the two diets.  
 Fig 3.4 A representative GC-MS total ion chromatogram (TIC) from the analysis of methyl 
esterification-derivatized organic extracts of the adipose tissue (retention time 4.00–20.00 
minutes). IS, internal standard (D25-tridecanoic acid). Total fatty acids are identified from 
extract retention times, referring to a FAME standard mix and comparison of corresponding mass 
spectrum within the NIST Mass Spectral Library. 
 
 
 Fig 3.5 Total fatty acid (FA) composition in adipose tissues from ob/ob (OB) mice and wild-type (WT) 
controls aged between 2 and 14 months fed by regular chow diet (RCD) and high-fat diet 
(HFD), and total FA composition in the two diets. The color depth indicates the relative content 
of the FA comparing different animal groups (Red means more; blue means less). 
It is obvious in Fig 3.5 that the adipose tissues of RCD-fed wild-type (WT-RCD) mice have 
markedly different total FA compositions compared with the RCD diet itself. The content of 
C18:2ω6 was decreased from 51.59% in the RCD diet to 15.02%-29.72% in adipose tissues of 
WT-RCD mice (P<0.0001 using two-way ANOVA). C18:3ω3 was also decreased from 5.05% 
to 0.56%-1.50% but not significantly (P>0.05) according to the results of two-way ANOVA. 
On the contrary, the percentages of C16:0 (from 16.35% to 19.98%-29.43%), C16:1ω7 (from 
0.63% to 4.41%-7.13%) and C18:1ω9 (from 19.50% to 31.70%-53.23%) were increased in 
WT-RCD mice compared with the RCD diet. The adjusted P-values by Dunnett's multiple 
comparisons test in two-way ANOVA were summarized as below (P<0.05 were in red). These 
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changes suggest that DNL, desaturation by SCDs, and elongation by ELOVL6 play an 
important role in the FA composition of WT-RCD adipose tissues.  
 14:0 16:0 16:1ω7 18:0 18:1ω9 18:2ω6 18:3ω3 Others 
RCD vs. WT-RCD-2 month 0.9974 <0.0001 0.2657 0.9997 <0.0001 <0.0001 0.2176 0.9994 
RCD vs. WT-RCD-4 month 0.9997 <0.0001 0.0932 0.9996 <0.0001 <0.0001 0.3238 0.9999 
RCD vs. WT-RCD-10 month 0.9997 0.0076 0.3659 0.9996 <0.0001 <0.0001 0.2288 >0.9999 
RCD vs. WT-RCD-14 month 0.9998 0.0086 0.1502 0.9943 <0.0001 <0.0001 0.2317 0.9999 
RCD vs. OB-RCD-2 month 0.9971 <0.0001 0.0057 >0.9999 <0.0001 <0.0001 0.2809 0.9997 
RCD vs. OB-RCD-4 month 0.9996 <0.0001 0.0115 0.9974 <0.0001 <0.0001 0.1713 >0.9999 
RCD vs. OB-RCD-10 month >0.9999 0.2879 0.2491 0.947 <0.0001 <0.0001 0.1324 0.9999 
RCD vs. OB-RCD-14 month 0.9997 0.149 0.1551 0.9995 <0.0001 <0.0001 0.1328 >0.9999 
 
Total FA composition of the RCD-fed ob/ob mice (OB-RCD) clearly exhibit further increases 
in C18:1ω9 (from 31.70%-38.05% to 38.22%-53.23%, P<0.0001 in every age group) and a 
considerable decrease in C18:2ω6 (from 26.96%-29.72% to 15.02%-18.24%, P<0.0001 in 
every age group) compared with the WT-RCD group. The adjusted P-values by Dunnett's 
multiple comparisons test in two-way ANOVA were summarized as below (P<0.05 were in 
red). Thus, the efficiency of de novo synthesis of fatty acids was increased in ob/ob mice, 
presumably because of their raised appetite and hence increased consumption of carbohydrates 
from the RCD diet, and further modification related enzymes, such as the Δ6 desaturase FADS2, 
is not enough for the newly synthesized FAs. The newly synthesized 16-carbon FAs (C16:0 
and C16:1ω7) were more in younger (2 and 4 months) OB-RCD mice compared with older (10 
and 14 months) OB-RCD animals, as C18:1ω9 dominated the total fatty acid profile of the 
older animals (over a half).  
 14:0 16:0 16:1ω7 18:0 18:1ω9 18:2ω6 18:3ω3 Others 
WT-RCD-2 month vs. OB-RCD-2 month >0.9999 0.0773 0.2745 0.9998 <0.0001 <0.0001 0.9998 0.9999 
WT-RCD-4 month vs. OB-RCD-4 month >0.9999 0.7573 0.7565 0.6718 <0.0001 <0.0001 0.9976 >0.9999 
WT-RCD-10 month vs. OB-RCD-10 month >0.9999 0.0814 >0.9999 0.9745 <0.0001 <0.0001 >0.9999 >0.9999 
WT-RCD-14 month vs. OB-RCD-14 month >0.9999 0.5309 >0.9999 >0.9999 <0.0001 <0.0001 >0.9999 >0.9999 
However, in the profile of WT-HFD mice, C16:0 (from 23.02%-26.30% to 14.28%-15.81%) 
and C16:1ω7 (from 4.23%-5.34% to 1.63%-2.24%) significantly decreased, whereas C18:1ω9 
(from 31.70%-38.05% to 40.62%-42.79%) and C18:2ω6 (from 26.96%-29.72% to 30.90%-
32.91%) increased in all age groups compared with the corresponding WT-RCD mice at any 
ages. The adjusted P-values by Dunnett's multiple comparisons test in two-way ANOVA were 
summarized as below (P<0.05 were in red). This phenomenon has been pretty obvious in the 
2-month old mice which were switched to HFD only after weaning period (5 weeks) with 
shorter HFD feeding (3 weeks) compared with other groups (3 months). These changes largely 
follow the fatty acid profiles of the HFD itself, showing the adipose tissue is dominated by diet. 
However, adipose tissue from WT-HFD mice still has significantly more C16:0 and C18:1ω9 
and slightly less C18:2ω6 and C18:3ω3 compared with the HFD diet, indicating a certain level 
of de novo lipogenesis.  
 14:0 16:0 16:1ω7 18:0 18:1ω9 18:2ω6 18:3ω3 Others 
WT-RCD-2 month vs. WT-HFD-2 month 0.9998 <0.0001 0.3024 >0.9999 <0.0001 0.0572 0.9242 0.9992 
WT-RCD-4 month vs. WT-HFD-4 month 0.8924 <0.0001 <0.0001 0.8831 <0.0001 <0.0001 0.9966 0.9986 
WT-RCD-10 month vs. WT-HFD-10 month 0.9957 <0.0001 0.0887 0.9910 <0.0001 0.0006 0.9948 0.8609 
 
In OB-HFD mice, the FA composition is a mixture of HFD dietary FAs and de novo 
synthesized FAs. The HFD still exhibited a great effect to increase specific FAs like C18:1ω9, 
C18:2ω6 and C14:0 when compared to OB-RCD mice, while the inability to produce leptin 
also triggered more de novo synthesis of FAs and increased the content of C16:0 and C18:1ω9 
compared with the WT-HFD mice. The adjusted P-values by Dunnett's multiple comparisons 
test in two-way ANOVA were summarized as below (P<0.05 were in red). 
 14:00 16:00 16:1ω7 18:00 18:1ω9 18:2ω6 18:3ω3 Others 
OB-RCD-2 month vs. OB-HFD-2 month >0.9999 <0.0001 0.0005 >0.9999 0.0006 <0.0001 >0.9999 >0.9999 
OB-RCD-4 month vs. OB-HFD-4 month >0.9999 <0.0001 <0.0001 0.9783 <0.0001 <0.0001 0.9999 >0.9999 
OB-RCD-10 month vs. OB-HFD-10 month 0.9985 0.7740 0.8756 0.7417 0.1607 <0.0001 0.9997 0.9964 
WT-HFD-2 month vs. OB-HFD-2 month >0.9999 0.0012 >0.9999 0.9998 0.9452 <0.0001 0.9998 0.9976 
WT-HFD-4 month vs. OB-HFD-4 month 0.9996 0.0005 >0.9999 >0.9999 <0.0001 <0.0001 0.8943 0.9823 
WT-HFD-10 month vs. OB-HFD-10 month >0.9999 <0.0001 0.9581 >0.9999 <0.0001 <0.0001 0.9620 >0.9999 
 
In addition, aging is also associated with more C18:1ω9 in adipose tissue of most of the four 
groups of animals, while C16:0, C18:2ω6 and C18:3ω3 decline in adipose tissue in older mice, 
which means more DNL and FA elongation by ELOVL6 and desaturation by SCDs occurring 
as the mice ages, which is remarkably similar to the FA alteration pattern induced by leptin 
deficiency. Moreover, the FA composition in ob/ob mice is more unstable to the aging factor 
than that in wild-type animals. These suggest there might be some connection between obesity 
and aging in metabolism. The adjusted P-values by Dunnett's multiple comparisons test 
comparing in two-way ANOVA 2-month old mice and 10-month old mice were summarized 
as below (P<0.05 were in red). 
 
14:00 16:00 16:1ω7 18:00 18:1ω9 18:2ω6 18:3ω3 Others 
WT-RCD-2 month vs. WT-RCD-10 month >0.9999 0.3780 >0.9999 >0.9999 0.0014 0.6445 >0.9999 0.9993 
OB-RCD-2 month vs. OB-RCD-10 month 0.9645 <0.0001 0.0740 0.5950 <0.0001 >0.9999 0.9953 >0.9999 
WT-HFD-2 month vs. WT-HFD-10 month >0.9999 0.9683 >0.9999 >0.9999 0.8673 0.9245 >0.9999 0.7703 
OB-HFD-2 month vs. OB-HFD-10 month 0.9994 >0.9999 >0.9999 >0.9999 <0.0001 <0.0001 0.9423 0.9931 
 
The influences on major FAs in adipose tissue are summarized as below:  
 16:0 16:1ω7 18:1ω9 18:2ω6 18:3ω3 
Ob/ob      
HFD      
Aging      
 
3.4.3 Multivariate analysis of lipids in adipose tissues from different mouse models  
Next, neutral lipids (TGs, DGs, and sterols) from all the adipose tissue samples were 
determined by DI-MS. Because neural lipids dominate the adipose tissue and few polar lipids 
can be identified from the DI-MS profile, an SPE-UPLC-MS method was developed to separate 
and detect membrane lipids (lysoPCs, PCs, PEs, PSs) from adipose tissues. Following the Bligh 
and Dyer (BD) method [435, 447] for tissue extraction of both polar and neutral lipids, different 
SPE methods were tested as a preliminary experiment to further separate different fractions of 
lipids and improve their detection. The optimized pre-treatment method as described in section 
2.6 gives four fractions which separated phospholipids well according to the total ion 
chromatography (TIC) (Fig 3.6). The fraction D was used for studying membrane lipids 
(lysoPCs, PCs, PEs, PSs) from adipose tissues. 
 
Fig. 3.6 Total ion chromatographs (TICs) of fractions by the optimized solid phase extraction 
(SPE) method. (A) the fraction of cholesteryl esters; (B) the fraction of 
triacylglycerides; (C) the fraction of monoacylglycerides; (D) the fraction of 
phospholipids. Internal standard: lyso-phosphocholine C17:0.  
D (Phospholipids)
A (Cholesteryl
esters?)
B (Triglycerides)
C (Diglycerides)
Internal Standard
(PC 17:0)
R
e
la
ti
v
e
 a
b
u
n
d
a
n
c
e
 
 
(A) 
 
(B) 
 
(C) 
 
(D) 
 
In total, I systematically measured 157 species in 7 major lipid classes—FA, DG, TG, lysoPC, 
PC, PE, and PS. These metabolites in adipose tissue of the ob/ob and wild-type mice fed on the 
RCD and HFD diets were readily differentiated by two-way orthogonal partial least squares 
(O2PLS-DA, Fig 3.7A first row, Q2=0.850). It is apparent in the O2PLS-DA scores plot both 
the WT-HFD and OB-RCD groups can be separated well from the WT-RCD group along 
directions of the first component (horizontal) and the second component (vertical), respectively. 
The OB-HFD group is closer to the WT-HFD group than to the OB-RCD ones, indicating that 
the genotype does not influence the metabolic profile as much as HFD does, reflecting that the 
composition of the HFD had a more profound effect on the composition of adipose tissue than 
obesity per se. This analysis shows that in the upper right loading plot TG species have the 
widest distribution along both the first and second components, but phospholipids were only 
distributed along the first component (horizontal). This suggests that TGs were altered by both 
genotype and diet, whereas PC composition was influenced more by diet than by genotype (and 
hence contributing to only one component). Applying OPLS, the model for correlating lipids 
with aging was not as strong as the models for genotype and diet (Fig 3.7A second row, Q2 
=0.562). However, it is apparent from the loading plot that the TGs explain aging effects better 
than other lipid species, as TGs have the widest distribution along the first OPLS component 
(horizontal). Furthermore, more OPLS-DA and OPLS models were established in segments 
according to the three factors (diet, genotype, and aging) using each class of these metabolites 
(FA, DG, TG, PC, lysoPC, PE, PS). The table in Fig 3.7B shows how well the lipid data fitted 
the models. All the neutral lipids (FA, DG, and TG) were fitted well in OPLS-DA models that 
differentiate different diets and genotypes (all Q2>0.48), while for the phospholipids only PCs 
could be used to build a good model to differentiate OB/WT mouse genotype. LysoPCs, PEs 
or PSs can be used to build a moderately significant (Q2 >0.4) OPLS-DA model for diet 
comparison. As for age, only the PLS model of TGs has a relatively high Q2 (0.602), while PCs 
produce models with acceptable Q2 values (0.409). Interrogation of the corresponding loadings 
plots and the variable influence on projection (VIP) for these OPLS (-DA) models identified 
individual metabolites responsible for the separation across the two diets, two genotypes and 
ages examined. The validity of these models built by OPLS or OPLS-DA were checked by a 
cross-validation function using a permutation approach within the SIMCA P+ software. The 
ANOVA of the cross-validated residuals (CV-ANOVA) was applied to ensure that these 
models were not over-fitted. As shown in Table 3.2, all the models used for further 
investigation pass validation. For every successive component built for a model, the cross-
validation was calculated until the generation of new components doesn’t improve the model’s 
predictive power. Models with Q2 values greater than 0.4 are considered significantly 
predictive. Fig 3.7C illustrates metabolites changed most significantly with diet, genotype, and 
age from acceptable multivariate models in Fig 3.7B. Moreover, percentages of lipids with the 
same total FA carbons or total FA unsaturation are added up respectively for the seven lipid 
classes in Fig 3.8 (the corresponding significance statistics is in Table 3.3) and Fig 3.9 (the 
corresponding significance statistics is in Table 3.4), to provide weighted average information 
about how individual lipid classes are influenced by elongation and desaturation according to 
genotype, diet and age factors. 
Quantity SS DF MS F p SD 
Genotype 
      
FA 
      
Total corr. 91 91 1 
  
1 
Regression 44.1973 2 22.0987 42.0229 1.41E-13 4.70092 
Residual 46.8027 89 0.525873 
  
0.725171 
DG 
      
Total corr. 91 91 1 
  
1 
Regression 51.1833 6 8.53055 18.2109 1.76E-13 2.92071 
Residual 39.8167 85 0.468432 
  
0.684421 
TG 
      
Total corr. 91 91 1 
  
1 
Regression 79.6603 10 7.96603 56.9019 1.99E-32 2.82242 
Residual 11.3397 81 0.139996 
  
0.37416 
PC 
      
Total corr. 91 91 1 
  
1 
Regression 52.8279 8 6.60349 14.3584 6.21E-13 2.56972 
Residual 38.1721 83 0.459905 
  
0.678163 
Diet 
      
FA 
      
Total corr. 91 91 1 
  
1 
Regression 61.8452 4 15.4613 46.1377 9.59E-21 3.93209 
Residual 29.1547 87 0.335112 
  
0.578889 
DG 
      
Total corr. 91 91 1 
  
1 
Regression 70.3386 6 11.7231 48.2284 2.53E-25 3.4239 
Residual 20.6614 85 0.243075 
  
0.493026 
TG 
      
Total corr. 91 91 1 
  
1 
Regression 80.2061 4 20.0515 161.617 0 4.47789 
Residual 10.7939 87 0.124068 
  
0.352233 
PC 
      
Total corr. 91 91 1 
  
1 
Regression 72.5976 8 9.07469 40.9294 1.10E-25 3.01242 
Residual 18.4024 83 0.221716 
  
0.470867 
Age 
      
TG 
      
Total corr. 91 91 1 
  
1 
Regression 54.7458 8 6.84322 15.6668 8.10E-14 2.61596 
Residual 36.2542 83 0.436798 
  
0.660907 
PC 
      
Total corr. 91 91 1 
  
1 
Regression 37.1973 8 4.64966 7.17291 3.50E-07 2.15631 
Residual 53.8027 83 0.648225 
  
0.805125 
Table 3.2 Results from CV-ANOVA of the OPLS/OPLS-DA models for lipid species changed 
most significantly by genotype/diet/age 
 OPLS (Age)
R2X(cum)=0.462
R2Y(cum)=0.697
Q2(cum)=0.562
Loading Plot
WT RCD
OB HFD
OB RCD
WT HFD
Age
(A)
(B) Genotype (OPLS-DA) Diet (OPLS-DA) Age (OPLS)
R
2
X(cum) R
2
Y(cum) Q
2
(cum) R
2
X(cum) R
2
Y(cum) Q
2
(cum) R
2
X(cum) R
2
Y(cum) Q
2
(cum)
All 0.617 0.946 0.872 0.299 0.931 0.894 0.462 0.697 0.562 
FA 0.181 0.555 0.486 0.297 0.765 0.680 0.164 0.419 0.371 
DG 0.844 0.585 0.562 0.573 0.892 0.881 0.865 0.421 0.368 
TG 0.872 0.905 0.875 0.672 0.892 0.862 0.843 0.665 0.602
PC 0.720 0.686 0.581 0.731 0.852 0.798 0.728 0.612 0.409
lysoPC 0.463 0.434 0.392 0.615 0.658 0.592 0.679 0.476 0.370 
PE 0.324 0.419 0.331 0.740 0.683 0.595 0.489 0.484 0.384 
PS 0.394 0.278 0.192 0.821 0.602 0.447 0.327 0.123 0.056 
(C)
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Fig 3.7 (A) Multivariate analysis of adipose tissues from different mouse models (OB/WT, 
RCD/HFD, 2/4/10/14-month) using all classes of lipids (30-40 samples in each group); 
(B) OPLS-DA and OPLS model for each class of lipids detected in adipose tissue, and 
the specific lipids which changed the most according to these models. (C) Lipid species 
changed most significantly by genotype/diet/age according to the models in (B) 
 
3.4.4 Neutral lipids and phospholipids exhibit opposite changes in chain length and 
unsaturation in ob/ob mice 
As shown in the first row of Fig 3.8, the total content of  16-carbon FAs increased in all 
younger ob/ob groups (2 months and 4-month animals) fed on either RCD or HFD. This could 
be due to the increase in total C16:0 (palmitate) and C16:1ω7 (palmitoleate) which was 
reported in Fig 3.5. On the other hand, the total content of 18-carbon FAs slightly decreased, 
in part because of the decrease of C18:2ω6 off-setting the increase of C18:1ω9 in ob/ob mice. 
Thus, the average per chain length carbon number decreased from 17.49 (WT) to 17.40 (ob/ob) 
(Fig 3.10, the corresponding significance statistics is in Table 3.5). Side chain length also 
decreased in DGs and TGs, due to rise in 32/34-carbon DGs and 50/52-carbon TGs, and a 
decrease in 36-carbon DGs and 54-carbon TGs in most groups (Fig 3.8, second and third rows). 
The average per chain carbon number decreased from 17.49 and 17.42 to 17.44 and 17.39 for 
DGs and TGs, respectively (Fig 3.10A). Interestingly, total content of 16-carbon FAs were 
moderately decreased while total content of 18-carbon FAs increased a bit in adipose tissue of 
older ob/ob mice fed on RCD diet (10 months and 14 months), as C18:1ω9 synthesized from 
DNL induced by aging dominated the total fatty acid profile of older animals (over a half). 
 
The changes in unsaturation of all neutral lipids are much more significant than changes in 
chain length across the individual animal models. The major peak that dominated the FA 
profiles was monosaturated FAs in all ob/ob profiles (Fig 3.9, first row) because of the 
dominance of C18:1ω9 (Fig 3.5). In the left column of Fig 3.7C, it is also obvious that all the 
monosaturated FAs are more in the ob/ob adipose tissue. All other FAs decreased to some 
degree compared with monosaturated FAs, although the saturated FAs didn’t decrease as much 
as polyunsaturated FAs presumably because of increased de novo FA synthesis provided a 
supply of C16:0. Overall this meant the average per chain degree of unsaturation (DU) of FA, 
DG and TG declined markedly from wild-type (1.07, 1.19 and 1.12) to ob/ob mice (0.92, 1.07 
and 1.03) (Fig 3.10B).  
 
Interestingly, phospholipids, especially PCs exhibited a completely opposite trend in ob/ob 
mice. PCs were slightly longer and more unsaturated in ob/ob mice (WT, 17.53, 0.99 vs. OB, 
17.63, 1.12), in particular in older animals (10 months, 14 months) fed on RCD diet and 
younger animals (2 months) fed on HFD diet (Fig 3.10). It is apparent that the most significant 
change in the fifth row of Fig 3.8 is that all the DU>2 PCs increased, forming an even 
distribution in the OB-RCD unsaturation profiles. The left column of Fig 3.9 also demonstrates 
that in spite of the flood of newly synthesized C16:0 and C18:1 from DNL, more highly 
unsaturated FAs (DU>2) are selectively incorporated into PCs, in contrast with the increased 
neutral lipids (FAs, DGs and TGs) with DU<2. There are more fluctuations in the DU of PCs 
in adipose tissue of wild-type animals compared with ob/ob mice, presumably because 
activated DNL by leptin deficiency in ob/ob mice led to more control on the lipid composition. 
LysoPCs and PEs also become more unsaturated in ob/ob (lysoPC 0.73, PE 0.77) compared to 
WT mice (lysoPC 0.71, PE 0.72) in older animals fed on the RCD diet and younger animals 
fed on the HFD diet (Fig 3.10B). Interestingly, the DU of phospholipids was decreased in 
adipose tissue of mice fed on HFD at 10 months. The mechanism to maintain unsaturation of 
membrane lipid may be impaired in old mice fed on HFD. Furthermore, longer FAs (>18 
carbons) were incorporated into the PEs and PSs (Fig 3.8, the sixth and seventh rows), 
compared with other lipids (FA, DG, TG, lysoPC, PC). The PEs containing 38 carbons are the 
dominant species in every PE chain length profile, and the PS profiles have three major 
components (36-carbon, 38-carbon, 40-carbon). For neither phospholipid class was the average 
per chain carbon number less than 18.  
3.4.5 The High-fat diet (HFD) itself is the determining factor for the lipid composition in 
mice adipose tissue 
When examining FA chain length differences (Fig 3.8, the first row), it is consistent with Fig 
3.5 that more 18-carbon FAs and fewer 16-carbon FAs were detected in adipose tissue from 
HFD-fed mice reflecting the FA-content of the diet. This resulted in an elongation for all other 
lipid classes following feeding of HFD. The increases and decreases in side chain length of 
DGs and TGs largely reflects the variations of 16-carbon and 18-carbon FAs (Fig 3.8, the 
second and third rows), e.g. 54-carbon TGs (mostly comprised of three 18-carbon FA chains) 
increased in HFD-fed mice, while 50-carbon TGs (mostly composed of two 16-carbon FAs 
and one 18-carbon FA) and 52-carbon TGs (one 16-carbon and two 18-carbon FA chains) 
decreased when changing the diet from RCD to HFD. The changes of 32, 34, 36-carbon DGs 
in HFD-fed mice adipose tissues are similar to the 50, 52, 54-carbon TGs, respectively. The 
average per chain carbon number in every lipid class increased after HFD feeding (FA, 17.51, 
DG, 17.59, TG, 17.44) compared with the RCD diet (FA 17.37, DG 17.37, TG 17.38) (Fig 
3.10A).  
 
Considering the degree of unsaturation (DU), changes were not as large as those in FA chain 
length of these lipids. As described above, C16:0 and C16:1 decreased, while C18:1, C18:2 
and C18:3 increased across the neutral lipids. The decline in C16:0 resulted in decreases of 
total saturated FA species (Fig 3.9), whereas decreased C16:1 and increased C18:1 contributed 
to a slight increase in the total monounsaturated FAs content. The small increase in C18:2 also 
produced a small rise of lipids whose DU is 2. These changes in unsaturation of FAs were also 
detected in the profiles of DGs and TGs, with increased highly unsaturated TGs (DU>3) and 
DGs (DU>2), and decreased TGs (DU<3) and DGs (DU<2). The average per chain DU of FA, 
DG and TG increased from 0.95, 1.06 and 1.05 to 1.01, 1.22 and 1.12, respectively in HFD-
fed mice compared with RCD-fed ones (Fig 3.10B). 
 
In phospholipids, the chain length changes of lysoPC and PC with diet were similar to those of 
FAs and DGs. While 16-carbon lysoPCs and 32/34-carbon PCs decreased, 18-carbon lysoPCs 
and 36-carbon PCs increased notably in the adipose tissue of HFD-fed mice compared with the 
RCD feeding (Fig 3.8, the fourth and fifth rows). Computed average per chain length carbon 
number of the four phospholipid classes also demonstrate that they have become longer in 
HFD-fed mice (lysoPC, 17.80, PC, 17.65, PE, 18.68, PS, 18.27) in comparison to those in 
RCD-fed mice (lysoPC, 17.64, PC, 17.51, PE, 18.63, PS, 18.13) (Fig 3.10A). Moreover, all the 
membrane lipids exhibit similar trends to neutral lipids to become more desaturated when 
comparing HFD-fed mice with RCD-fed mice (Fig 3.9, the 4th-7th rows). The average per chain 
DU increased from (0.70, 1.03, 0.72 and 0.51) to (0.74, 1.08, 0.78 and 0.57) for lysoPC, PC, 
PE and PS, respectively (Fig 3.10B). 
  
Considering the identified lipids which are most changed by HFD in Fig 3.7C (medium 
column), it is striking that although there are more 18-carbon FAs in HFD-fed mice (red blots), 
all the 20-carbon FAs were increased in RCD-fed mice (blue blots). This reflects the fact that 
adipose tissue from the RCD-fed mice has a more diversified distribution of lipids in part due 
to in vivo DNL and modifications. In HFD-fed mice, most of the FAs stored in adipose tissue 
directly relate to diet with few modifications. Accordingly, a large number of long, highly 
unsaturated TGs were in higher concentration in adipose tissue from RCD-fed mice, even 
though the average chain length and average DU of TGs were greater in HFD-fed mice (18-
carbon FAs and 54-carbon TGs account for a greater proportion in adipose tissue lipid 
composition). More long, highly unsaturated PCs were detected in RCD-fed mice adipose 
tissues but the trend is not as apparent as in the pool of TGs. This suggests some selective 
partition of most dietary FAs incorporated into TGs, so that membrane lipids are more 
determined by DNL and in vivo modifications and less directly by the fat content of the diet. 
3.4.6 Longer triacylglycerides (TGs) and saturated phosphatidylcholines (PCs) 
accumulate in adipose tissue of aged mice 
As discussed previously in Fig 3.5, C18:1 increased while C16:0 decreased sharply with age. 
These total FA changes are mostly reflected in longer-chain containing TGs in aged mice as 
shown in Fig 3.7C. There are more 54-carbon TGs and less 50-carbon TGs in older mice (the 
third row of Fig 3.8). The average per chain carbon numbers of TG in adipose tissue is 17.33, 
17.42, and 17.47 for 2-month, 4-month, and 10-month mice respectively (Fig 3.10A). DGs also 
exhibit a similar trend, containing longer fatty acids (average per chain carbon number: 
17.41<17.47<17.52 for 2, 4, 10-month respectively, Fig 3.10A).  
 
Interestingly, PCs again demonstrated a totally different trend compared with neutral lipids. In 
the bottom right plot of Fig 3.7B, there are more saturated and monounsaturated PCs in older 
mice compared with the equivalent younger animals. The averaged DU of PCs in adipose tissue 
is 1.12, 1.09, and 1.08 for 2-month, 4-month, and 10-month mice, respectively (Fig 3.10B). 
Saturated and DU=1 PCs increased with age while DU=2 PCs decreased with age in WT-RCD, 
OB-RCD, and OB-HFD profiles (the fifth row of Fig 3.9). In the WT-HFD group, the DU=2 
PCs increased in aged mice. One possible explanation is that HFD influences more greatly the 
PC composition of adipose tissue in aged mice. Other phospholipids show a similar trend, 
becoming more saturated (average per chain DU: PE 0.78>0.77>0.76 and PS 0.58>0.50>0.49 
for 2, 4, 10-month respectively, Fig 3.10B).  
 
  
Fig 3.8 Side chain length varies in adipose tissues from ob/ob (OB) mice and wild-type (WT) 
controls aged between 2 and 14 months fed on a regular chow diet (RCD) or a high-fat 
diet (HFD). The values are the percentage relative to the sum of all the lipids of the same 
category (e.g. the sum of all the FAs/DGs/TGs…) 
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Mean Difference (%) 16C-FA 18C-FA 50C-TG 52C-TG 54C-TG 32C-PC 34C-PC 36C-PC 38C-PC 
Genotype 
WT-RCD-4 month vs. OB-RCD-4 month -2.7640 2.6010 -4.0620 0.0185 4.4910 -2.6340 -6.7920 1.7410 5.8280 
WT-RCD-10 month vs. OB-RCD-10 month 2.9280 -3.4950 0.0425 -0.7343 -0.7149 4.1320 0.5932 2.8750 -7.3040 
WT-HFD-4 month vs. OB-HFD-4 month -4.9220 3.2520 -0.1759 -4.4540 0.4872 -5.0680 -3.1080 9.3040 -0.6535 
WT-HFD-10 month vs. OB-HFD-10 month -8.6240 7.9510 -2.2540 -3.4930 4.2640 -10.2600 -5.1570 16.1900 0.2295 
Diet 
WT-RCD-4 month vs. WT-HFD-4 month 15.1600 -14.0700 9.8790 9.8000 -16.8900 3.5120 4.4390 -18.4100 7.8310 
WT-RCD-10 month vs. WT-HFD-10 month 11.3600 -9.7770 5.8420 7.4110 -11.8500 15.7800 10.1700 -21.7900 -5.9000 
OB-RCD-4 month vs. OB-HFD-4 month 13.0000 -13.4200 13.7600 5.3270 -20.8900 1.0790 8.1230 -10.8500 1.3490 
OB-RCD-10 month vs. OB-HFD-10 month -0.1916 1.6680 3.5450 4.6530 -6.8700 1.3830 4.4190 -8.4790 1.6340 
Aging 
WT-RCD-4 month vs. WT-RCD-10 month 3.9270 -4.1750 4.3120 1.0240 -5.9190 -10.2600 -5.1860 2.1440 12.1200 
WT-HFD-4 month vs. WT-HFD-10 month 0.1280 0.1176 0.2747 -1.3650 -0.8776 2.0070 0.5445 -1.2370 -1.6110 
OB-RCD-4 month vs. OB-RCD-10 month 9.6180 -10.2700 8.4160 0.2707 -11.1200 -3.4910 2.1990 3.2770 -1.0130 
OB-HFD-4 month vs. OB-HFD-10 month -3.5740 4.8170 -1.8040 -0.4033 2.8990 -3.1860 -1.5050 5.6480 -0.7281 
 
Adjusted P-value 16C-FA 18C-FA 50C-TG 52C-TG 54C-TG 32C-PC 34C-PC 36C-PC 38C-PC 
Genotype 
WT-RCD-4 month vs. OB-RCD-4 month 0.8183 0.8607 0.3265 >0.9999 0.2053 0.8525 0.0073 0.9828 0.0398 
WT-RCD-10 month vs. OB-RCD-10 month 0.9140 0.8074 >0.9999 0.9999 >0.9999 0.3782 >0.9999 0.8062 0.0037 
WT-HFD-4 month vs. OB-HFD-4 month 0.1457 0.6603 >0.9999 0.1852 >0.9999 0.0968 0.6757 <0.0001 >0.9999 
WT-HFD-10 month vs. OB-HFD-10 month 0.0007 0.0026 0.9549 0.6758 0.4183 <0.0001 0.1825 <0.0001 >0.9999 
Diet 
WT-RCD-4 month vs. WT-HFD-4 month <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.4866 0.1887 <0.0001 0.0003 
WT-RCD-10 month vs. WT-HFD-10 month 0.0003 0.0033 0.0801 0.0070 <0.0001 <0.0001 <0.0001 <0.0001 0.1036 
OB-RCD-4 month vs. OB-HFD-4 month <0.0001 <0.0001 <0.0001 0.0660 <0.0001 0.9993 0.0007 <0.0001 0.9968 
OB-RCD-10 month vs. OB-HFD-10 month >0.9999 0.9812 0.4740 0.1433 0.0027 0.9948 0.2230 <0.0001 0.9857 
Aging 
WT-RCD-4 month vs. WT-RCD-10 month 0.7330 0.6667 0.2204 0.9991 0.0187 <0.0001 0.1031 0.9457 <0.0001 
WT-HFD-4 month vs. WT-HFD-10 month >0.9999 >0.9999 >0.9999 0.9977 0.9999 0.9762 >0.9999 0.9988 0.9935 
OB-RCD-4 month vs. OB-RCD-10 month <0.0001 <0.0001 0.0001 >0.9999 <0.0001 0.6038 0.9454 0.6789 0.9995 
OB-HFD-4 month vs. OB-HFD-10 month 0.4627 0.1143 0.9707 >0.9999 0.7219 0.6469 0.9913 0.0396 >0.9999 
Table 3.3 The mean differences (A) and adjusted P-values (B) when comparing side chain length in the adipose tissues from ob/ob (OB) mice 
and wild-type (WT) controls aged between 4 and 10 months fed on a regular chow diet (RCD) or a high-fat diet (HFD) using the Dunnett's 
multiple comparisons test in two-way ANOVA (P<0.05 were in red). The values are the percentage relative to the sum of all the lipids of the 
same category (e.g. the sum of all the FAs/DGs/TGs…)
(A) 
 
(B) 
 
 Fig 3.9 Side chain unsaturation varies in adipose tissues from ob/ob (OB) mice and wild-type 
(WT) controls aged between 2 and 14 months fed on a regular chow diet (RCD) or 
a high-fat diet (HFD). The values are the percentage relative to the sum of all the 
lipids of the same category (e.g. the sum of all the FAs/DGs/TGs…) 
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Mean Difference (%) 0U-FA 1U-FA 2U-FA 2U-TG 3U-TG 4U-TG 5U-TG 0U-PC 1U-PC 2U-PC 3U-PC 4U-PC 
Genotype 
WT-RCD-4 month vs. OB-RCD-4 month 0.4584 -13.5900 12.3000 -6.4030 -3.3780 5.3960 5.7000 -1.5930 -1.1130 -1.8690 -3.5320 6.9600 
WT-RCD-10 month vs. OB-RCD-10 month 4.5030 -14.5300 9.8970 -3.7650 -6.3520 3.7850 5.5500 4.1740 4.1150 5.6450 -0.4061 -9.1570 
WT-HFD-4 month vs. OB-HFD-4 month -2.3520 -9.5830 10.4700 -0.9616 -2.1010 -0.5938 1.9900 -4.5870 -2.0690 8.7070 0.7126 -3.3370 
WT-HFD-10 month vs. OB-HFD-10 month -5.7470 -15.6700 20.3100 -3.3590 -3.4190 1.7070 4.1820 -9.7790 -11.2100 23.6800 -0.8240 -3.3790 
Diet 
WT-RCD-4 month vs. WT-HFD-4 month 9.5880 -6.8820 -3.0270 4.9120 -1.0220 -2.9790 -3.7980 2.2500 10.2300 -22.0900 -4.6670 12.0100 
WT-RCD-10 month vs. WT-HFD-10 month 5.9990 -0.7747 -4.7160 3.6460 0.6786 -1.8080 -3.3950 14.1700 23.6500 -28.3900 -2.1460 -3.8640 
OB-RCD-4 month vs. OB-HFD-4 month 6.7770 -2.8720 -4.8540 10.3500 0.2548 -8.9690 -7.5090 -0.7442 9.2720 -11.5100 -0.4218 1.7180 
OB-RCD-10 month vs. OB-HFD-10 month -4.2520 -1.9120 5.7010 4.0510 3.6110 -3.8860 -4.7620 0.2190 8.3250 -10.3500 -2.5640 1.9150 
Aging 
WT-RCD-4 month vs. WT-RCD-10 month 4.5290 -6.5680 0.7618 1.7090 -1.5040 -1.8730 -0.5707 -9.5010 -8.2740 0.4545 -1.6030 14.5000 
WT-HFD-4 month vs. WT-HFD-10 month 0.9401 -0.4612 -0.9265 0.4425 0.1961 -0.7021 -0.1671 2.4220 5.1470 -5.8460 0.9173 -1.3760 
OB-RCD-4 month vs. OB-RCD-10 month 8.5740 -7.5090 -1.6410 4.3480 -4.4780 -3.4840 -0.7209 -3.7340 -3.0450 7.9680 1.5230 -1.6150 
OB-HFD-4 month vs. OB-HFD-10 month -2.4550 -6.5480 8.9130 -1.9550 -1.1220 1.5990 2.0250 -2.7710 -3.9920 9.1230 -0.6193 -1.4180 
 
Adjusted P-value 0U-FA 1U-FA 2U-FA 2U-TG 3U-TG 4U-TG 5U-TG 0U-PC 1U-PC 2U-PC 3U-PC 4U-PC 
Genotype 
WT-RCD-4 month vs. WT-RCD-10 month >0.9999 <0.0001 <0.0001 0.1865 0.8866 0.398 0.3245 0.9988 0.9999 0.9966 0.8796 0.1373 
WT-RCD-4 month vs. WT-HFD-4 month 0.8667 0.0003 0.0017 0.7938 0.1674 0.7893 0.3241 0.7763 0.7887 0.4128 >0.9999 0.0154 
WT-RCD-4 month vs. OB-RCD-4 month 0.9862 0.0065 0.0007 >0.9999 0.99 >0.9999 0.9928 0.6143 0.9922 0.0145 >0.9999 0.8929 
WT-RCD-10 month vs. WT-HFD-10 month 0.4714 <0.0001 <0.0001 0.9379 0.9321 0.9989 0.8247 0.0146 0.0023 <0.0001 >0.9999 0.9361 
Diet 
WT-RCD-10 month vs. OB-RCD-10 month 0.0126 0.1996 0.924 0.4893 >0.9999 0.9299 0.7862 0.985 0.001 <0.0001 0.5579 <0.0001 
WT-HFD-4 month vs. WT-HFD-10 month 0.6979 >0.9999 0.7167 0.9065 >0.9999 0.9984 0.9345 <0.0001 <0.0001 <0.0001 0.9964 0.9003 
WT-HFD-4 month vs. OB-HFD-4 month 0.1109 0.9419 0.5418 0.0013 >0.9999 0.0102 0.0626 >0.9999 0.0134 0.0005 >0.9999 0.9983 
WT-HFD-10 month vs. OB-HFD-10 month 0.6726 0.9944 0.2897 0.7251 0.8269 0.7657 0.5311 >0.9999 0.0238 0.0013 0.9728 0.9952 
Aging 
OB-RCD-4 month vs. OB-RCD-10 month 0.8833 0.5214 >0.9999 0.9972 0.9988 0.995 >0.9999 0.0073 0.0349 >0.9999 0.9987 <0.0001 
OB-RCD-4 month vs. OB-HFD-4 month >0.9999 >0.9999 >0.9999 >0.9999 >0.9999 >0.9999 >0.9999 0.9901 0.6164 0.4481 >0.9999 0.9997 
OB-RCD-10 month vs. OB-HFD-10 month 0.0126 0.0496 0.9982 0.6779 0.6435 0.8691 >0.9999 0.8609 0.9489 0.0608 0.9992 0.9989 
OB-HFD-4 month vs. OB-HFD-10 month 0.9752 0.1391 0.0078 0.9935 0.9998 0.9982 0.992 0.9584 0.7659 0.0082 >0.9999 0.9993 
 
Table 3.4 The mean differences (A) and adjusted P-values (B) when comparing side chain unsaturation in the adipose tissues from ob/ob (OB) 
mice and wild-type (WT) controls aged between 4 and 10 months fed on a regular chow diet (RCD) or a high-fat diet (HFD) using the Dunnett's 
multiple comparisons test in two-way ANOVA (P<0.05 were in red). The values are the percentage relative to the sum of all the lipids of the 
same category (e.g. the sum of all the FAs/DGs/TGs…)
(B) 
 
(A) 
 
 Fig 3.10 (A) Average per chain Carbon Number and (B) average per chain Degree of 
Unsaturation (DU) in adipose tissues from ob/ob (OB) mice and wild-type (WT) 
controls aged between 2 and 14 months fed by regular chow diet (RCD) and high-fat 
diet (HFD). The color depth indicates the relative content of the FA comparing 
different animal groups (Red means more; blue means less).  
 
  
Genotype Diet Age FA DG TG LysoPC PC PE PS
2 month 17.33 17.33 17.36
4 month 17.38 17.40 17.36 17.80 17.74 18.76 18.25
10 month 17.44 17.46 17.46 17.54 17.27 18.58 17.81
14 month 17.43 17.46 17.44 17.59 17.22 18.47 17.70
2 month 17.22 17.17 17.22 17.68 17.77 18.84 18.35
4 month 17.29 17.27 17.28 17.59 17.53 18.64 18.39
10 month 17.50 17.48 17.46 17.64 17.51 18.57 18.25
14 month 17.45 17.48 17.46 17.55 17.47 18.60 18.42
2 month 17.47 17.63 17.40 17.89 17.52 18.54 18.01
4 month 17.63 17.65 17.45 17.84 17.73 18.88 18.43
10 month 17.63 17.64 17.49 17.84 17.80 18.89 18.54
2 month 17.41 17.50 17.36 17.76 17.77 18.61 18.38
4 month 17.53 17.62 17.51 17.76 17.60 18.59 18.09
10 month 17.44 17.54 17.48 17.73 17.53 18.63 18.27
OB HFD
RCD
OB RCD
WT HFD
WT
Genotype Diet Age FA DG TG LysoPC PC PE PS
2 month 1.02 1.09 1.11
4 month 1.01 1.14 1.10 0.85 1.18 0.80 0.51
10 month 1.02 1.15 1.11 0.58 0.82 0.62 0.56
14 month 1.03 1.15 1.10 0.53 0.78 0.58 0.75
2 month 0.85 0.92 0.96 0.80 1.26 0.82 0.48
4 month 0.87 0.95 0.95 0.70 1.08 0.74 0.39
10 month 0.96 1.04 1.01 0.72 1.06 0.72 0.42
14 month 0.97 1.06 1.02 0.73 1.07 0.74 0.36
2 month 1.15 1.28 1.15 0.70 0.92 0.66 0.74
4 month 1.13 1.27 1.16 0.80 1.10 0.82 0.55
10 month 1.14 1.26 1.16 0.83 1.18 0.86 0.47
2 month 0.99 1.17 1.09 0.71 1.20 0.86 0.51
4 month 0.97 1.21 1.11 0.70 1.07 0.75 0.55
10 month 0.85 1.14 1.08 0.74 1.05 0.73 0.56
OB HFD
WT HFD
OB RCD
WT RCD
±0.02 ±0.02 ±0.01
±0.02 ±0.08 ±0.01 ±0.07 ±0.10 ±0.10 ±0.15
±0.03 ±0.01 ±0.01 ±0.04 ±0.14 ±0.11 ±0.22
±0.04 ±0.03 ±0.01 ±0.03 ±0.09 ±0.10 ±0.17
±0.02 ±0.02 ±0.01 ±0.02 ±0.02 ±0.02 ±0.05
±0.03 ±0.02 ±0.01 ±0.02 ±0.04 ±0.07 ±0.11
±0.02 ±0.02 ±0.02 ±0.03 ±0.05 ±0.04 ±0.06
±0.04 ±0.02 ±0.01 ±0.01 ±0.04 ±0.07 ±0.09
±0.01 ±0.04 ±0.00 ±0.04 ±0.1 ±0.09 ±0.11
±0.06 ±0.01 ±0.01 ±0.02 ±0.05 ±0.06 ±0.11
±0.04 ±0.01 ±0.01 ±0.04 ±0.01 ±0.05 ±0.11
±0.03 ±0.01 ±0.01 ±0.02 ±0.01 ±0.07 ±0.04
±0.03 ±0.01 ±0.01 ±0.02 ±0.03 ±0.05 ±0.05
±0.03 ±0.05 ±0.03 ±0.05 ±0.05 ±0.04 ±0.12
±0.02 ±0.02 ±0.01
±0.02 ±0.06 ±0.01 ±0.08 ±0.09 ±0.05 ±0.07
±0.02 ±0.01 ±0.01 ±0.09 ±0.12 ±0.07 ±0.07
±0.03 ±0.03 ±0.01 ±0.03 ±0.08 ±0.04 ±0.03
±0.02 ±0.01 ±0.01 ±0.03 ±0.01 ±0.01 ±0.04
±0.02 ±0.01 ±0.00 ±0.03 ±0.04 ±0.03 ±0.05
±0.01 ±0.01 ±0.01 ±0.02 ±0.02 ±0.02 ±0.04
±0.02 ±0.01 ±0.01 ±0.04 ±0.03 ±0.04 ±0.03
±0.01 ±0.03 ±0.01 ±0.07 ±0.09 ±0.05 ±0.02
±0.01 ±0.01 ±0.00 ±0.07 ±0.04 ±0.04 ±0.04
±0.01 ±0.01 ±0.00 ±0.08 ±0.01 ±0.02 ±0.07
±0.02 ±0.01 ±0.00 ±0.02 ±0.01 ±0.02 ±0.03
±0.03 ±0.01 ±0.00 ±0.02 ±0.03 ±0.02 ±0.03
±0.02 ±0.03 ±0.01 ±0.03 ±0.04 ±0.03 ±0.07
(A)
(B)
Adjusted P-value FA DG TG LysoPC PC PE PS 
Genotype 
WT-RCD-4 month vs. WT-RCD-10 month 0.9826 0.8252 0.9915 0.2662 0.3054 0.9048 0.7730 
WT-RCD-4 month vs. WT-HFD-4 month 0.9994 >0.9999 >0.9999 0.9659 0.1686 >0.9999 <0.0001 
WT-RCD-4 month vs. OB-RCD-4 month 0.9681 >0.9999 0.9953 0.9864 0.8642 0.0266 0.0045 
WT-RCD-10 month vs. WT-HFD-10 month 0.5053 0.9728 >0.9999 0.9668 0.1044 0.1487 0.1241 
Diet 
WT-RCD-10 month vs. OB-RCD-10 month 0.1535 0.1995 0.9693 >0.9999 >0.9999 0.8637 0.4392 
WT-HFD-4 month vs. WT-HFD-10 month 0.7945 0.6194 >0.9999 0.0915 <0.0001 0.0565 <0.0001 
WT-HFD-4 month vs. OB-HFD-4 month 0.0949 0.0015 0.1549 0.6473 0.9956 0.9994 0.0322 
WT-HFD-10 month vs. OB-HFD-10 month 0.9934 0.9946 >0.9999 0.9696 >0.9999 0.9963 >0.9999 
Aging 
OB-RCD-4 month vs. OB-RCD-10 month 0.9993 0.9982 0.9376 0.0814 <0.0001 0.5124 <0.0001 
OB-RCD-4 month vs. OB-HFD-4 month >0.9999 >0.9999 >0.9999 >0.9999 0.9938 >0.9999 0.9464 
OB-RCD-10 month vs. OB-HFD-10 month 0.2118 0.2509 0.4669 0.9997 >0.9999 0.9933 0.8284 
OB-HFD-4 month vs. OB-HFD-10 month 0.9488 0.9859 >0.9999 >0.9999 0.9901 0.9998 0.4670 
 
 
  
 
 
   
Adjusted P-value FA DG TG LysoPC PC PE PS 
Genotype 
WT-RCD-4 month vs. WT-RCD-10 month 0.2794 0.0263 0.1726 0.1566 0.6937 0.9805 0.4952 
WT-RCD-4 month vs. WT-HFD-4 month 0.9952 0.5265 0.6429 0.3403 0.0036 0.7353 0.2448 
WT-RCD-4 month vs. OB-RCD-4 month 0.1412 0.9805 0.9956 0.6744 0.9994 0.8875 >0.9999 
WT-RCD-10 month vs. WT-HFD-10 month 0.0005 0.5051 0.9226 0.8431 0.4182 0.5083 0.8446 
Diet 
WT-RCD-10 month vs. OB-RCD-10 month 0.6211 0.4949 0.9715 0.9854 0.8894 0.9999 0.9922 
WT-HFD-4 month vs. WT-HFD-10 month 0.8330 0.6211 0.9924 0.0054 <0.0001 0.0123 0.8434 
WT-HFD-4 month vs. OB-HFD-4 month 0.7052 0.0001 0.0885 >0.9999 >0.9999 >0.9999 0.1408 
WT-HFD-10 month vs. OB-HFD-10 month 0.5388 0.6597 0.9048 0.9999 >0.9999 >0.9999 0.2158 
Aging 
OB-RCD-4 month vs. OB-RCD-10 month >0.9999 >0.9999 >0.9999 0.0003 <0.0001 0.0677 0.9785 
OB-RCD-4 month vs. OB-HFD-4 month >0.9999 >0.9999 >0.9999 0.9992 0.9201 0.9990 0.8946 
OB-RCD-10 month vs. OB-HFD-10 month 0.7708 0.7635 0.9838 >0.9999 >0.9999 >0.9999 0.9997 
OB-HFD-4 month vs. OB-HFD-10 month 0.4657 0.8815 0.9984 0.9954 0.9999 >0.9999 >0.9999 
Table 3.5 The adjusted P-values when comparing (A) average per chain Carbon Number and 
(B) average per chain Degree of Unsaturation (DU) in adipose tissues from ob/ob (OB) 
mice and wild-type (WT) controls aged between 4 and 10 months fed by regular chow 
diet (RCD) and high-fat diet (HFD) using the Dunnett's multiple comparisons test in 
two-way ANOVA (P<0.05 were in red). 
 
 
  
(A) 
 
(B) 
 
The major changes in intact lipids in adipose tissue are summarized as below:   
 
Neutral Lipids Membrane Lipids 
Diversity 
Sum FA Carbons Unsaturation Sum FA Carbons Unsaturation 
Ob/ob 
   
( but  in HFD-10M) 
 
(but  in HFD-10M) 
- 
HFD      
Aging  -   - 
 
3.5 Discussion 
Lipids in adipose tissue are derived from either dietary lipids or DNL and subsequent 
modifications. When fed with the RCD diet, which only has 11.5% fat and over a half of this 
is accounted for by C18:2, DNL plays a significant role in determining the adipose FA 
composition and results in a dominant content of C16:0, C16:1, and C18:1, while there is 
relatively low proportion of C18:2 in the WT-RCD adipose tissues. DNL is further activated 
in ob/ob mice fed on either RCD or HFD as leptin deficiency leads to mice eating more food 
and taking in higher carbohydrate from the diet. The activated DNL resulted in shorter and 
more saturated neutral lipids, dominated by C18:1 rather than other newly synthesized FAs 
(C16:0, C16:1 and C18:0). This indicates that increased carbohydrate consumption in the 
leptin-deficient ob/ob mice triggers not only DNL through ACC and FAS but also desaturation 
by SCDs and elongation by ELOVL6. The domination of C18:1 also indicates that further FA 
modification occurs at a slower pace in ob/ob mice, ‘flooding’ the tissue with newly 
synthesized FAs. The activities of Δ5-eicosatrienoyl-CoA desaturase and Δ6-
oleoyl(linolenoyl)-CoA desaturase are reported to be associated with hyperglycemia and non-
alcoholic steatohepatitis, and palmitate can compete with ω-6 linoleic and ω-3 α-linolenic acids 
for FADS2 mediated Δ6-desaturation [448-450].  
 
Numerous studies have shown that the consumption of dietary MUFAs like oleate (C18:1ω9), 
as opposed to saturated fats such as palmitate (C16:0), is protective for insulin resistance and 
metabolic dysfunctions [451, 452]. However, it is also reported that elevated SCD activity 
within adipose tissue is closely coupled with the development of insulin resistance [453]. Tan 
et al. [454] demonstrated that 18-carbon and ∆9 desaturated TGs, especially oleate, were 
increased in ob/ob mice. They suggested that the protective effects of MUFA-rich diets cannot 
work by simply increasing the body’s oleate levels and it may be due to a selective partitioning 
for the DNL-synthesized oleate toward specific metabolic processes, as opposed to dietary 
oleate per se. It is also possible that increasing the body’s oleate levels benefits metabolic health, 
and the enhancement of oleate in ob/ob mice may be just a compensatory mechanism to 
maintain normal cellular function through the regulation of the ratio of monounsaturated to 
saturated fatty acids in conditions of overfeeding induced obesity and increased total fat weight. 
Actually, many metabolic alterations in obesity which were thought to be pathological 
mechanisms may be protective in response to nutrient excess [455]. In addition, Tan et al. found 
that the AdTG-ob/ob mice which had increased SCD ratios but decreased Elovl6 ratios in 
adipose tissue were more obese but relatively metabolic healthy compared with the ob/ob mice, 
while the AKT2 KO mice which are lean but insulin resistant have bigger Elovl6 ratios but not 
significantly changed SCD ratios compared with wild-type mice. This suggests SCD activity 
is changed in response to the altered DNL. The more FAs synthesized by the body through 
DNL, the more SCD activity is activated to alleviate the harmful effects of adiposity. The 
decreased Elovl6 activity in AdTG-ob/ob mice (compared with ob/ob mice) indicates that 
Elovl6 cannot be regulated in response to the DNL activity in the same manner as SCD, and is 
more likely to be directly influenced by insulin. It has been reported that the Elovl6 activity 
could be thermogenically regulated in BAT and the Elovl6 KO mice have impaired 
thermogenic capacity [442] which could be tested in the future. Nevertheless, the strategy of 
producing more C18:1 cannot fully compensate dysfunction caused by a declining proportion 
of essential FAs (n-3 and n-6 FAs) such as linoleate (C18:2ω6). Another compensatory 
protective mechanism for over nutrition-induced obesity is to maintain normal membrane 
phospholipid composition. 
 
Increased C16:0 and C18:1ω9, and dropped C18:2ω6 led to relatively short and saturated 
neutral lipids (FAs, DGs, TGs) in ob/ob adipose tissue fed on any diet through an increase in 
16-carbon FAs, 32-carbon DGs and 50-carbon TGs, and a decrease in 18-carbon FAs, 36-
carbon DGs and 54-carbon TGs. However, membrane lipids, especially the PCs, become 
longer and more unsaturated in ob/ob mice. More unsaturated FAs are incorporated into 
membrane lipids in ob/ob mice to maintain the fluidity and normal function of cell membrane 
against increased DNL. What is more, many HUFA species have been found to increase in PC 
species (Fig 3.7C). HUFAs, in contrast to MUFAs and precursor PUFAs, are usually found in 
membrane lipids as components of phospholipids where they contribute to the maintenance of 
membrane fluidity and sensitivity to hormones, and also regulate gene expression through 
various transcription factors, such as the PPAR receptors, liver-X receptor, HNF4, and SREBP-
1c [40, 175, 456]. Generally, saturated fatty acids make the membrane bilayer less fluid and 
inactive, which in turn has consequences for protein function and membrane transport [168], 
whereas unsaturated fatty acids result in a more plastic membrane and improve the function of 
membrane receptors and sensitivity to hormones [169, 170]. The geometry of the cis-double 
bond induces a bend in the molecule, thereby precluding rigid lipid bilayers. One process of 
high relevance to T2DM is glucose transport across the membrane which may be influenced 
by membrane fluidity [171]. There have been studies reporting the relationship between 
membrane fluidity of erythrocytes and insulin sensitivity in hypertensive subjects [172], and 
also changes in the composition of membrane lipids associated with increased insulin 
sensitivity in skeletal muscles after physical training [173]. However, a study in rat brown 
adipose tissue [174] showed that the increase of mitochondrial activity in this tissue was related 
to phospholipid composition changes rather than to membrane fluidity. PUFAs result in an 
even greater increase in plasticity of membranes [40, 175], and have been associated with 
improved cardiac function following arrhythmias.  
 
This could be another protective mechanism to maintain normal function and membrane 
fluidity of adipocytes when there is a large consumption of carbohydrates activates and 
increased DNL activity in ob/ob mice. The FA composition of the cell membrane plays an 
essential role in metabolic syndrome and a variety of cardiovascular diseases [457, 458]. 
Generally, saturated fatty acids make the bilayer membrane less fluid and then inactive, while 
polyunsaturated fatty acids result in a more plastic membrane and improved function of 
membrane receptors and sensitivity to hormones. The sensitivity of adipocytes to insulin could 
depend on the composition of their plasma membrane, and greater membrane fluidity improves 
the incorporation of GLUT4, which results in increased glucose uptake. Interestingly, this 
protective mechanism seems to be impaired in adipose tissue of mice fed on HFD at the age of 
10 months, presumably through oxidative damage from long-term HFD diet [459, 460]. 
 
The adipose tissues of WT-HFD mice exhibited similar FA composition to that of the HFD 
diet, except there was a moderate increase in C16:0 and C18:1 which comes from DNL. Dietary 
C18:1 and C18:2 led to a significant increase of 18-carbon FAs and DU=1 FAs and DU=2 FAs 
in WT-HFD adipose tissues compared with WT-RCD mice, making the average composition 
of all neutral lipids (FAs, DGs, TGs) longer and more unsaturated the following feeding of 
HFD. Under the HFD diet all the four classes of phospholipids (lysoPCs, PC, PE, and PS) 
exhibited the same changes in direction as neutral lipids becoming longer and more unsaturated. 
However, the diversification of lipids decreased significantly in HFD-fed mice due to the 
domination of the few dietary FA species consumed in the diet. HFD-fed mice have decreased 
very long (>18 carbon) and highly-unsaturated (DU>2) FAs incorporated in both neutral and 
membrane lipids, which could impair the normal functions of adipose tissue. Thus, the HFD-
induced adiposity might be more harmful than the ob/ob-induced obesity because the 
regulation effects of transcription factors on DNL, elongation, and desaturation are less 
effective when most of the FAs incorporated into complex lipids are directly incorporated from 
diets. Moreover, the high-fat diet produces oxidative stress in cells. Wang [95] demonstrated 
that myocardial mitochondrial dysfunction was detectable in OB-HFD mice (3 months), much 
earlier than in OB-RCD mice (14 months), which might also act in adipose tissue as discussed 
in the next Chapter. 
 
Aged mice seemed to have more C18:1ω9 and less C16:0 in their adipose tissue no matter in 
which genotype or diet group, which led to increases in long-chain TGs as the mice aged. Long-
chain TGs seem to be easily stored in adipose tissue and are less consumed compared with 
short-chain TGs, and thus, they accumulate with age. Interestingly, the Elovl6 ratios are 
reported to be related to insulin resistance, but the deletion of Elovl6 does not prevent the 
development of insulin resistance or fatty liver disease [461]. Other lipids didn’t change as 
significantly as the TGs did, with the exception of more saturated PCs, which appeared more 
in older mice. This could impair membrane fluidity and decrease the incorporation of insulin 
or GLUT4 receptors. Both of these effects might contribute to the increased risk of T2DM 
which accompanies the normal aging process.  
3.6 Conclusions 
This chapter demonstrated that FA de novo synthesis was activated in ob/ob mice by leptin 
deficiency. In contrast to the shorter and more saturated TGs from DNL, more unsaturated PCs 
are synthesized in ob/ob mice to maintain the fluidity and normal function of cell membrane 
against increased de novo synthesis. However, this protective mechanism can be impaired by 
the long-term administration of HFD, presumably through oxidative damage. Moreover, most 
of the lipids stored in the adipose tissue of HFD-fed mice are assembled directly using dietary 
fatty acids, which dramatically decreased the diversity of lipid composition. Longer TGs and 
saturated PCs accumulated in adipose tissue of aged mice, which increases susceptibility to 
metabolic diseases. These characteristic changes nicely complement previous lipidomic studies 
only focused on FAs and TGs in adipose tissue, and depict a more comprehensive metabolic 
network profile in adipose tissue.  
  
Chapter 4 Transcriptomics demonstrates that the peroxisome, 
AMPK, and PPARγ pathways are most perturbed in adipose tissue 
during the progression of obesity and during aging 
4.1 Introduction 
The previous Chapter focused on lipid profiling of adipose tissue from animal models of 
genetic and/or diet-induced obesity, and how aging interacts with this process. The 
predominance of oleate (C18:1ω9), the main product from a combination of DNL, elongation 
by ELOVL6 and desaturation by SCDs, is the key feature of both obesity and aging. However, 
despite the dominance of oleate in terms of total fatty acid content, neutral lipids (FAs, DGs, 
TGs) and phospholipids (lysoPCs, PCs, PEs, PSs) exhibited different patterns in chain length 
and unsaturation. Increased DNL resulted in a decrease in both total chain length and degree 
of unsaturation of neutral lipids in genetic-induced obesity resulting from a failure to produce 
leptin in the ob/ob mice. In contrast, more elongated and desaturated phospholipids 
accumulated in adipose tissue of ob/ob mice compared with wild-type controls, but then 
decreased in the older ob/ob animals fed on HFD, where previous studies have shown the 
combination of both an HFD and the ob/ob genotype induced metabolic dysfunctions in a range 
of tissues [94, 95, 462]. The chain length and degree of unsaturation of phospholipids also 
decreased moderately during aging, while TGs with longer chain lengths accumulated in 
adipose tissue of aged mice. Moreover, the HFD repressed lipid biosynthesis and decreased the 
diversity of all the lipids in adipose tissue. Overall, these results suggest a presumably 
protective mechanism associated with the desaturation of membrane lipids in adipose tissue for 
maintaining metabolic functions in the initiation of obesity, which becomes impaired when the 
mice become too obese and as they age. However, the regulatory pathways behind these 
mechanisms are still unknown. In this Chapter, changes at the transcriptional level resulting 
from genetic-induced obesity, diet-induced obesity, and aging were compared and contrasted. 
Gene Ontology (GO, http://www.geneontology.org) and Kyoto Encyclopaedia of Genes and 
Genomes (KEGG, http://www.kegg.jp) enrichment analysis were used to depict 
comprehensive molecular changes across the network, correlating the processes of obesity and 
aging.   
 
GO is an international standardized gene function classification system. The aim is to establish 
a language standard that can be applied to various species to define and describe the functions 
of genes and proteins and to be updated as research proceeds on these genes. GO is divided 
into three levels of ontology: molecular functions (MF), biological processes (BP), and cell 
composition (CC). The basic unit of the GO database is the ‘term’, and each term corresponds 
to a function or attribute. The software used for GO enrichment analysis is GOseq 
(http://www.bioconductor.org/packages/release/bioc/html/goseq.html). This method is based 
on the Wallenius non-central hypergeometric distribution. Compared with the ordinary 
hypergeometric distribution (Hyper-geometric distribution) algorithm, this method considers 
the probability of individual extraction from one class is different from the probability of 
selecting it from outside of this class, and this difference of probability is estimated from the 
different preference to the length of the gene, which can be more accurate to calculate the 
probability of a differential gene enriched GO term.   
 
The expression of different genes is coordinated with one another in vivo in order to result in a 
function. KEGG is a system for gene function analysis and provides a genome information 
database. The basic unit of the KEGG database is Pathway. It is helpful to the study of gene 
expression information to consider it as a whole network with integrated queries of metabolic 
pathways. By means of Pathway enrichment [463, 464], the major biochemical metabolic 
pathways and signal transduction pathways behind the differentially expressed genes can be 
determined.  
 
4.2 Aims and objectives 
In this Chapter I aim to: 
i. Profile the transcriptomic changes associated with genetic-induced obesity resulting from 
a failure to produce leptin in the ob/ob mouse. 
ii. Profile the transcriptomic changes associated with diet-induced obesity. 
iii. Profile the transcriptomic changes associated with aging. 
iv. Compare and contrast the influence of obesity and aging on adipose tissue 
v. Correlate the transcriptomic changes with lipid changes described in the previous Chapter. 
4.3 Materials and Methods 
4.3.1 Animals and diets 
We compared changes at both 2 months and 10 months of age as this time point had both genotypes 
and diets. 40 adipose tissue samples as described in Chapter 2 (section 2.3) were randomly selected 
(5 in each group of 8 for different genotype (ob/ob or wild-type), diet (RCD or HFD) and aging 
(2 months or 10 months)), as shown below: 
 
Samples Genotype 
Age  
(months) 
Diet Samples Genotype 
Age  
(months) 
Diet 
5 WT 2 RCD 5 ob/ob 2 RCD 
5 WT 10 RCD 5 ob/ob 10 RCD 
5 WT 2 HFD 5 ob/ob 2 HFD 
5 WT 10 HFD 5 ob/ob 10 HFD 
 
4.3.2 Sample preparation and microarray analysis 
RNA extraction and microarray analysis of mouse adipose tissue were performed according to 
Chapter 2 (section 2.9).  
 
4.3.3 Statistical analysis 
Statistical analyses were performed using the software R (R software environment for 
statistical computing; http://www.R-project.org). Samples of adipose tissue were matched for 
genotype (ob/ob or wild-type), diet (RCD or HFD) and aging (2 months or 10 months) to 
calculate the p-value of the difference of gene expression. The genes with the level of 
significance P < 0.05 were used for GO and KEGG enrichment analysis.  
 
The National Center for Biotechnology Information Reference Sequence (NCBI RefSeq) 
database (Build 36, Release 22) was used for gene annotation. For the GO enrichment analysis, 
GOseq (version 1.22.0), topGO (version 2.22.0), GO.db (version 3.2.2), and Kyoto 
Encyclopaedia of Genes and Genomes (KEGG, kobas 2.0, http://www.kegg.jp) were used 
within software tools within packages in R (https://www.r-project.org/).  
 
The hypergeometric test / Fisher's exact test was used to find enriched pathways from 
differentially expressed genes, compared with the whole transcriptome background. The Q-
value for multiple testing were calculated using an optimized FDR correction method defined 
by the Benjamini–Hochberg method. 
4.4 Results 
4.4.1 Overview and correlation of the transcriptomic changes in adipose tissue ob/ob 
genotype, HFD diet intake, and aging factors 
To better understand what molecular changes were associated with the lipidomic patterns 
detected in the two mouse strains fed on two diets at different ages, a transcriptomic study was 
conducted to compare the differences in gene expression of adipose tissues using the Illumina 
MouseRef-8 v2.0 BeadChip which targets approximately 25,600 well-annotated RefSeq 
transcripts, equating to over 19,100 unique genes. Gene expression was compared using a 95% 
(p<0.05) confidence interval for each factor (genotype, diet, and age). As a result, a total of 
5341 genes were found to be changed in expression significantly (Table 4.1). The majority of 
these genes were associated with the ob/ob genotype, while fewer transcriptomic changes were 
found resulting from an HFD. The severity of obesity (as shown in Chapter 3.4.1) may be a 
reason for this discrepancy. Aging changed the expression of more genes in ob/ob mice 
compared with wild-type animals. This suggests the aging process might be accelerated in 
obese mice, which is consistent with the fact that obese people are more likely to be exposed 
to insulin resistance and metabolic diseases while those with a normal range of BMI tend to 
have a longer life expectancy. This will be discussed in greater detail below.  
 
Transcriptomic changes associated with each factor (genotype, diet, and aging) were compared 
across the different groups. Keeping diet and age consistent across comparisons, genotype 
resulted in significant changes in more than 1000 genes in either of the four group comparisons 
(comparing different genotypes in the groups of RCD-2, RCD-10, HFD-2, and HFD-10). 
Interestingly, there were more genes down-regulated (1565) than up-regulated (498) by ob/ob 
genotype in the HFD-10 group, while ob/ob genotype resulted in more genes upregulated in 
the other 3 groups (1219, 819 and 1251 in the RCD-2, HFD-2 and RCD-10 group, respectively). 
The HFD diet did not exhibit such a significant effect on gene expression patterns of the wild-
type mice until they get old (311 genes significantly changed by HFD in the WT-10 group), 
while expression of 761 genes was altered by HFD in adipose tissue of ob/ob mice even in 2-
month-old mice (OB-2). This early-onset of the influence of HFD could be attributed to the 
rapid accumulation of fat as demonstrated in Chapter 3.4.1. Aging resulted in significantly 
more changes in gene expression in ob/ob mice compared with the wild-type controls, 
indicating the association between obesity and accelerated the aging process. Interestingly, the 
expression of more (758) genes was up-regulated by the aging factor in the OB-RCD group 
compared with the number of genes up-regulated in the OB-HFD group (309). In contrast, 
many as 1119 genes were down-regulated by aging in the OB-HFD group, while only 321 
down-regulated in the OB-RCD group. 
 
Comparison  Gene GO_MF GO_CC GO_BP 
WT vs OB 
RCD-2 
All 2,077 134 153 1,024 
 858 16 36 50 
 1,219 119 137 1,173 
HFD-2 
All  1,086   112   140   1,112  
  267   2   15   2  
  819   121   138   1,207  
RCD-10 
All  1,895   133   133   1,314  
  644   8   22   15  
  1,251   165   160   1,591  
HFD-10 
All 2,063 80 126 700 
 1,565 44 88 431 
 498 37 90 431 
RCD vs HFD 
WT-2 
All 2 - - - 
 - - - - 
 2 - - - 
OB-2 
All 311 19 58 386 
 120 - 6 7 
 191 12 67 309 
WT-10 
All 761 59 85 419 
 248 1 22 - 
 513 76 99 596 
OB-10 
All 1 - - - 
 1 - - - 
 - - - - 
2-month vs 
10 month 
WT-RCD 
All 5 - - - 
 2 - - - 
 3 - - - 
WT-HFD 
All 80 - - - 
 14 - - - 
 66 - - - 
OB-RCD 
All 1,079 90 104 1,078 
 321 5 13 46 
 758 91 111 1,055 
OB-HFD All 1,428 48 105 599 
 1,119 24 71 303 
 309 22 80 249 
Table 4.1 The number of genes of which expression is significantly changed (p-value < 0.05) 
by genotype/diet/aging in each group and the Gene Ontology (GO) terms enriched 
from the genes. In total 5341 different genes were found to be changed significantly 
(p < 0.05). MF: molecular function, CC: cellular component, BP: biological process. 
The color means increased (red) or decreased (blue) by OB/HFD/aging.  
In order to explore the correlation between transcriptomic changes from different factors, the 
number of genes simultaneously changed in any two of the 12 groups with 95% (p<0.05) 
confidence interval were calculated as shown in Table 4.2. Expression of many genes was 
changed in the same direction (increase/decrease) by ob/ob genotype in the RCD-2, RCD-10, 
HFD-2 groups. However, 435 genes were down-regulated in ob/ob mice fed on HFD diet in 
the 10 month age group (HFD-10), but are expressed more in adipose tissue of ob/ob mice in 
the RCD-2 group, compared with the corresponding wild-type mice (Table 4.2). This suggests 
some pathways upregulated by leptin deficiency and overfeeding in the younger mice cannot 
be activated to a greater extent for older animals fed on an HFD.  
 
Considering the overlap of the alterations induced by genotype and diet-caused obesity on the 
transcriptomic pattern, a number of genes were found to be changed in the same direction 
(increased/decreased) in adipose tissues of ob/ob and HFD-fed animals. These were the 
pathways influenced by both the HFD diet and ob/ob genotype and will be discussed in the 
next Chapter. The only exception is that there were very few genes changed by HFD that are 
influenced also by genotype in the HFD-10 group. The down-regulated genes in adipose tissue 
of ob/ob mice in the HFD-10 group were related to different pathways compared with the genes 
influenced by an HFD. 
 
There are more genes up or down-regulated both by aging and genotype compared with those 
influenced by both genotype and diet. 902 genes were down-regulated by aging in the OB-
HFD group and also by genotype in the HFD-10 group (the low right rectangle in Table 4.2). 
209 genes were both up-regulated in the two situations. Interestingly, the influence of age on 
the OB-HFD mice was also very different compared with the effect of genotype on adipose 
tissue of mice in the RCD-2 group (431 genes were down-regulated by aging in the OB-HFD 
group but up-regulated by ob/ob genotype in the RCD-2 group). Some pathways inhibited in 
the aging process were also down-regulated by ob/ob genotype in the HFD-10 group but up-
regulated by ob/ob genotype in the RCD-2 group. 
 
There is some intriguing similarity observed between aging influence and the HFD effect. 
Among the 758 genes up-regulated by aging in the OB-RCD group, there were 175 of them 
up-regulated by HFD in the WT-10 group, and 111 of them were also up-regulated by HFD in 
the OB-2 group. However, the similarity was not observed in the OB-HFD group. 
 Table 4.2 The genes of which expression were down-regulated () or up-regulated () simultaneously by any two of the three influence factors 
(OB genotype, HFD diet, and 10-month age compared with WT, RCD, 2-month, respectively) in different groups. The color depth is 
corresponding to the number of genes. The blue boxes indicate that a large number of genes (431 and 902) changed both by genotype 
and aging in the corresponding groups, and expression of 435 genes was changed in different directions by OB genotype in HFD-10 and 
RCD-2 groups. 
 858  
 -  1219
 83    -  267  
 3      395  -  819
 102  24    74    1      644  
 12    364  1      515  -  1251
 49    435  5      109  148  10    1565
 39    64    6      79    -  141  -  498  
 -  -  -  -  -  -  -  -  -  
 -  2      -  1      -  -  -  -  -  2      
 14    17    11    -  53    -  38    -  -  -  120  
 -  72    -  106  1      124  10    36    -  1      -  191  
 67    2      51    -  154  -  9      4      -  -  21    -  248  
 3      238  -  276  -  372  57    37    -  -  -  78    -  513  
 -  1      -  1      -  1      -  -  -  -  -  -  -  -  1      
 -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  
 1      -  -  -  -  1      -  -  -  -  -  -  -  -  -  -  2      
 -  2      -  -  1      -  -  1      -  -  -  -  1      -  -  -  -  3      
 6      -  14    -  2      -  -  -  -  -  -  -  5      -  -  -  -  -  14    
 -  38    -  62    -  27    27    -  -  -  -  3      -  28    -  -  -  -  -  66    
 15    85    5      13    166  1      183  -  -  -  66    -  20    8      -  -  -  -  -  5      321  
 28    170  -  302  1      625  6      142  -  -  -  111  -  175  -  -  -  -  -  13    -  758  
 19    431  -  179  76    38    902  1      -  -  16    17    2      59    1      -  -  -  -  30    143  2      1119
 41    16    15    24    3      65    -  209  -  -  2      16    4      14    -  -  -  -  -  1      -  87    -  309  
                       
WT-HFD
OB-RCD
WT vs OB RCD vs HFD 2 month vs 10 month
RCD-2 HFD-2 RCD-10 HFD-10 WT-2 OB-2 WT-10 OB-10 WT-RCD WT-HFD OB-RCD OB-HFD
2 month
vs
10 month
WT
vs
OB
RCD
vs
HFD
RCD-2
HFD-2
RCD-10
HFD-10
WT-2
OB-2
WT-10
OB-10
WT-RCD
OB-HFD
4.4.2 Gene Ontology (GO) enrichment analysis reveals the different regulation of 
inflammatory and metabolic pathways in adipose tissue of ob/ob mice fed on an HFD 
Fig 4.1 illustrates the biological themes annotating genes differentially expressed in adipose 
tissue of ob/ob mice compared with the wild-type controls in four groups in terms of RCD/HFD 
diet and 2 month/10 month aging, indicated by GO categories using the Molecular Function 
(MF), Cellular Component (CC) and Biological Process (BP) ontologies.  
 
The genes upregulated in adipose tissue of ob/ob mice across the comparisons were mostly 
annotated by extracellular, vesicle and membrane-bound CC themes, while the majority of the 
downregulated ones were associated with intracellular CC ontologies, in particular, organelle 
and cytoplasm themes. Interestingly, a lot of genes downregulated in adipose tissue of ob/ob 
mice at the age of 10 months were annotated by some CC mitochondrial themes, while some 
genes down-regulated in 2-month ob/ob mice were associated with the nucleus and 
nucleoplasm. This suggests that changes in transcription factors directly affecting the nucleus 
preceded mitochondrion dysfunction in adipose tissue during both the progression of obesity 
and aging as reviewed in some other studies [465, 466]. Moreover, 10-month age ob/ob mice 
fed on HFD exhibited fewer changes in genes with catalytic activity annotated, such as 
oxidoreductase and transferases. 
 
The genes up-regulated in ob/ob mice in the RCD-2, HFD-2 and RCD-10 groups are annotated 
mostly by functional themes associated with the immune system, inflammation, and signaling 
processes, compared with the wild-type controls. The phosphorus metabolic process was also 
significantly up-regulated in adipose tissue of ob/ob mice in the RCD-3 group. Interestingly, 
the BP ontologies enriched in ob/ob mice of the HFD-10 group exhibited significantly up-
regulation of metabolism-associated pathways, while most of the inflammation-related 
pathways were moderately up-regulated. Most of the down-regulated genes associated with the 
ob/ob genotype in all four comparisons were annotated by different kinds of metabolic GO 
themes.  
 
 Fig 4.1(A) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the ob/ob mice (OB) 
compared with wild-type controls (WT) in four groups fed on regular chow diet (RCD) at 
the age of 2 month. *The corrected p-value of this GO term calculated by the FDR 
correction method of Benjamini and Hochberg [467] is less than 0.05. 
WT > OB
WT < OB
Mice fed on RCD at 2 months of age: 
 
Fig 4.1(B) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the ob/ob mice (OB) 
compared with wild-type controls (WT) in four groups fed on high-fat diet (HFD) at the age 
of 2 month. *The corrected p-value of this GO term calculated by the FDR correction 
method of Benjamini and Hochberg [467] is less than 0.05. 
WT > OB
WT < OB
Mice fed on HFD at 2 months of age: 
 
Fig 4.1(C) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the ob/ob mice (OB) 
compared with wild-type controls (WT) in four groups fed on regular chow diet (RCD) at 
the age of 10 month. *The corrected p-value of this GO term calculated by the FDR 
correction method of Benjamini and Hochberg [467] is less than 0.05. 
WT > OB
WT < OB
Mice fed on RCD at 10 month of age: 
 
Fig 4.1(D) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the ob/ob mice (OB) 
compared with wild-type controls (WT) in four groups fed on high-fat diet (HFD) at the age 
of 10 month. *The corrected p-value of this GO term calculated by the FDR correction 
method of Benjamini and Hochberg [467] is less than 0.05. 
WT > OB
WT < OB
Mice fed on HFD at 10 months of age: 
GO terms enriched by genes significantly up-regulated or down-regulated by HFD diet are 
shown in Fig 4.2. There was no GO terms significantly enriched in the WT-2 and OB-10 groups 
with the threshold of adjusted p-value > 0.05. In the OB-2 group, adipose tissue from mice fed 
on the HFD diet was significantly annotated by extracellular and membrane-bounded CC terms. 
However, intracellular cellular component GO terms were not enriched by the genes down-
regulated by the HFD diet in the OB-2 group. The contrast is more obvious in the group of 10-
month wild-type mice, in which intracellular CC terms such as nuclear parts were enriched for 
the genes down-regulated by HFD diet. There were a smaller number of transcription factors 
influenced by the HFD diet compared with the ob/ob genotype, in part because DNL and related 
metabolic pathways were inhibited when adipose tissue directly stored lipid components of the 
HFD diet.  
 
The BP terms annotating genes up-regulated by HFD in the OB-2 group were predominantly 
signaling and cytokine-related biological process, while in the WT-10 group the inflammatory 
and immune system-related BP terms dominated. Adipose tissue from ob/ob mice fed on HFD 
at the age of 2 months indicated markers of pro-inflammatory status and resembled many of 
the inflammatory changes in the old wild-type mice fed on HFD. The genes down-regulated in 
adipose tissue of mice fed on HFD were associated with metabolic processes in both the OB-2 
and WT-10 groups, compared with the corresponding animals fed on RCD. 
 Fig 4.2(A) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the HFD-fed ob/ob 
mice at the age of 2 months compared with RCD-fed controls. *The corrected p-value of 
this GO term calculated by the FDR correction method of Benjamini and Hochberg [467] 
is less than 0.05. 
RCD < HFD
RCD > HFD
 
Fig 4.2(B) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the HFD-fed wild-type 
mice at the age of 10 months compared with RCD-fed controls. *The corrected p-value of 
this GO term calculated by the FDR correction method of Benjamini and Hochberg [467] 
is less than 0.05. 
RCD < HFD
RCD > HFD
The influence of aging on gene expression of WAT as determined by annotated GO terms is 
shown in Fig 4.3. Interestingly, the aging factor resulted in significant differences in ob/ob 
mice compared with wild-type mice, as discussed previously. Interestingly, most of the GO 
terms significantly influenced by aging are also affected by the ob/ob genotype as shown in 
Fig 4.1. The genes down-regulated in older animals were annotated by intracellular CC terms, 
especially organelles such as the mitochondrion, whereas extracellular and membrane-bounded 
cellular component GO terms were enriched in the 10-month ob/ob mice fed on an HFD, 
compared with corresponding 2-month controls. BP terms associated with different metabolic 
pathways, in particular, lipid metabolism-related pathways, predominated in adipose tissue of 
all the younger groups of ob/ob mice. The genes up-regulated by aging in adipose tissue of 10-
month old ob/ob mice fed on RCD were annotated by mostly the immune system and cell-cell 
adhesion processes GO terms, but this pattern disappeared in the OB-HFD group in which the 
metabolic processes predominated again. 
 
 Fig 4.3(A) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the 10-month ob/ob 
mice fed on RCD (10M) compared with the 2-month controls (2M). *The corrected p-value 
of this GO term calculated by the FDR correction method of Benjamini and Hochberg [467] 
is less than 0.05. 
2M < 10M
2M > 10M
 
Fig 4.3(B) The TOP 30 GO Molecular Function (MF), Cellular Component (CC) and Biological 
Process (BP) ontologies annotating genes differentially expressed in the 10-month ob/ob 
mice fed on HFD (10M) compared with the 2-month controls (2M). *The corrected p-value 
of this GO term calculated by the FDR correction method of Benjamini and Hochberg [467] 
is less than 0.05. 
2M < 10M
2M > 10M
4.4.3 KEGG pathway enrichment analysis reveals the different regulation of 
inflammatory and metabolic pathways in adipose tissue of ob/ob fed on HFD 
To further explore the specific pathways regulated by the ob/ob genotype, HFD diet, and aging 
factors, KEGG Pathway Enrichment analysis was conducted among the different groups. The 
Q-values calculated by Benjamini and Hochberg FDR correction indicated the significance of 
each enriched pathway. The inflammatory and immune system pathways dominated the up-
regulated terms. The Q-values of KEGG pathways annotating the genes significantly changed 
by genotype/diet/aging factors is summarized in Table 4.3. As shown by the shade of every 
cell, these pathways can be clustered in two typical expression patterns: inflammation-related 
pathways, and metabolic pathways. All the inflammation-related pathways were significantly 
up-regulated by the ob/ob genotype in all but the HFD-10 group, by the HFD diet in the WT-
10 group and by aging in the OB-RCD group. It is interesting that the ob/ob genotype, the HFD, 
and aging didn’t increase inflammation in the HFD-10 group, OB-10 group and OB-HFD 
group, respectively. One possible reason is that inflammation is already upregulated in these 
adipose tissues and cannot be aggravated anymore.    
 
The KEGG pathways annotated by genes up-regulated by the ob/ob genotype in adipose tissue 
of younger (2 months) mice fed on RCD were associated with the lysosome, phagosome, and 
diseases associated with inflammation and immune system. In other groups, the ob/ob genotype 
also activated signaling pathways that play a key role in the immune system, such as toll-like 
receptor, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
chemokine signaling pathways. Incorrect regulation of these proteins has been linked to cancer, 
inflammatory and autoimmune diseases, viral infection, and improper immune development.  
 
The KEGG pathways enriched by genes significantly up- or down-regulated by HFD diet and 
aging are also similar to those enriched by ob/ob genotype. Inflammatory pathways and 
remodeling associated with organelles like the phagosome and lysosome pathways were up-
regulated by the HFD diet in WT-10 and HFD-2 groups, indicating accumulation of fat either 
by aging or overfeeding could increase the inflammatory response. 
 
The influence of aging on the OB-RCD group is similar to that of ob/ob genotype and HFD 
diet, causing the upregulation of inflammatory and remodeling pathways, for example, the 
lysosome, B cell and T cell receptor signaling pathway, Osteoclast differentiation, 
Hematopoietic cell lineage, NF-kappa B signaling pathway and Rheumatoid arthritis pathways. 
However, aging no longer demonstrated an obvious effect on the inflammation-related 
pathways in OB-HFD mice, but demonstrated significantly down-regulated peroxisome and 
metabolic pathways in general, including carbon metabolism and fatty acid metabolism which 
are significantly down-regulated in both OB-RCD and OB-HFD groups. 
 
Some of the metabolic pathways (peroxisome, carbon metabolism, fatty acid metabolism, and 
steroid biosynthesis) were up-regulated in the ob/ob genotype for the RCD-2 group and by 
aging in wild-type animals. However, most of the metabolic pathways were down-regulated by 
the ob/ob genotype in aged mice and by aging in ob/ob mice. This is in accordance with the 
correlation results of gene expression shown in Table 4.2 that many genes up-regulated by the 
ob/ob genotype in the RCD-2 group were down-regulated by ob/ob genotype in HFD-10 group, 
and also down-regulated by aging in adipose tissue of ob/ob mice. In order to elucidate what 
the underlying mechanisms could be for the reversion of these pathways, all the pathways 
changed significantly (adjusted p-value < 0.05) by genotype in RCD-2 and HFD-10 groups, 
and by aging in OB-HFD group were investigated. Most of the key genes of lipid metabolic 
pathways (Table 4.4) were inhibited by combining obesity and aging. To further elucidate the 
regulating network, changes of genes from Peroxisome, AMPK signaling pathways, insulin 
pathways, and PPAR signaling pathways are illustrated in Fig 4.4-4.6. It is apparent that a lot 
of important genes of the four key lipid pathways were up-regulated by leptin deficiency in the 
RCD-2 group, but down-regulated in the HFD-10 group and by aging in the OB-HFD group. 
 
 Table 4.3 Q-values of KEGG pathways annotating the genes significantly down-regulated 
(blue) or up-regulated (red) by ob/ob genotype / HFD diet / aging factors. The shade 
represents the significance of the enrichment of the pathway indicated by Q-value 
(showed by the color depth) calculated by the FDR correction method of Benjamini 
and Hochberg.  
 
 
                       
Metabolic pathways 0.93 1.00 0.88 1.00 0.00 1.00 0.00 1.00 1.00 1.00 0.63 0.88 0.05 1.00 1.00 1.00 1.00 0.19 0.49 0.94 0.01 1.00 0.00 0.94
Peroxisome 1.00 0.01 0.83 1.00 0.11 1.00 0.00 1.00 1.00 1.00 0.61 0.87 0.43 1.00 1.00 1.00 1.00 0.02 1.00 1.00 0.17 1.00 0.00 1.00
Valine, leucine and isoleucine degradation 1.00 1.00 1.00 1.00 0.98 1.00 0.00 1.00 1.00 1.00 0.76 1.00 0.78 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.87 1.00 0.01 0.94
Carbon metabolism 0.99 0.49 1.00 1.00 0.98 1.00 0.00 1.00 1.00 1.00 0.61 1.00 0.39 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.35 1.00 0.01 0.98
AMPK signaling pathway 0.98 1.00 0.83 1.00 0.98 1.00 0.01 1.00 1.00 1.00 0.61 1.00 0.78 1.00 1.00 1.00 1.00 1.00 1.00 0.70 0.27 1.00 0.51 0.94
Fatty acid metabolism 1.00 0.42 0.83 1.00 0.24 1.00 0.01 1.00 1.00 1.00 0.63 1.00 0.50 0.84 1.00 1.00 1.00 1.00 1.00 1.00 0.12 1.00 0.01 0.94
Non-alcoholic fatty liver disease (NAFLD) 0.98 1.00 0.83 1.00 0.98 1.00 0.01 1.00 1.00 1.00 0.76 0.87 0.88 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.92 1.00 0.78 0.99
Propanoate metabolism 1.00 0.77 1.00 1.00 0.98 1.00 0.09 1.00 1.00 1.00 0.72 1.00 0.39 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.10 1.00 0.26 0.94
Butanoate metabolism 0.73 1.00 0.83 1.00 0.79 1.00 0.13 1.00 1.00 1.00 0.72 1.00 0.39 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.27 1.00 0.26 0.94
Glycine, serine and threonine metabolism 0.72 1.00 0.83 1.00 0.34 1.00 0.17 1.00 1.00 1.00 0.76 1.00 0.78 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.07 1.00 0.63 1.00
Glutathione metabolism 0.72 1.00 0.00 1.00 0.06 1.00 0.26 1.00 1.00 1.00 1.00 0.87 0.05 1.00 1.00 1.00 0.01 1.00 0.10 1.00 0.87 1.00 0.99 1.00
Glyoxylate and dicarboxylate metabolism 0.89 1.00 1.00 1.00 0.79 1.00 0.26 1.00 1.00 1.00 0.61 1.00 0.78 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.27 1.00 0.78 1.00
Pyruvate metabolism 0.98 1.00 0.83 1.00 0.79 1.00 0.26 0.94 1.00 1.00 0.61 1.00 0.44 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.21 1.00 0.62 0.91
Steroid biosynthesis 1.00 0.17 1.00 0.20 0.98 1.00 0.44 1.00 1.00 1.00 1.00 1.00 1.00 0.84 1.00 1.00 1.00 1.00 1.00 0.64 0.01 1.00 0.15 1.00
Metabolism of xenobiotics by cytochrome P4500.98 0.99 0.00 1.00 0.00 1.00 0.47 1.00 1.00 1.00 1.00 1.00 0.05 1.00 1.00 1.00 0.01 1.00 1.00 1.00 0.88 1.00 1.00 0.94
Drug metabolism - cytochrome P450 0.89 1.00 0.01 1.00 0.06 1.00 0.54 1.00 1.00 1.00 1.00 1.00 0.22 1.00 1.00 1.00 0.01 1.00 1.00 1.00 0.83 1.00 1.00 1.00
Glycerophospholipid metabolism 0.99 1.00 1.00 1.00 0.20 1.00 0.54 1.00 1.00 1.00 1.00 0.76 0.80 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.49 1.00 0.26 0.94
Biosynthesis of unsaturated fatty acids 1.00 0.96 0.68 1.00 0.98 1.00 0.70 1.00 1.00 1.00 0.72 1.00 0.78 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.27 1.00 0.26 0.94
Dorso-ventral axis formation 1.00 1.00 1.00 1.00 0.98 1.00 0.90 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.07 1.00 1.00 1.00
Ribosome 1.00 1.00 0.88 1.00 0.98 1.00 1.00 0.00 1.00 1.00 1.00 0.87 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.96 1.00 1.00 0.00
Mineral absorption 0.89 1.00 0.83 1.00 1.00 1.00 1.00 0.04 1.00 1.00 1.00 0.87 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.92 1.00 0.99 0.31
FoxO signaling pathway 0.89 0.98 0.88 0.53 0.98 0.84 1.00 1.00 1.00 1.00 0.64 0.82 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.69 0.92 0.03 1.00 0.94
Systemic lupus erythematosus 1.00 1.00 1.00 0.02 0.98 0.20 1.00 0.93 1.00 1.00 1.00 0.69 0.88 0.02 1.00 1.00 1.00 1.00 1.00 1.00 0.92 0.34 0.99 0.94
Regulation of actin cytoskeleton 0.98 0.88 0.83 0.03 0.98 0.18 1.00 1.00 1.00 1.00 0.79 0.72 1.00 0.26 1.00 1.00 1.00 1.00 0.13 0.64 0.92 0.19 1.00 0.94
Leukocyte transendothelial migration 1.00 0.64 1.00 0.25 0.98 0.11 1.00 1.00 1.00 1.00 0.81 0.71 1.00 0.01 1.00 1.00 1.00 1.00 1.00 0.64 0.90 0.05 0.99 0.94
Viral myocarditis 1.00 1.00 1.00 0.47 1.00 0.09 1.00 1.00 1.00 1.00 1.00 0.74 0.80 0.05 1.00 1.00 1.00 1.00 1.00 0.64 1.00 0.05 1.00 0.94
Fc gamma R-mediated phagocytosis 1.00 0.50 1.00 0.04 0.98 0.07 1.00 0.70 1.00 1.00 0.76 0.76 0.80 0.38 1.00 1.00 1.00 1.00 1.00 0.64 1.00 0.01 1.00 0.78
Allograft rejection 1.00 1.00 1.00 0.24 1.00 0.05 1.00 1.00 1.00 1.00 1.00 0.77 0.78 0.09 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.03 1.00 1.00
Antigen processing and presentation 1.00 1.00 1.00 0.24 0.98 0.03 1.00 1.00 1.00 1.00 1.00 0.31 0.80 0.05 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.10 1.00 0.94
Natural killer cell mediated cytotoxicity 1.00 0.99 1.00 0.09 0.98 0.03 1.00 1.00 1.00 1.00 0.81 0.87 0.86 0.25 1.00 1.00 1.00 1.00 1.00 0.69 1.00 0.02 1.00 0.98
Salmonella infection 1.00 0.42 0.83 0.02 0.98 0.03 1.00 0.85 1.00 1.00 1.00 0.69 1.00 0.17 1.00 1.00 1.00 1.00 0.10 0.64 0.92 0.01 1.00 0.94
Legionellosis 0.82 0.96 1.00 0.01 0.98 0.02 1.00 0.50 1.00 1.00 1.00 0.77 0.78 0.38 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.05 1.00 0.94
HTLV-I infection 1.00 1.00 0.88 0.06 0.98 0.02 1.00 1.00 1.00 1.00 0.76 0.76 1.00 0.25 1.00 1.00 1.00 1.00 1.00 0.87 0.92 0.07 1.00 0.94
Inflammatory bowel disease (IBD) 1.00 0.96 1.00 0.32 1.00 0.01 1.00 1.00 1.00 1.00 0.76 0.77 0.78 0.88 1.00 1.00 1.00 1.00 1.00 1.00 0.92 0.05 1.00 1.00
Cell adhesion molecules (CAMs) 1.00 1.00 0.88 0.19 1.00 0.01 1.00 1.00 1.00 1.00 1.00 0.74 1.00 0.09 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.15 1.00 0.99
Malaria 1.00 0.10 1.00 0.29 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.25 1.00 1.00 1.00 1.00 1.00 0.69 1.00 0.10 0.97 0.94
Chagas disease (American trypanosomiasis)1.00 0.31 0.83 0.03 0.98 0.00 1.00 0.94 1.00 1.00 0.76 0.86 1.00 0.84 1.00 1.00 1.00 1.00 1.00 0.69 0.92 0.10 1.00 0.94
Toxoplasmosis 0.80 0.42 0.86 0.06 0.98 0.00 1.00 1.00 1.00 1.00 0.61 0.74 0.78 0.32 1.00 1.00 1.00 1.00 1.00 0.70 0.95 0.29 1.00 0.98
B cell receptor signaling pathway 1.00 1.00 1.00 0.02 0.98 0.00 1.00 0.93 1.00 1.00 0.76 0.74 1.00 0.84 1.00 1.00 1.00 1.00 1.00 0.64 1.00 0.00 1.00 0.91
Asthma 1.00 0.64 1.00 0.02 1.00 0.00 1.00 1.00 1.00 1.00 1.00 0.31 1.00 0.26 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.94
Pertussis 1.00 0.42 0.84 0.02 0.98 0.00 1.00 0.93 1.00 1.00 1.00 0.80 1.00 0.04 1.00 1.00 1.00 1.00 1.00 1.00 0.92 0.07 1.00 0.94
Cytokine-cytokine receptor interaction 1.00 0.96 0.83 0.04 1.00 0.00 1.00 1.00 1.00 1.00 1.00 0.91 1.00 0.34 1.00 1.00 1.00 1.00 1.00 0.70 0.92 0.01 1.00 0.94
Tuberculosis 1.00 0.05 0.90 0.00 0.98 0.00 1.00 0.93 1.00 1.00 1.00 0.31 1.00 0.09 1.00 1.00 1.00 1.00 1.00 0.76 0.94 0.05 1.00 0.89
Phagosome 1.00 0.01 1.00 0.00 0.98 0.00 1.00 0.93 1.00 1.00 0.88 0.31 1.00 0.01 1.00 1.00 1.00 1.00 1.00 0.64 0.94 0.02 1.00 0.79
TNF signaling pathway 1.00 0.99 0.86 0.34 0.98 0.00 1.00 1.00 1.00 1.00 0.80 0.74 0.83 0.29 1.00 1.00 1.00 1.00 1.00 0.70 0.88 0.14 1.00 0.94
Chemokine signaling pathway 1.00 0.17 0.83 0.01 0.98 0.00 1.00 1.00 1.00 1.00 0.89 0.83 1.00 0.17 1.00 1.00 1.00 1.00 1.00 0.64 0.98 0.01 1.00 0.94
Primary immunodeficiency 1.00 1.00 1.00 0.01 1.00 0.00 1.00 1.00 1.00 1.00 1.00 0.74 1.00 0.49 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00
T cell receptor signaling pathway 1.00 1.00 0.86 0.04 0.98 0.00 1.00 1.00 1.00 1.00 0.76 0.77 0.82 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.94 0.00 1.00 1.00
Hematopoietic cell lineage 1.00 0.78 1.00 0.01 0.98 0.00 1.00 1.00 1.00 1.00 0.76 0.76 1.00 0.37 1.00 1.00 1.00 1.00 1.00 1.00 0.93 0.00 0.97 0.94
Toll-like receptor signaling pathway 1.00 0.10 0.86 0.00 0.98 0.00 1.00 0.40 1.00 1.00 0.79 0.77 0.82 0.84 1.00 1.00 1.00 0.02 1.00 1.00 0.94 0.01 1.00 0.87
Intestinal immune network for IgA production1.00 1.00 0.83 0.20 0.98 0.00 1.00 1.00 1.00 1.00 1.00 0.74 1.00 0.19 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00
Staphylococcus aureus infection 1.00 0.31 0.83 0.00 0.98 0.00 1.00 0.93 1.00 1.00 1.00 0.76 0.78 0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.94
NF-kappa B signaling pathway 1.00 1.00 0.83 0.00 0.99 0.00 1.00 0.85 1.00 1.00 1.00 0.86 1.00 0.08 1.00 1.00 1.00 1.00 1.00 0.69 1.00 0.00 1.00 0.94
Lysosome 1.00 0.00 0.88 0.00 0.98 0.00 1.00 0.00 1.00 1.00 1.00 0.07 0.86 0.04 1.00 1.00 1.00 1.00 1.00 1.00 0.92 0.00 1.00 0.06
Leishmaniasis 1.00 0.42 1.00 0.00 0.98 0.00 1.00 1.00 1.00 1.00 1.00 0.52 1.00 0.01 1.00 1.00 1.00 1.00 1.00 0.69 0.92 0.01 1.00 0.94
Osteoclast differentiation 1.00 0.17 0.88 0.00 0.98 0.00 1.00 0.94 1.00 1.00 0.81 0.16 0.86 0.01 1.00 1.00 1.00 1.00 1.00 1.00 0.96 0.00 1.00 0.94
Rheumatoid arthritis 1.00 0.04 1.00 0.00 0.98 0.00 1.00 0.94 1.00 1.00 0.76 0.20 1.00 0.03 1.00 1.00 1.00 1.00 1.00 0.69 0.92 0.00 1.00 0.81
KEGG pathways RCD-2 HFD-2 RCD-10 HFD-10
2 month vs 10 month
W T-2 OB-2 W T-10
W T vs OB RCD vs HFD
OB-10 W T-RCD W T-HFD OB-RCD OB-HFD
Up-regulated:
Down-regulated:
Q-value
10 0.5
Group 
Pathway 
RCD-2 HFD-10 OB-HFD 
WT > OB WT < OB WT > OB WT < OB 2M > 10M 2M < 10M 
AMPK signaling 
pathway 
Ulk1, Ccnd1, 
Tbc1d1, Stk11, 
Akt1s1, Pdpk1 
Gys2, Igf1, Pparg, Pik3cb, 
Akt2, Pfkp, Lep, Pik3cg, 
Foxo1, Srebf1, Fasn, 
Camkk2, Rheb, Ppp2r5b 
Cab39l, Prkag3, Stk11, Prkaa2, 
Pparg, Fasn, Crem, Tsc2, 
Stradb, Adra1a, Foxo1, Irs2, 
Irs3, Insr, Adipoq, Ppp2r1b, 
Adipor2, Slc2a4, Akt2, Gys2, 
Eif4ebp1, Lipe, Creb5, Akt1s1, 
Ppp2r5d, Ppp2r5e, Pfkfb3, 
Ppp2r5b 
Ccnd1, Rab8a, 
Adipor1 
Cab39l, Adipor2, Scd2, 
Foxo1, Irs3, Lep, Pparg, 
Stradb, Gys2, Fasn, Crem, 
Pik3r1, Prkaa2, Eif4ebp1, 
Ppp2r5b 
Ccnd1, Rab8a 
PPAR signaling 
pathway 
Pdpk1, Fads2, 
Cyp4a12a 
Dbi, Acaa1b, Aqp7, Acsl1, 
Pparg, Angptl4, Pltp, 
Fabp5, Acadl, Acadm, 
Nr1h3 
Acaa1b, Acaa1a, Cpt2, Aqp7, 
Slc27a1, Rxrg, Scp2, Rxra, 
Pparg, Fabp4, Angptl4, Acadl, 
Sorbs1, Ehhadh, Acadm, 
Adipoq, Plin1 
 
Acaa1b, Acaa1a, Cpt2, Aqp7, 
Scd2, Acsl1, Scp2, Rxrg, 
Pparg, Fabp4, Angptl4, 
Sorbs1, Slc27a1, Plin1 
 
Insulin signaling 
pathway 
Cblc, Pdpk1, 
Map2k2, Prkacb 
Eif4e2, Rheb, Ppp1r3b, 
Hk3, Pik3cb, Foxo1, 
Pik3cg, Mapk3, Sh2b2, 
Gys2, Prkaca, Flot1, Prkx, 
Fasn, Akt2, Srebf1, Pygl 
Prkag3, Prkaa2, Fasn, Tsc2, 
Ppp1r3c, Mknk2, Insr, Irs2, 
Irs3, Foxo1, Slc2a4, Phkb, 
Akt2, Gys2, Eif4ebp1, Sorbs1, 
Phkg1, Lipe, Hras, Pygb, 
Rapgef1, Prkaca 
Rps6, Hk1, 
Calm2, Prkacb 
Eif4e2, Ppp1r3c, Sh2b2, 
Mknk2, Prkaa2, Eif4ebp1, 
Irs3, Foxo1, Gys2, Prkaca, 
Flot1, Pik3r1, Sorbs1, Fasn, 
Phkb, Kras 
Rps6, Prkacb 
Adipocytokine 
signaling pathway 
Stk11, Npy Lep, Camkk2, Akt2, 
Acsl1, Tnfrsf1a 
Stk11, Adipor2, Ptpn11, Slc2a4, 
Prkaa2, Irs2, Rxrg, Akt2, Rxra, 
Irs3, Prkag3, Adipoq 
Npy, Slc2a1, 
Adipor1 
Acsl1, Adipor2, Ptpn11, Rxrg, 
Prkaa2, Irs3, Lep 
 
Fatty acid metabolism 
Fads2 Acaa1b, Hacd2, Echs1, 
Acsl1, Acaa2, Elovl5, 
Fasn, Mecr, Acadl, Acadm 
Hsd17b12, Acaa1b, Acaa1a, 
Acads, Echs1, Acadl, Cpt2, 
Tecr, Acaa2, Acat2, Acadvl, 
Fasn, Mecr, Hacd2, Ehhadh, 
Acadm 
Ppt1 Hsd17b12, Acaa1b, Acaa1a, 
Cpt2, Echs1, Scd2, Acsl1, 
Tecr, Acaa2, Hacd2, Acads, 
Fasn, Mecr 
Fads1 
Fatty acid elongation 
 
Hacd2, Acaa2, Echs1, 
Elovl5, Mecr, Acot7 
Hsd17b12, Hacd2, Echs1, Tecr, 
Acaa2, Mecr 
Acot7, Acot1, 
Ppt1 
Hsd17b12, Hacd2, Echs1, 
Tecr, Acaa2, Mecr 
 
Fat digestion and 
absorption 
Got2, Plpp2 Lipf, Pla2g12a, Dgat2, 
Pla2g2e, Agpat2, Mogat2 
Plpp3, Dgat1, Pla2g12a, Dgat2, 
Acat2, Mogat2, Agpat2, 
Pla2g2e 
 
Plpp1, Plpp3, Dgat1, 
Pla2g12a, Dgat2, Mogat2, 
Agpat2, Pla2g2e 
 
Biosynthesis of 
unsaturated fatty acids 
Fads2 Acot7, Hacd2, Elovl5, 
Acaa1b 
Hsd17b12, Acaa1b, Acaa1a, 
Hacd2, Tecr 
Acot7, Acot1 Hsd17b12, Acaa1b, Acaa1a, 
Hacd2, Scd2, Tecr 
Fads1 
Fatty acid degradation 
Cyp4a12a Acaa1b, Echs1, Acsl1, 
Acaa2, Acadl, Acadm 
Acaa1b, Acaa1a, Acads, Echs1, 
Acadl, Cpt2, Acat2, Acaa2, 
Eci1, Acadvl, Adh4, Ehhadh, 
Acadm 
Aldh2 Acaa1b, Acaa1a, Cpt2, Echs1, 
Acsl1, Acaa2, Eci1, Acads 
Aldh2 
Fatty acid biosynthesis 
 
Acsl1, Fasn Fasn 
 
Acsl1, Fasn 
 
Sphingolipid 
metabolism 
Sphk1, Plpp2, 
Kdsr, Sgpp1 
Degs1, Smpd1, Asah1, 
Smpd3 
Plpp3, Cers4, Smpd1, Smpd3, 
Asah2 
Acer3, Sphk1, 
Asah1, Sgpl1, 
Glb1, Neu1, 
Sgpp1 
Plpp1, Plpp3, Smpd1, Cers4 Sphk1, Asah1, 
Glb1, Neu1 
Ether lipid metabolism 
Plpp2 Agps, Pla2g12a, Pla2g6, 
Pla2g7, Pla2g2e, Pafah1b1 
Plpp3, Chpt1, Pla2g2e, 
Pla2g12a, Ept1 
Pafah1b3, Pld3 Plpp1, Plpp3, Pla2g12a, Ept1, 
Chpt1, Pla2g2e 
 
Glycerolipid 
metabolism 
Mboat2, Plpp2, 
Akr1b7 
Agpat2, Lipf, Dgat2, 
Akr1b8, Lpin1 
Plpp3, Gpat4, Lpin1, Dgat1, 
Glyctk, Dgat2, Mgll, Pnpla2, 
Agpat2, Agpat9 
Akr1a1, Lpin2, 
Akr1b8, Aldh2 
Plpp1, Plpp3, Lpin1, Dgat1, 
Mgll, Dgat2, Glyctk, Pnpla2, 
Agpat2 
Akr1b8, Aldh2, 
Akr1a1 
Glycerophospholipid 
metabolism 
Mboat2, Pcyt1b, 
Taz, Plpp2 
Pla2g15, Lpin1, Pla2g12a, 
Pla2g6, Gpd1, Agpat2, 
Pgs1, Pla2g2e, Lpgat1 
Plpp3, Gpat4, Lpin1, Pla2g12a, 
Pcyt2, Ept1, Chpt1, Gpd1, 
Agpat2, Gnpat, Crls1, Pla2g2e, 
Chka, Agpat9 
Lpin2, Pld3 Plpp1, Plpp3, Lpin1, 
Pla2g12a, Pcyt2, Ept1, Chpt1, 
Gpd1, Agpat2, Gnpat, 
Pla2g2e, Chka, Lpcat3 
Pisd-ps3 
Glycosphingolipid 
biosynthesis - ganglio 
series 
B3galt4, St8sia5 Hexa St6galnac5 St6galnac4, 
Hexb, Glb1 
 
Glb1 
Glycosphingolipid 
biosynthesis - lacto and 
neolacto series 
B4galt3, Abo B3gnt3, Gcnt2 St3gal3, B4gat1, St3gal6, Gcnt2 
 
St3gal3, Gcnt2 
 
Glycosphingolipid 
biosynthesis - globo 
series 
 
Hexa, B3galnt1 
 
Hexb A4galt 
 
Oxidative 
phosphorylation 
Ndufa6, Ndufa5, 
Ndufa3, Ndufa1, 
Ndufb7, Ndufs6, 
Cox6b2 
Atp6v1c1, Atp6v1a, 
Atp6v1e1, Atp6v1h, 
Tcirg1, Atp6v1b2, 
Atp6v0d1 
Atp5c1, Ndufc1, Ndufa8, 
Ndufa9, Sdhc, Atp5g3, Uqcr10, 
Uqcr11, Ndufs3, Cox6b1, 
Uqcrc2, Ndufb8, Ndufb6, 
Ndufb3, Ppa1, Ndufv3, Ndufv1, 
Cyc1, BC002163, Cox4i2, 
Cox7a1, Atp6v0e2, Cox6a1 
Atp6v1d, 
Atp6v1h, 
Atp6v1g1 
Uqcr11, Ndufb3, Ndufa8, 
BC002163, Cox4i2, Ndufs3, 
Atp5o, Ppa1, Cox6b1, 
Cox6a1, Atp5g3, Cox6a2 
Atp6v1d, 
Ndufa5, 
Atp6v1g1 
 
Table 4.4 The genes associated with lipid metabolic pathways changed significantly (p<0.05) by genotype in the RCD-2 and HFD-10 groups, and by aging in 
the OB-HFD group. 
 Fig 4.4 The genes associated with peroxisome changed significantly (p<0.05) by genotype in 
the RCD-2 and the HFD-10 groups, and by aging in the OB-HFD group. : up-
regulated in the OB-RCD-2 group compared with the WT-RCD-2 group; : down-
regulated in the OB-HFD-10 group compared with the WT-HFD-10 group; : 
down-regulated in the OB-HFD-10 group compared with the OB-HFD-2 group. 
The figure is modified from the KEGG reference pathway 
(http://www.genome.jp/kegg/pathway.html) by (c) Kanehisa Laboratories 04146 
5/14/14. 
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 Fig 4.5 The genes associated with AMPK signaling pathways changed significantly (p<0.05) 
by genotype in RCD-2 and HFD-10 groups, and by aging in the OB-HFD group. 
: up-regulated in the OB-RCD-2 group compared with the WT-RCD-2 group; : 
down-regulated in the OB-HFD-10 group compared with the WT-HFD-10 group; 
: down-regulated in the OB-HFD-10 group compared with the OB-HFD-2 group. 
The figure is modified from the KEGG reference pathway 
(http://www.genome.jp/kegg/pathway.html) by (c) Kanehisa Laboratories 04152 
3/6/17. 
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Fig 4.6 (A) The genes associated with insulin signaling pathways changed significantly 
(p<0.05) by genotype in the RCD-2 and HFD-10 groups, and by aging in the OB-
HFD group. : up-regulated in the OB-RCD-2 group compared with the WT-RCD-
2 group; : down-regulated in the OB-HFD-10 group compared with the WT-HFD-
10 group; : down-regulated in the OB-HFD-10 group compared with the OB-
HFD-2 group. The figure is modified from the KEGG reference pathway 
(http://www.genome.jp/kegg/pathway.html) by (c) Kanehisa Laboratories 04910 
8/14/15. 
(B) The genes associated with the PPAR signaling pathways changed significantly 
(p<0.05) by genotype in the RCD-2 and HFD-10 groups, and by aging in the OB-
HFD group. : up-regulated in the OB-RCD-2 group compared with the WT-RCD-
2 group; : down-regulated in the OB-HFD-10 group compared with the WT-HFD-
10 group; : down-regulated in the OB-HFD-10 group compared with the OB-
HFD-2 group. The figure is modified from the KEGG reference pathway 
(http://www.genome.jp/kegg/pathway.html) by (c) Kanehisa Laboratories 03320 
6/3/16. 
 
4.4.4 The expression pattern of selected genes in lipid metabolism and adipose tissue 
demonstrated the similarity between lipidomic and transcriptomic results   
To clearly demonstrate the changes in the progression of obesity (induced by ob/ob and HFD) 
and aging, I selected some of the genes described in the literature as regulating pathways of 
DNL (Fasn [468]), desaturation (Scd1 [469], Fads1 [470], Fads2 [470]), elongation (Elovl1-7 
[208, 219, 471]), endoplasmic reticulum (ER) stress (Xbp1 [472], Edem1 [473], and Calr3 
[474]), TG biosynthesis and lipid remodeling (Agpat6 [475], Mboat1-2 [476, 477]) and some 
essential transcription factors known to regulate lipid metabolism (Insig1-2 [37, 478-480], 
Srebf1-2 [481-483], PPARα/δ/γ [70, 429, 484], Pgc1α/β [421, 485-487] and Myc [488-490]) 
to determine variations in expression (Fig 4.7A). The transcriptomic patterns of Fasn, Insig1, 
Insig2, PPARγ, and Srebf1 were highly similar, and all up-regulated in adipose tissue of ob/ob 
mice at the age of 2 months compared with wild-types but down-regulated at 10 months 
compared with wild-type controls, up-regulated in adipose tissue of 10 months old wild-type 
mice during aging but down-regulated in 10 month old ob/ob mice compared with the younger 
animals. It suggests that DNL was activated by leptin deficiency in younger mice and with 
aging in wild-type animals, but inhibited in adipose tissue of old ob/ob mice. Scd1 and Elovl6 
were regulated in similar directions with Fasn in these groups. Interestingly, average chain 
length and degree of unsaturation of PCs, as described in Chapter 3.4.3, was increased in 
younger ob/ob mice but decreased in 10-month mice fed the HFD, and also decreased with 
aging, showing similar changes to the genes involved in DNL. Further research is needed to 
demonstrate whether the down-regulated elongases and desaturases and related transcription 
factors resulted in short and saturated PCs accumulated, or the unsaturation status of PCs in the 
cell membrane is the reason for the changed expression of these genes.  
 
Expression of Elovl1 was up-regulated by ob/ob, the HFD diet and aging in many groups, while 
Elovl6 was down-regulated significantly by HFD in the same groups (Fig 4.7B), suggesting 
elongation of C18:0 by ELOVL1 is activated to form more VLCFAs in adipose tissue of either 
old or obese mice. However, further desaturation of oleate was inhibited as the desaturase genes 
(Fads1 and Fads2) were down-regulated by ob/ob, HFD, and aging. This agrees with the 
dominance of oleate in adipose tissue of obese and aged mice described in Chapter 3. 
Moreover, the expression of TG biosynthesis and lipid remodeling genes (Mboat1 and Mboat2) 
were down-regulated by obesity from either ob/ob or HFD. Thus, a further modification of FAs 
and remodeling of WAT were inhibited by obesity and aging while DNL was overly activated. 
 
The ER stress-related genes were not significantly regulated except Edem1, which was up-
regulated by the HFD diet in the WT-10 group. UCP2, which is involved in regulating the 
generation of mitochondrial-derived ROS [491], was up-regulated not only by leptin deficiency 
but also by the HFD diet, indicating the increased oxidative stress in adipose tissue of obese 
mice. Interestingly, UCP3 which transports FA anions into the mitochondrial intermembrane 
to form neutral FAs and reduces proton gradients via the PPAR signaling pathways [492-494], 
was slightly (not significantly) up-regulated by obesity and aging, but significantly down-
regulated in 10-month ob/ob mice fed on HFD compared with wild-type controls. The 
increased ER and oxidative stress together may impair fat storage capacity and lead to more 
dysfunctions of the adipose tissue.   
  
Fig 4.7 (A) Selected gene expression in adipose tissues from ob/ob (OB) mice and wild-type 
(WT) controls aged between 2 (2M) and 10 (10M) months fed on a regular chow diet 
(RCD) or high-fat diet (HFD), all data normalized to the WT-RCD-2M group. The 
genes up-regulated (red) or down-regulated (blue) significantly (p < 0.05) are indicated 
by * in (B).  
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4.5 Discussion 
In this Chapter, transcriptomic patterns of two models of obesity associated with leptin 
deficiency and/or high-fat diet were studied at two-time points. Alterations in the expression 
of genes were more pronounced in the adipose tissue of ob/ob mice, compared with the HFD 
model. Interestingly, 1565 genes were significantly down-regulated by leptin deficiency in the 
HFD-10 group, whereas most of the genes were up-regulated by ob/ob genotype in the RCD-
2 (1219), HFD-2 (819) and RCD-10 (1251) groups compared with the wild-type controls. As 
many as 902 genes were down-regulated not only by ob/ob genotype in the HFD-10 group but 
also by aging in the OB-HFD group. This suggests that the initial stages of obesity are 
associated with an increase in many transcripts but during severe obesity and aging these 
patterns are reversed. As far as I know, this reversion correlating obesity and aging has never 
been reported before.  
 
Genes up-regulated by each of the three factors (ob/ob genotype, HFD diet, and aging) were 
mostly annotated by GO functional themes and KEGG pathways associated with the immune 
system, inflammation, and signaling processes. Both obesity and aging are closely associated 
with low-grade chronic inflammation [495] characterized by immune system dysfunction. The 
pro-inflammatory phenotype which alters intercellular communication and accompanies aging 
in mammals has been termed ‘inflammaging’ [496] and could be caused by different factors 
such as pro-inflammatory tissue damage, dysfunctional immune system, cytokines secreted by 
senescent cells, NF-κB activation and decreased autophagy [497]. Interestingly the enrichment 
of immune and inflammatory biological process GO terms only appeared in the 10-month old 
wild-type animals on an HFD, suggesting that obesity caused by leptin-deficiency on any diet 
is more associated with inflammation than diet-induced obesity. However, cell signaling and 
cytokine production were upregulated most significantly in the OB-2M group, which might be 
an initial signal of a pro-inflammatory state.  
 
Extracellular, vesicle and membrane-related cellular components were enriched by the genes 
up-regulated by the ob/ob genotype. Interestingly, the HFD diet also led to an upregulation of 
genes predominantly annotated by extracellular CC terms, indicating the two models of obesity 
in our study both resulted in increased extracellular matrix remodeling which has been reported 
to be a link between obesity and vascular fibrosis and stiffness [498]. Vascular and cardiac 
fibrosis, amyloid infiltration [499], accumulation of collagen [500] and reduced elastin, lead to 
impaired functionality of the cardiovascular system by thickening, stiffening and calcification 
of the vessel wall and cardiac valves [501]. Moreover, the ob/ob genotype and HFD diet 
activate the expression of genes related to lysosome and phagosome even at early time points 
(2 months) RCD-fed mice. The autophagy of adipocytes is another common biological process 
between obesity [372] and aging [502]. 
 
A significant number of intracellular components were associated with genes downregulated 
in ob/ob mice, especially mitochondrion-related GO terms in the 10-month aged mice. 
Reportedly, the progressive expansion of WAT is associated with aging through mitochondria 
dysfunction [503]. Mitochondrial dynamics are controlled by Sirtuins, AMPK, mTOR, sexual 
hormones and emerging factors such as prohibitins and sestrins [504]. During obesity, FA 
oxidation is reduced with inhibition of mitochondrial complex IV by hypoxia-inducible factor-
1α (HIF-1α) repressing cytochrome c oxidase 5b (Cox5b) [505]. Mitochondrial dysfunction 
and increased production of ROS can induce insulin resistance, and a local pro-inflammatory 
status is created by chemokines and cytokines released by immune cells like macrophages and 
accumulated adipokines together with senescent cells [506]. Fusion, fission and turnover 
through mito- and autophagy also play important functions in mitochondrial dysfunction. 
Mitochondrial dysfunction and oxidative stress contribute to both aging and obesity along with 
chronic inflammation [503, 505]. Increased ROS in adipocytes caused by obesity can cause 
telomere damage, activation of the tumor suppressor p53, inflammation, and promotion of 
insulin resistance [507, 508]. The endoplasmic reticulum (ER) is another cellular component 
enriched by the genes down-regulated in adipose tissue of the obese mice. The ER is where TG 
droplet formation takes place. ER-dysfunction leads to misfolded or unfolded proteins which 
may induce inflammation and cell death via apoptosis [509-511]. 
 
Aging results in much more significant differences in adipose tissue of ob/ob mice than in wild-
type animals. Furthermore, the GO enrichment patterns of aging were relatively similar to those 
of the two obesity models. Extracellular and membrane cellular component-related genes were 
up-regulated in the 10-month ob/ob mice fed on HFD, whereas intracellular component terms, 
especially for organelles such as the mitochondrion, were down-regulated by aging. The genes 
up-regulated in 10-month old mice fed on RCD were annotated by mostly the immune system 
and cell-cell adhesion processes GO terms. This correlates the aging process with obesity, as 
reported in many previous studies [495, 504, 512-518]. Obesity is associated not only with a 
lot of age-related disorders but also with the process of aging itself. Obesity shares a lot of 
biological similarities with the aging process especially in terms of progressive dysfunction of 
WAT including metabolic dysfunction (increased adiposity and adipokine production, altered 
mitochondrial function, accumulated ROS, decreased BAT functional activity), chronic 
inflammation, impaired function of the immune and endocrine systems, macrophage 
infiltration, accumulated senescent cells, and disturbed gene expression pattern (DNA damage, 
telomere shortening, epigenetic alterations) [495, 504, 512-518]. Obese people have been 
considered by some to be associated with premature aging [517]. Accumulation of lipids and 
lipophilic compounds with age is considered a heritage of the evolutionary past, resulting in 
age-related dysfunction of WAT and ectopically stored lipids in non-adipose tissues [519]. As 
we age, adiposity increases while senescent cells accumulate in the adipose tissue. Adipocyte 
size, vascularization, and angiogenic capacity are reduced along with increased tissue fibrosis 
and endothelial dysfunction [502], resulting in excessive FFA release into plasma and 
subsequent lipotoxicity in the whole body. The risk of obesity increases with age meanwhile 
the rate of aging is accelerated by obesity [507, 520-522].  
 
The most intriguing biological alterations linking aging and obesity were observed in a number 
of metabolic pathways as shown in Table 4.3. Genes associated with peroxisomes, steroid 
biosynthesis, carbon metabolism, and FA metabolism were up-regulated by the ob/ob genotype 
in the RCD-2 group, but down-regulated significantly by leptin deficiency in the HFD-10 group. 
Most of the other metabolism associated genes were down-regulated by the ob/ob genotype in 
all four groups. Interestingly, peroxisome-related genes were also significantly up-regulated by 
aging in the WT-RCD group, and the AMPK signaling pathway and steroid biosynthesis were 
enriched moderately by genes up-regulated by aging in WT-RCD, but all of these genes were 
down-regulated significantly by aging in the OB-HFD group. In addition, almost all of the 
metabolism-associated genes were down-regulated by the HFD diet, significantly in the WT-
10 group and moderately in the OB-2 group, but no significant alterations were caused by HFD 
diet in the WT-2 and OB-10 groups. In further investigations of the selected genes, some lipid 
metabolism-related genes (Fasn, Insig1, Insig2, PPARγ, and Srebf1) were found up-regulated 
by leptin deficiency when the mice were young. These genes were also moderately up-
regulated when the mice aged. However, expression of these genes was down-regulated 
dramatically in adipose tissue of aged ob/ob mice. This suggests that their regulation is 
impaired during extreme obesity.  
 
Soukas et al. [523] established that 25% of the expressed transcripts were differentially 
expressed in ob/ob adipose tissue, most of which were inflammatory markers, acute-phase 
genes, and genes important in lipid biosynthesis. This is similar to our results that most genes 
related to the immune system were overexpressed in ob/ob adipocytes and the enriched GO 
terms related to the immune system and inflammation, both consistently up-regulated by leptin 
deficiency. However, they found expression of FA biosynthesis genes such as Fasn was 
decreased 3.1-fold in ob/ob WAT. However, some studies have demonstrated increased 
expression of key lipogenic enzymes in WAT of young ob/ob mice [524] and young obese 
Zucker rats [525-527]. Soukas et al. suggested that the primary source of DNL of FAs may 
shift from WAT to the liver as ob/ob mice age. Our study established not only FA metabolism, 
but pathways associated with peroxisome, steroid biosynthesis, and carbon metabolism were 
also activated in WAT of young ob/ob mice, but down-regulated in WAT of the older ob/ob 
mice.  
 
The peroxisome, a single-membrane bound ER-derived organelle of the endomembrane system, 
is involved in catabolism of very long chain FAs, branched chain FAs, D-amino acids and 
polyamines, biosynthesis of plasmalogens, and detoxification of ROS (especially hydrogen 
peroxide [528]), but has a highly adaptable enzymatic content [529, 530]. The peroxisome also 
contains almost 10% of the whole activity of two enzymes in the pentose phosphate pathway 
[531]. It is still uncertain whether they are involved in cholesterol and isoprenoid synthesis in 
animals[531]. There have been other metabolic functions of peroxisomes reported in seeds 
("glyoxysomes"), leaves, trypanosomes ("glycosomes"), and some yeasts. In our study, a sharp 
contrast appeared within the peroxisome genes for fatty acid-oxidation (DBP, SCPX, ACAA1, 
CRAT, etc.), lipid biosynthesis (DHAPAT, PMVK) and ROS metabolism (MPV17, PXMP4) 
by genotype in the RCD-2 and HFD-10 groups and by aging in the OB-HFD group. It is clear 
that these peroxisomal pathways were activated in the early stage of obesity, but reduced in 
WAT of old ob/ob mice. FAs with longer chain lengths (>20 carbons) and dicarboxylic FAs 
have to be degraded by β-oxidation in peroxisome which directly produces H2O2. The 
peroxisomal genes that were reduced in expression might be one reason for the accumulation 
of TGs containing longer fatty acids in the WAT of aged mice (as shown in Chapter 3.4.4). 
The antioxidant systems in peroxisomes were also inhibited in WAT of aged ob/ob mice. The 
increased ROS production by peroxisomes is a key feature for both obesity and aging [532, 
533]. Lack of the ROS detoxifying catalase activity results in impaired redox balance [533, 
534] and increases the susceptibility to aging-related diseases, e.g. diabetes, atherosclerosis and 
cancer [535]. Both mitochondria [536, 537] and peroxisomes [538, 539] are major sources of 
ROS and are critical for intracellular redox balance. They share structural components for 
dynamic fission and have molecular tethers, most likely via the endoplasmic reticulum (ER) 
[540-542]. The peroxisome-mitochondria connection has a great impact on ROS production, 
redox homeostasis, aging and diseases such as obesity and diabetes [529]. Interestingly, in our 
KEGG enrichment results, the changes in the peroxisome appeared earlier and to a greater 
magnitude than those in mitochondria. The study of peroxisomal dysfunction in obesity and 
aging has lagged mitochondria, but recent studies have demonstrated the damage to 
mitochondria caused by peroxisomal dysfunction in cultured mammalian cells [543-546], and 
peroxisomes might be an early target of cellular oxidative damage arising from obesity or aging 
[547]. Fransen et al. [548] suggested that mitochondria are downstream of peroxisomal 
generated ROS from lipid peroxidation, rather than a simple diffusion of ROS from 
peroxisomes to mitochondria. While the mechanisms of the interplay between organelles and 
ROS are still unknown, some interorganelle contact sites between peroxisomes and 
mitochondria have been found in yeast model including the ERMES (endoplasmic reticulum-
mitochondria encounter structure) and Mdm34-Pex11 interaction [549, 550]. The functional 
interplay of the two organelles needs to be further studied in terms of the regulation of oxidative 
stress, dynamic fission, and autophagy. Moreover, the up-regulation of lysosome-related genes 
by both obesity and aging in almost all groups suggest that autophagy of peroxisomes 
(pexophagy) and mitochondria (mitophagy) were activated to eliminate dysfunctional 
peroxisomes or mitochondria, which is an important mechanism to decrease ROS production 
in damaged peroxisomes and maintain correct redox balance [551]. Starvation also results in 
pexophagy and mitophagy to eliminate superfluous peroxisomes and mitochondria to decrease 
in cellular ROS levels [529], which could be studied using obese animal models in the future.  
 
AMPK is a ubiquitous cellular gauge that increases ATP production and reduces energy 
wastage. The hypothalamic and vascular AMPK signaling pathways have been proven to be 
important targets for drug development against obesity and its complications [552, 553]. The 
results of our transcriptomic study suggest that AMPK signaling also plays a key role in the 
regulation of WAT during obesity and aging. Membrane receptors for leptin (Adra1a), 
adiponectin (Adipor2), glucose (GLUT4) and insulin (Insr) were all down-regulated in WAT 
of old ob/ob mice, along with inhibited AMPK expression in both obesity and aging. 
Interestingly, downstream genes such as Akt, FoxO1, Srebp1c, Fasn, PPARγ, and Gys2 were 
up-regulated by leptin deficiency in the RCD-2 group but then inhibited in the old ob/ob mice. 
This suggests that in the initiation of obesity caused by leptin deficiency, FA biosynthesis, and 
mitochondrial biogenesis are activated, but then impaired in the progression of aging. Akt and 
its downstream FoxO proteins are major targets of insulin and can sense nutrients and mediate 
gluconeogenesis, glycolysis, lipogenesis, and lipolysis [554-556]. The fluctuation of Akt and 
FoxO1 represent the major changes resulting from insulin resistance. Wu et al. [557] suggested 
PGC-1α is a direct FoxO1 transcriptional target. Reduced expression of FoxO1 and PGC-1α 
contribute to mitochondrial dysfunction and increased ROS generation. Interestingly, it is also 
reported that PGC-1α binds and co-activates FoxO1 but is inhibited by Akt-mediated 
phosphorylation [558]. FoxO1 inhibits adipogenesis by binding to the promoter sites of PPARγ 
but is excluded from the nucleus after being phosphorylated by Akt stimulated by insulin [559]. 
Moreover, it is reported FoxO1 can be trapped in the nucleus via sirtuin- and NAD+- dependent 
deacetylation against Akt-phosphorylation-dependent nuclear exclusion. The activity of Sirtuin 
1 (SIRT1) has been reported to be inhibited by both a high-fat diet [560] and aging [561]. 
Expression of the Sirt1 gene in WAT of mice in our study was not found to be significantly 
down-regulated. However, the reduced expression of AMPK in WAT of old ob/ob mice will 
decrease NAD+ production and lead to inhibited SIRT1 activity. This arises because the 
enzymatic activity of sirtuins is directly linked to the energy status of the cell via NAD+, NADH, 
and nicotinamide, as the sirtuin-mediated deacetylation reaction couples lysine deacetylation 
to NAD+ hydrolysis which yields nicotinamide as an inhibitor of sirtuin activity [562-564]. 
SIRT1 can improve sensitivity to both leptin and insulin and prevents inflammation and 
macrophage infiltration [565] by deacetylation of substrates like PGC-1α and NF-κB, and is 
increased by caloric restriction and decreased by aging and overfeeding [566]. The 
transcriptional activity of PPARγ and TNFα in adipose tissue could be repressed by SIRT1, 
increasing fat mobilization and protecting cells from insulin resistance [567, 568]. Moreover, 
resveratrol, a possible SIRT1 activator, and resveratrol-mimicking drugs such as SRT1720 
extended the lifespan of obese mice by 44% [569].   
 
When examining the detailed PPAR signaling pathway, it is found that the expression of 
PPARγ is influenced much more than PPARα and PPARδ by leptin deficiency, diet-induced 
obesity, and aging. PPAR is highly expressed in the liver, heart, muscle, and kidney where it 
promotes fatty acid β-oxidation and decreases glycolysis [216, 430]. PPARδ ubiquitously 
increases total oxidative and the TCA cycle to burn fat and restore insulin sensitivity [373, 570, 
571]. PPARg is predominantly expressed in adipocytes, promoting adipocyte differentiation, 
and sequesters glucose and lipids into WAT [373, 572]. PPARγ is the only factor without which 
the adipocyte differentiation cannot occur and no other factor has been identified that can 
rescue adipogenesis in the absence of PPARγ. The significant up-regulation but then down-
regulation of PPARγ by combining obesity and aging might be a key node of dysfunctional 
adipose tissue. Moreover, epigenetic and chromatin-modifying proteins have been found to 
contribute to adipogenesis and maintenance of mature adipocytes through PPARγ [273]. There 
is a complex feedback regulatory system between PPARγ, insulin, Insig1, and SREBP1. Firstly, 
PPARγ agonists can induce Insig1 expression in vitro and in vivo in WAT [262, 263] to limit 
the promotion of adipocyte differentiation by PPARγ itself. Insulin can also activate SREBP1 
to promote lipogenesis, while, at the same time inducing the expression of Insig1 for restricting 
the production of too much active SREBP1 [262, 264-266]. This autoregulatory feedback loop 
has not only been suggested as a control mechanism for cholesterol synthesis in the liver [264, 
267] but also reported to be involved in the pathophysiological dysregulation of WAT for in 
vivo and in vitro obesity models [37]. In the insulin-resistant (IR) state, this negative 
Insig1/SREBP1 regulatory feedback is suggested to be reset for the downregulation of Insig1 
and maintenance of active SREBP1 levels for maintaining lipid homeostasis. Active SREBP1 
ensures an adequate supply of specialized FAs used for the maintenance of membrane lipid 
homeostasis, effectors of intracellular signaling, and lipid modification of proteins [254]. The 
concept that SREBP1 needs to be activated to restore the biosynthesis of phosphatidylcholine 
(PC) and phosphatidylethanolamine (PE) has been suggested both in Caenorhabditis elegans 
and mammalian cells [39] and Drosophila heart [41]. This regulatory feedback can compensate 
lipid perturbations in membranes and specific signaling pathways in obesity and IR, but, 
simultaneously, increases lipogenesis [37, 41] and may aggravate the associated pathology. 
 
Expression patterns of selected genes involved in the pathways of lipid synthesis and further 
modification, ER stress, mitochondrial stress, adipose tissue remodeling, and some essential 
transcription factors have been described in Chapter 4.4.4. DNL genes (Fasn, Elovl6, Scd1) 
and related transcription factors (Insig1, Srebf1, PPARγ) were up-regulated by ob/ob genotype 
and aging, respectively, but were down-regulated in adipose tissue of older ob/ob mice 
compared with wild-type or younger animals. Further FA modification by Elovl1 was up-
regulated by Elovl1 in obese and aged mice, while desaturases (Fads1 and Fads2) were down-
regulated in ob/ob mice and in older animals. TG synthesis and lipid remodeling were also 
reduced in adipose tissue when the mice became obese and aged (Agpat6, Mboat1, and Mboat2 
were down-regulated). It is interesting that lipid remodeling genes correlate well with Srebp2 
while FA synthetic genes are similarly co-regulated with Srebp1c and PPARg. Srebp2 is more 
related to cholesterol synthesis while Srebp1c regulates fatty acid synthesis [573]. The role of 
cholesterol in regulating the physiology of bio-membranes implies the important aspects of 
Srebp2 in obesity and insulin resistance. However, although there are some studies associating 
FA composition with the mRNA levels of enzymes like SCDs in adipose tissue, it has also 
been reported that the liver is the major organ where FAs are synthesized through DNL, 
elongation, and desaturation and adipose tissue lipid composition is just a hybrid of dietary and 
de novo synthesized FAs [454]. Thus, the lipid composition in adipose tissue should be the 
readout of enzymatic activity of the whole body, especially in the liver, rather than just in 
adipose tissue. In addition, ER stress (Edem1) and mitochondrial oxidative stress (Ucp2) were 
induced significantly by an HFD, which impaired coordinated remodeling of the structure and 
metabolism of adipose tissue developing insulin resistance and cardiovascular diseases [372, 
574, 575].  
4.6 Conclusion 
This Chapter investigated the correlation between transcriptomic patterns of obesity and aging 
using three factors, i.e. two models of obesity induced by leptin deficiency (ob/ob genotype) 
and high-fat diet (HFD), respectively, and aging. The two obesity models exhibited differently 
featured expression patterns but both had some changes in common with aging. Inflammation 
and immune system-related pathways were activated not only in the two models of obesity but 
also in white adipose tissue of aged mice. On the contrary, metabolic pathways, in particular, 
those related to lipid metabolism, were activated by leptin deficiency in the initiation of obesity 
of ob/ob mice, but inhibited to a large extent in white adipose tissue of aged ob/ob mice, 
compared to both the wild-type controls and the younger controls. The GO and KEGG 
enrichment analysis of these genes suggested that peroxisome and AMPK and PPARγ 
signaling pathways may act at the forefront in the progression of obesity and aging, as a 
protective mechanism in the initiation of oxidative damage, but then accumulated damage 
results in insulin resistance, the metabolic syndrome and T2DM. 
 
 
 
  
Chapter 5 One-Carbon Cycle and DNA Methylation in Adipose 
Tissue of High-Fat-Diet and ob/ob mouse models 
5.1 Introduction 
Metabolic pathways can be regulated not only transcriptionally but also through epigenetic 
modifications which refers to the heritable changes in gene expression resulting from 
modifications to DNA or histones rather than changes in the nucleotide sequence [269, 270]. 
Epigenetic changes, including methylation and acetylation of DNA and histones, chromatin 
remodeling, and noncoding RNA expression, have attracted extensive attention in recent years 
as an alternative mechanism for pathologies associated with metabolic disorders. For example, 
the epigenetic profile of the genome was suggested to be altered after a carbohydrate-based 
diet was replaced by a high-fat diet, which resulted in insulin resistance and T2DM in mice 
[279, 280]. Moreover, although the DNA sequence is comparatively stable, epigenetic patterns 
can be greatly influenced by external factors, and remain dynamic all the way through the life 
course [272], providing an important interface between environmental factors and genetics.  
 
Obesity has been associated with accelerated DNA methylation in the human liver [576]. 
Changed DNA methylation and gene expression have been linked to generation, distribution, 
and metabolism of subcutaneous adipocytes of obese women [577]. Drogan et al. suggested 
methylation of the gene (LPL) encoding lipoprotein lipase might be a reason for differential 
body fat distribution (increased waist circumference), increased methylation in the promoter of 
LPL was associated with higher BMI, higher visceral adipose tissue mass and weight gain 
[578]. Accordingly, aging has been reported to be associated with changes in the distribution 
of 5-methylcytosine and a decrease in genome-wide methylation but more methylation in the 
promoter regions of specific genes resulting in gene silencing [579]. However, DNA 
methylation status is in a tissue-specific manner (different in the liver compared within the 
adipose tissue), especially at intergenic sequences and conserved noncoding elements of some 
genes that are involved in metabolism and metabolic regulation [580]. Chromatin dysregulation, 
mRNA metabolism, and RNA slicing have also been reportedly involved in aging from adipose 
tissue [581].  
 
DNA methylation (e.g. cytosine → 5-methylcytosine) is a major epigenetic modification of the 
genome that regulates gene expression [271]. S-adenosylmethionine (SAM) is the principal 
biological methyl donor for DNA and histone methyltransferases in all mammalian cells and 
plays an important role in a lot of biological processes such as transmethylation, 
transsulfuration, and polyamine synthesis [285]. The methyl group from SAM can be 
transferred to nucleic acids, proteins, phospholipids, hormones, neurotransmitters, and certain 
drugs [281]. SAM is mainly derived from the reaction between methionine and adenosine 
triphosphate via the enzyme methionine adenosyltransferase (MAT) as part of the choline and 
one-carbon (1-C) pathway [282-284]. Interestingly, choline is the head group of 
phosphatidylcholines (PCs) and the normal ratio of PCs to Phosphatidylethanolamines (PEs) 
are established by SAM methylation [285], which plays a role in lipid metabolism and 
determines the fluidity or viscosity of the membrane [287]. The greater amount of PC is 
associated with more fluid or less viscous cell membrane which facilitate the lateral movement 
of membrane receptors [582]. Thus, this Chapter aims to investigate the interaction of obesity 
and aging in lipid metabolism, 1-carbon cycle, and DNA methylation in adipose tissues of mice. 
5.2 Aims and objectives 
In this Chapter I aim to: 
i. Profile the changes in 1-carbon metabolites associated with genetic-induced obesity 
resulting from a failure to produce leptin in the ob/ob mouse. 
ii. Profile the changes in 1-carbon metabolites associated with diet-induced obesity. 
iii. Profile the changes in 1-carbon metabolites associated with aging. 
iv. Correlate the 1-carbon changes with lipid changes in an integrated regulating network. 
v.  Profile the global methylation status of the mouse models of obesity and age, and validate 
this using some genes selected from the literature.   
5.3 Materials and Methods 
5.3.1 Animals and diets 
All animals and samples described in Chapter 2 (section 2.2) were used for 1-carbon metabolite 
determination in this Chapter. For the determination of the methylation status of selected genes, we 
compared changes at 10 months of age with both genotypes and diets. 20 adipose tissue samples 
as described in Chapter 2 (section 2.2) were randomly selected (5 in each group for different 
genotype (ob/ob or wild-type), diet (RCD or HFD)), as shown in red below: 
No. Genotype 
Age  
(months) 
Diet No. Genotype 
Age  
(months) 
Diet 
wt 01-10 WT 2 RCD ob 01-10 ob/ob 2 RCD 
wt 11-20 WT 4 RCD ob 11-20 ob/ob 4 RCD 
wt 21-30 WT 10 RCD ob 21-30 ob/ob 10 RCD 
wt 31-40 WT 14 RCD ob 31-40 ob/ob 14 RCD 
wt 41-50 WT 2 HFD ob 41-50 ob/ob 2 HFD 
wt 51-60 WT 4 HFD ob 51-60 ob/ob 4 HFD 
wt 61-70 WT 10 HFD ob 61-70 ob/ob 10 HFD 
 
5.3.2 Determination of 1-carbon metabolites by UHPLC-SRM-MS 
The aqueous component of all the extract described in Chapter 2 (section 2.3.2) was used and 
the determination of 1-carbon metabolites by UHPLC-SRM-MS were performed according to 
Chapter 2 (section 2.7).  
 
5.3.3 Measurement of DNA Percent Methylation 
Extraction of DNA and measurement of percent methylation of the genes (Mus musculus acyl-
CoA synthetase long-chain family member 1 (Acsl1), Mus musculus thymoma viral proto-
oncogene 2 (Akt2), Mus musculus regulator of G-protein signaling 3 (Rgs3), Mus musculus 
lipoma HMGIC fusion partner-like 2 (Lhfpl2)) selected from literature [583-585] were 
performed according to Chapter 2 (section 2.8). 
5.3.4 Multivariate statistical analysis 
Correlation of different data was performed using the Orthogonal Partial Least Squares (OPLS) 
method by SIMCA 14 (Umetrics, Umea, Sweden) according to Chapter 2 (section 2.10). 
 
5.4 Results 
5.4.1 1-carbon metabolism in adipose tissue of mice changes significantly with genotypes 
and correlates well with Phosphatidylcholine data 
The 1-carbon metabolites in adipose tissues were semi-quantified from aqueous fraction of 
adipose tissue through developing a sensitive UHPLC-SRM-MS method. Differences between 
different genotype/diet-mice became larger in older mice, and the most significant comparison 
profiles appeared in the 10-month group as shown in Fig 5.1 (adjusted P-values in Table 5.1). 
It is obvious that there was a great upsurge of almost every 1-carbon metabolite comparing 
ob/ob mice with wild-type controls at the late age states (10 months and 14 months). However, 
this is not significant in adipose tissue of young (2 months and 4 months) fed on RCD. This 
suggested the 1-carbon metabolism was activated by leptin deficiency, in particular when the 
animals became old. Activated lipid metabolism in ob/ob mice might be a reason for the 
increased 1-C intermediates, considering SAM can be used for biosynthesis of PCs, and choline, 
the head group of PC, is used for production of betaine which is a methyl donor for the 
transformation from homocysteine to methionine and then SAM (Fig 5.2). 
 
The diet exhibits different effects in ob/ob and wild-type mice. Most of the 1-C metabolites 
decreased in adipose tissue from wild-type mice fed on HFD compared with WT-RCD animals, 
while this pattern disappeared in adipose tissues from ob/ob mice. OB-HFD mice had less 
homocysteine, betaine, cysteine, and glycine but more SAM, SAH, methionine, serine, 
cytosine, and 5-methylcytosine in adipose tissues compared with OB-RCD mice. The 
decreased 1-C metabolites in HFD-fed wild-type mice might be due to the decrease of DNL 
and lipid metabolic pathways as most of the FAs are directly from the diet as discussed in 
Chapter 3. 
 
Interestingly, aging also increased most of the 1-C metabolites in adipose tissue from ob/ob 
mice. This suggests another mechanism correlating the effect of obesity on the aging process. 
This increase was not significant in the adipose tissue of wild-type mice. 
 
 
 eine 
 Fig 5.1 1-Carbon metabolites varied in adipose tissues from ob/ob (OB) mice and wild-type (WT) controls fed by 
regular chow diet (RCD) and high-fat diet (HFD) across different age stages (2-14 months). The ion-
intensities for peaks of Cysteine and Homocysteine were normalized to the area of the internal standard 
Homocysteine-d5. Ion-intensities for all the other one-carbon metabolites were normalized to the area of 
the internal standard Glutamate acid 13C515N1. Note: the adipose tissue of the WT mice fed on RCD at 
2 months of age was used in previous experiments outlined in Chapter 3-4, therefore there was insufficient 
sample remaining for this study. Many 14-month-old mice died after switching to the HFD feeding, 
therefore they are not shown in the figure. 
Adjusted P-value Gly. Ser. Cys. Bet. SAM Homocys Mecyt. Meth. Cyt SAH Mecyt/Cyt 
Genotype 
WT-RCD-4 month vs. OB-RCD-4 month 0.3922 0.9646 0.2581 0.3394 0.4497 0.9818 0.9818 0.9818 0.9818 0.3489 0.4497 
WT-RCD-10 month vs. OB-RCD-10 month 0.0033 0.1226 <0.0001 0.1226 0.0221 0.1226 0.0187 0.0284 0.1226 0.4952 0.1226 
WT-HFD-4 month vs. OB-HFD-4 month 0.0009 0.0014 0.0014 0.4912 0.0091 0.0003 0.0014 0.0002 0.0002 0.0732 0.0179 
WT-HFD-10 month vs. OB-HFD-10 month 0.0177 0.0006 0.0003 0.0079 0.0646 0.0013 0.0256 0.0156 0.1000 0.1264 0.2610 
Diet 
WT-RCD-4 month vs. WT-HFD-4 month 0.0592 0.2203 0.2203 0.2504 0.2203 0.2203 0.1386 0.0636 0.2504 0.1386 0.8165 
WT-RCD-10 month vs. WT-HFD-10 month 0.4847 0.5813 0.1992 0.5813 0.8276 0.5813 0.4514 0.4503 0.4514 0.1614 0.8276 
OB-RCD-4 month vs. OB-HFD-4 month 0.0851 0.2823 0.1567 0.5257 0.2282 0.6073 0.1271 0.1126 0.6073 0.6073 0.5257 
OB-RCD-10 month vs. OB-HFD-10 month 0.9934 0.9934 0.9934 0.9687 0.7027 0.9531 0.9934 0.9934 0.6641 0.9400 0.9934 
Aging 
WT-RCD-4 month vs. WT-RCD-10 month 0.5191 0.8935 0.8481 0.6096 0.5103 0.9039 0.9039 0.9039 0.9039 0.8481 0.0848 
WT-HFD-4 month vs. WT-HFD-10 month 0.9639 0.9639 0.9639 0.8254 0.8456 0.9639 0.6313 0.5811 0.5400 >0.9999 0.0617 
OB-RCD-4 month vs. OB-RCD-10 month 0.0007 0.1706 <0.0001 0.0353 0.0258 0.1706 0.0159 0.0258 0.1706 0.1706 0.0353 
OB-HFD-4 month vs. OB-HFD-10 month 0.2450 0.2450 0.1428 0.2450 0.1565 0.1428 0.0378 0.2450 0.2450 0.2450 0.2450 
Table 5.1 The adjusted P-values when comparing 1-Carbon metabolites in adipose tissues from ob/ob (OB) mice and wild-type (WT) controls fed by regular chow 
diet (RCD) and high-fat diet (HFD) across different age stages (4-10 months) using one unpaired t-test. The ion-intensities for peaks of Cysteine and 
Homocysteine were normalized to the area of the internal standard Homocysteine-d5. Ion-intensities for all the other one-carbon metabolites were normalized 
to the area of the internal standard Glutamate acid 13C515N1. Gly, Glycine; Ser, Serine; Cys, Cysteine; Bet, Betaine; SAM, S-Adenosyl Methionine; Homocys, 
Homocysteine; Mecyt., Methylcytosine; Meth, Methionine; Cyt, Cytosine; SAH, S-Adenosyl Homocysteine. 
 Fig. 5.2 Interconnection between the 1-carbon cycle, Methylation pathway, Transsulfuration 
pathway and Kennedy pathway (modified from references [286, 287]). DHF, 
Dihydrofolate; THF, tetrahydrofolate; SAM, S-adenosyl methionine; SAH, S-
adenosyl homocysteine; GSH, glutathione. Metabolites increased in adipose tissue of 
ob/ob mice and aged mice are labeled in red. 
 
Cytosine methylation is widespread in both prokaryotes and eukaryotes. Around 60%-80% of 
CpG is methylated in somatic cells of vertebrates (80-90% for human) [586] while less than 
10% of CpG islands (made up of about 65% guanine and cytosine residues) are methylated in 
intergenic and intragenic regions. There is an inverse relationship between the transcriptional 
activity of a gene and the CpG methylation in the promoter of the gene. The ratios of 5-
methylcytosine to cytosine were calculated in different genotype/diet/age groups to estimate 
the DNA methylation status in adipose tissue. Fig 5.3 suggested that free cytosine was more 
methylated during obesity induced by leptin deficiency and also by aging (adjusted P-values in 
Table 5.1). Cytosine is a part of cytidine triphosphate (CTP) and which can act as an inhibitor 
of the enzyme aspartate carbamoyltransferase in pyrimidine biosynthesis [587], and deoxy 
CTPs are building blocks of DNA. More 5-methylcytosine indicates a possibility of higher 
DNA methylation level by incorporation as 5-methyl deoxycytidine, which means silencing of 
some gene expression and loss of pluripotency of adipocytes during obesity and aging. This 
may be the mechanism of how changes in 1-C metabolism influence gene and protein 
phenotypes in the process of getting obesity and aging.  
 
 
Fig 5.3 The relative abundance of 5-methylcytosine to cytosine varied in adipose tissues from ob/ob 
(OB) mice and wild-type (WT) controls fed by regular chow diet (RCD) and high-fat diet (HFD) 
across different age stages (2-14 months). Many 14-month-old mice died after switching to the 
HFD feeding, therefore they are not shown in the figure. 
 
 
In order to correlate lipidomic results and 1-C metabolic patterns, the Orthogonal Partial Least 
Squares (OPLS) method, a modification of the PLS algorithm, was used for data integration 
combining different metabolite data. With this methodology, a systematic variation that 
overlaps across analytical platforms can be separated from platform-specific systematic 
variation to validate the correlation between any two sets of data. FAs, TGs, PCs, and 1-C 
metabolites data were studied using this method in terms of their changes by genotype/diet/age 
factors. As a result, shown in Table 5.2, total FA data and TG data can be correlated well 
(Q2=53.7), which can be explained as most FAs detected are from TGs stored in adipose tissue 
as its major energy-storing function. What is more interesting, the 1-C metabolite data correlate 
with PC data (Q2=37.0) much better than with FA (Q2=7.0) and TG (Q2=14.3). This indicates 
that the PC metabolism disturbed in obesity and aging may also play a role in regulating 1-C 
metabolism and changing the supply of SAM for DNA methylation. One of the essential 
intermediates of 1-C metabolism is choline, which is also the head group of PCs. Moreover, 
the conversion between PCs and PEs also rely on the methylation function of SAMs (Fig 5.1). 
Another thought-provoking phenomenon is that both the correlations mentioned above are 
greater in ob/ob mice (with greater Q2 value) than in wild-type mice. One reason may be that 
the activated DNL and lipid metabolism by leptin deficiency led to more interactions between 
biological pathways involved in lipid and 1-C metabolism. 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
2 month 4 month 10 month 14 month
WT RCD WT HFD OB RCD OB HFD
R
e
la
ti
v
e
 a
b
u
n
d
a
n
c
e
 
 
  
Table 5.2 The O2PLS models correlating different metabolic data in adipose tissues from ob/ob (OB) 
mice and wild-type (WT) controls fed by regular chow diet (RCD) and high-fat diet (HFD) 
across different age stages (2-14 months). The color depth indicates the relative Q-value. 
 
5.4.2 Leptin deficiency results in significant changes in DNA methylation status to 
influence the gene expression 
As the SAM provides methyl groups for the DNA methylation, I also determined the 
methylation status of four genes screened from literature [583-585] which were highly-
correlated with obesity and diabetes. As shown in Fig 5.4, ACSL1 and AKT2 are much less 
methylated in ob/ob mice while Rgs3 was more methylated. Thus, in ob/ob mice 1-carbon 
cycle is heavily activated and produces a lot of SAM for DNA methylation which could be 
used to control the expression of some genes, whereas SAM is used to methylate different 
genes with high selectivity. This indicates control of methylation of different genes could be 
another important mechanism in response to obesity and aging. The HFD did not significantly 
change the methylation status of the four genes, which is consistent with fewer observed 1-C 
changes by diet compared with changes caused by genotype. But the trend in HFD-fed mice 
(moderately decreased methylation of ACSL1 and increased Rgs3) was similar to that in ob/ob 
mice compared with lean controls, respectively.  
Parameters All WT OB All WT OB
R2X(Cum)% 94.5 85.3 92.7 84.1 87.5 87.0
R2Y(Cum)% 60.0 58.3 63.6 47.5 58.4 50.8
Q2(Cum)% 53.7 48.4 51.9 37.0 27.1 40.0
Parameters All WT OB All WT OB
R2X(Cum)% 88.3 94.8 85.5 94.9 93.0
R2Y(Cum)% 41.9 40.0 55.8 27.0 32.5
Q2(Cum)% 15.7 0.0 30.6 14.3 16.4
Parameters All WT OB All WT OB
R2X(Cum)% 83.4 91.9 82.2 56.8 75.8
R2Y(Cum)% 29.3 68.4 50.2 10.2 14.6
Q2(Cum)% 20.4 35.1 34.5 7.0 10.2
No model
1-C vs. PC
1-C vs. TG
1-C vs. FA
FA vs. TG
TG vs. PC
PC vs. FA
No model
 
 
Fig 5.4 DNA methylation of four genes selected from literature in adipose tissues from 10-month ob/ob 
(OB) mice and wild-type (WT) controls fed by regular chow diet (RCD) and high-fat diet (HFD). 
All data are normalized to the gene methylation in adipose tissue of WT mice fed on RCD. 
Human Methylated DNA & Non-methylated DNA Standards with an MGMT primer set for 
validating the OneStep qMethyl™ system. 
  
ACSL1 AKT2 Lhfpl2 Rgs3 
Interaction 0.3488 0.4705 0.4662 0.7956 
Genotype 0.0002 <0.0001 0.0445 0.0241 
Diet 0.6812 0.6158 0.3633 0.2512 
Table 5.3 The P-values when comparing DNA methylation of four genes selected from literature in 
adipose tissues from 10-month ob/ob (OB) mice and wild-type (WT) controls fed by regular 
chow diet (RCD) and high-fat diet (HFD) using two-way ANOVA. Red: P <0.05. 
 
Methylation can change DNA activity without changing its sequence. DNA methylation 
typically represses gene transcription when located in the promoter [588, 589]. This is essential 
in a lot of important processes such as normal development, aging, repression of transposable 
elements, carcinogenesis, X-chromosome inactivation, and genomic imprinting. There are 
about 60-70% of genes of human have a CpG island in the promoter region. Around 50% of 
CpG islands of the human genome (about 25,000) lie in gene promoter regions, while another 
25% are located in gene bodies often serving as alternative promoters.  
 
Expression of these four genes was also determined (extracted from the transcriptomic data in 
Chapter 4) as shown in Fig 5.5. The genotype resulted in the most significant changes. 
Expression of Rgs3 was decreased in adipose tissue of 10-month ob/ob mice not only by ob/ob 
genotype but also by HFD diet, in part because of more methylation suppressed its expression. 
However, expression patterns of Acsl1, Akt2, and Lhfpl2 were not consistent with their 
methylation status. Expression of Acsl1 and Akt2 was increased in ob/ob mice at the age of 2 
months while moderately decreased in ob/ob mice fed on HFD at the age of 10 months 
compared with wild-type controls. Lhfpl2 was more expressed in ob/ob mice but its 
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methylation was not significantly changed by genotype. HFD also led to increased expression 
of Acsl1, Akt2, and Lhfpl2 in adipose tissue of 10-month old wild-type mice compared with 
animals fed on RCD, but their methylation status did not change accordingly. The influence of 
obesity on these genes might be through some other pathways or by some transcriptional 
factors rather than being directly affected by their methylation status. It seems that the DNA 
methylation status is an important factor in the regulation of gene expression but there should 
also be some other influential factors working together, which need to be studied in further 
research. 
 
 
Fig 5.5 Expression of four genes selected from literature in adipose tissues from ob/ob (OB) mice and 
wild-type (WT) controls fed by regular chow diet (RCD) and high-fat diet (HFD) at the age of  
2 months (A) and 10 months (B). All data are normalized to expression of the gene of 2-month 
WT mice fed on RCD.  
 
 
ACSL1 AKT2 LHFPL2 RGS3 
Age 0.9295 0.7919 0.0230 0.2620 
Genotype 0.0027 0.8591 <0.0001 0.1172 
Diet 0.0054 0.0010 0.0074 0.4276 
Age x Genotype 0.0006 0.0093 0.0494 0.0815 
Age x Diet 0.5950 0.6147 0.4477 0.2673 
Genotype x Diet 0.7301 0.2865 0.6847 0.0562 
Age x Genotype x Diet 0.1235 0.4343 0.0501 0.0320 
Fig 5.5 The P-values when comparing expression of four genes selected from literature in adipose 
tissues from ob/ob (OB) mice and wild-type (WT) controls fed by regular chow diet (RCD) and 
high-fat diet (HFD) at the age of 2 months (A) and 10 month (B) using three-way ANOVA. 
Red: P <0.05.  
 
5.5 Discussion 
In adipose tissue of ob/ob mice, the 1-C cycle was heavily activated and produced an abundance 
of SAMs for methylation of DNA and/or histones. There was an upsurge in every 1-carbon 
metabolite comparing ob/ob mice with wild-type controls. This indicates that DNL which could 
be increased by leptin deficiency is also positively correlated with 1-C metabolism. The 
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influence of HFD on 1-C metabolism was not as significant as leptin deficiency. The influence 
of aging was much more significant in adipose tissue from ob/ob mice compared with wild-
type ones and also led to an increased concentration of 1-C metabolites. As shown in Chapter 
3.4.1 showed that leptin deficiency caused a much more increase in body weight and body fat 
composition than the HFD did. Long-term raised blood glucose and insulin level and cardiac 
fibrosis were also detected significantly more in ob/ob mice. These demonstrated that 
overdose-induced obesity had more serious and deleterious effects on metabolic health than a 
high-fat diet.  
 
Zeisel et al. [282] proposed that 1-C metabolism and energy homeostasis can be correlated 
through choline. Rodents, cattle, swine, and humans with a choline-deficient diet or genetic 
defect in choline metabolism all become hypermetabolic. Increased betaine has been reported 
to be associated with insulin sensitivity and increased metabolic rates [590]. Cysteine inhibits 
lipolysis and stimulates utilization of glucose in DNL as insulin does [591]. This is somewhat 
intriguing as choline, betaine, and cysteine can be converted into each other in 1-C metabolism. 
One possible reason could be that increased 1-C metabolites save choline for the production of 
PCs, which is a type of vital membrane lipid for metabolic homeostasis as discussed in 
Chapter 3 and Chapter 4. The CDP-choline pathway links choline to PC formation [592]. In 
1-C metabolism, SAM can also be used to methylate PE to form PC. The PC composition is 
under the control of the two pathways (from DG/PE) as shown in Fig. 5.1. Reportedly, the 
SREBP-1 induced by insulin signaling can interact with SAM through 1-C metabolism and 
lipid metabolism [282, 593, 594]. All of these suggest crosstalk between lipid metabolism and 
SAM formation. In obese mice, excess fat storage results in greater demand for PCs to be 
utilized to form and enlarge membrane to support the adipocyte expansion and differentiation, 
as discussed in Chapter 3. It seems that in ob/ob mice the whole choline/1-carbon pathway 
was activated along with the PC formation. We suggest that activated lipid synthesis and 
metabolism increased the substrate influx into the 1-C cycle which produced increased SAM 
as a methylation donor for DNA and histones.  
 
A metabolic regulating network connecting choline, 1-carbon cycle and the DNA methylation 
pathways emerged from the results in this Chapter. The gene methylation profile can be 
selectively modified using the increased SAM for metabolic regulation of genes to adapt to the 
excess lipids and metabolic changes. There have been a lot of reports about interactions 
between lipid metabolism and methylation of DNA and histones. Epigenetic and chromatin-
modifying proteins have been found to contribute to adipogenesis and maintenance of mature 
adipocytes through PPARγ [273]. The fat mass and obesity associated gene (FTO) has been 
found to be associated with a type of demethylase [274]. Furthermore, there is evidence that 
high-fat diets can affect the methylation of the main anorexigenic neurohormone pro-
opiomelanocortin (POMC) and leptin related genes, having an impact on appetite [275, 276]. 
Methylation of the genes encoding PPARα and the glucocorticoid receptor (GR) have been 
shown to be decreased when maternal protein is restricted which have a long-term impact on 
systemic metabolism [277], and methylation of the melanocortin-r receptor (MC4R) is 
associated with exposure to long-term exposure to a high-fat diet [278]. 
 
In our study, ACSL1, AKT2, Rgs3, and Lhfpl2 were selected from the literature [583-585] 
which have been reported to undergo epigenetic changes in adipose tissue of both mice and 
humans. The results showed that SAMs were used to methylate different genes with high 
selectivity: ACSL1 and AKT2 were significantly less methylated whereas Rgs3 was more 
methylated in ob/ob mice, which are consistent with Multhaup’s diabetes-risk experiment [583]. 
The expression of Rgs3 was decreased in adipose tissues of 10-month old mice, which may be 
due to its high methylation status, but methylation and expression of the other three genes 
didn’t exhibit a good correlation. Disturbed lipid metabolism, in particular, PC metabolism, 
may result in insulin resistance through 1-C metabolism and methyl donor supplement for DNA 
and/or histone methylation as an important part of the energy homeostasis regulatory network. 
The detailed genes which are directly influenced by PC metabolism through this way need to 
be further investigated using the sequencing method in the future as discussed in Section 7.3. 
 
Moreover, this study lacks an investigation looking into the methylation status of protein or 
RNA. Lysine or arginine amino acid residues can be methylated by lysine methyltransferases 
or arginine methyltransferases, respectively. Methylation in the histones, the chief protein 
component of chromatin, has been widely studied. Methyl groups are transferred from SAMs 
to histones which are catalyzed by histone methyltransferases, epigenetically activating or 
repressing expression of the associated genes [595, 596]. There is a variety of RNA-
methyltransferases for RNA methylation which is thought to have existed longer than DNA 
methylation on the earth. In addition to 5-methylcytosine, N6-methyladenosine is also an 
abundant and common methylation modification in RNA affecting the regulation of many 
biological processes such as mRNA translation and RNA stability [597]. The methods to 
investigate the methylation status of histones and RNA will be discussed in Section 7.3. 
 5.6 Conclusions 
In ob/ob mice 1-C cycle was heavily activated and produced an abundance of SAMs for DNA 
and/or histone methylation. The produced SAM was used to methylate different genes with 
high selectivity. Lipid metabolism, 1-C metabolism, and epigenetic changes form a good 
combination for a better understanding of the extremely sophisticated role of adipose tissue in 
regulating energy homeostasis with the potential to be a barometer for pathophysiological 
processes of obesity and aging. Whether the activated 1-carbon and methylation pathways are 
consequences or adaptive protective mechanism along with obesity and aging need to be further 
validated.  
 
 
  
Chapter 6 The PPARα null mouse is characterized by saturated 
fatty acids in white and brown adipose tissues  
6.1 Introduction 
The PPAR family of nuclear receptors is composed of three members: PPARα, PPARβ/δ 
(commonly referred to as PPARδ), and PPARγ. In Chapter 4, it was found that the expression 
of PPARγ was influenced by leptin, diet-induced obesity, and aging, much more than PPARα 
and PPARδ. This may be due to PPARα and PPARδ being weakly expressed in adipose tissue 
compared with PPARγ. However, Li et al. [428] demonstrated that the expression of PPARγ 
increased significantly in PPARα null mice along with a profound perturbation induced by 
these changes in terms of metabolism in adipose tissues. Moreover, genes associated with the 
peroxisomes were changed significantly in obese and old mice, and only PPARα reportedly 
activates proliferation of peroxisomes [416], while the activation of PPARδ and PPARγ cannot 
lead to peroxisome proliferation. Furthermore, PPAR is important for the lipid homeostasis 
[598-600] through the activation of peroxisomal and mitochondrial β-oxidation, microsomal 
ω-hydroxylation/oxidation, lipogenesis, ketogenesis, lipid binding, and transport/lipoproteins, 
and cholesterol metabolism, and has anti-inflammatory and anti-atherogenic effects. PPAR 
is highly expressed in tissues that oxidize fatty acids at a rapid rate, such as liver, BAT, heart, 
intestines, muscle, and kidney [429], where it promotes FA β-oxidation and transport, and 
decreases glycolysis [216, 429, 430]. Uptake of FAs into the liver can be increased by 
activation of PPAR, followed by the activation of peroxisomal β-oxidation and mitochondrial 
β-oxidation. Thus, PPAR is thought to have a profound effect on systemic metabolism and in 
particular the handling of lipids across the organism. 
 
The different functional properties of the PPAR subtypes result from subtle differences in 
binding site preference, tissue distribution and their ability to bind different co-repressors and 
coactivators [415]. Roberts et al. [373, 374] contrasted the role of PPARδ in regulating 
metabolism in WAT with that of PPARg in terms of the TCA cycle, glucose and lipid metabolic 
pathways. Increased glycolysis and fatty acid desaturation were common pathways for the two 
nuclear receptors. However, PPARg, the master regulator of adipogenesis predominantly 
expressed in adipocytes, promotes adipocyte differentiation and sequesters glucose and lipids 
into WAT [373, 572]. The “lipid steal” hypothesis [601, 602] states that activation of PPARg 
as the target of the thiazolidinedione (TZD) class of insulin-sensitizing drugs facilitates dietary 
fatty acid storage in WAT rather than in peripheral tissues reducing ectopic lipid deposition 
which would otherwise bring about lipotoxicity. Treatment with TZDs also results in the 
normalization of adipocytokine levels [603]. In contrast, PPARδ is expressed almost 
ubiquitously and increases total oxidative metabolism and the TCA cycle to burn fat and restore 
insulin sensitivity [373, 570, 571]. PPARδ mRNA is expressed at 10 and 50 times the 
concentrations of PPARα and PPARγ mRNA, respectively, in skeletal muscle of adult rat [429]. 
PPARδ is activated by several 14 to 18 carbon containing PUFAs, including eicosanoids such 
as prostaglandin A1, iloprost and carbaprostacyclin, in the micromolar range [604]. 
Administration of PPARδ agonists to skeletal muscle of rodents increased the expression of 
genes involved in fatty acid oxidation, mitochondrial respiration, oxidative metabolism and 
slow twitch contractile apparatus [605], but are also linked to muscle atrophy, which has been 
suggested to be the side effect of increased metabolism of branch chain amino acids [373] and 
reduced synthesis of NAD+. In adipose tissue PPARδ is also related to adipocyte differentiation 
[606, 607], adipogenesis [608, 609], FFA oxidation and electron transport chain uncoupling 
protein 1 [610]. 
 
The PPAR null mice are used as a model of spontaneous late-onset obesity with stable caloric 
intake and a marked sexual dimorphism [426]. Indeed, females have higher serum triglycerides 
and adiposity than the males, while the males show a delayed occurrence of obesity and original 
centrilobular-restricted steatosis. Further, hepatic peroxisomal proliferation is inhibited along 
with decreased expression of some hepatic target genes in these transgenic mice [426]. In 
Section 4.4.4, the expression of genes associated with the peroxisome was perturbed in the 
obese and aged wild-type mice, which may indicate a possible correlation between PPAR and 
aging. Mice lacking the PPAR gene appear to have normal WAT weight relative to body 
weight, but are susceptible to adipocyte hypertrophy and spontaneous late onset obesity [426]. 
It appears that PPAR plays a limited role in adipogenesis due to the low levels of expression. 
The endogenous ligands PPARα include certain metabolites of arachidonic acid such as 
leukotriene B4 and 15-Hydroxyicosatetraenoic acid family. Activation of PPAR in 3T3-L1 
preadipocytes increases the expression of enzymes of the β-oxidation pathway when co-
expressed with PGC-1 [422]. Fibrates reportedly increase FA oxidation [423] and decrease 
VLDL particles and circulating TAGs [424] through activation of PPAR. Fibrates also 
increase HDL cholesterols in a similar way through the activated expression of lipoprotein 
lipase and apolipoprotein A-V, and increased macrophage cholesterol efflux helps to alleviate 
inflammation and atherosclerotic plaque formation in the vasculature, reducing the risk of 
cardiovascular disease [425]. Other factors that influence the expression and activity of PPAR 
include stress, insulin, leptin, growth hormone, hepatocyte nuclear factor 4 (HNF4), and 
COUP-TFII [611-615]. The metabolomics study conducted by Atherton et al. [431] 
demonstrated a decrease in the hepatic concentration of glucose and glycogen of PPAR null 
mice which increased in an age-dependent manner. This suggested the important role PPAR 
plays in gluconeogenesis and its interaction with the aging process. It also demonstrated 
changes in white adipose tissue despite the low expression of PPAR in this particular tissue. 
This was hypothesized to be a consequence of overall changes in systemic metabolism altering 
the lipids that are stored in white adipose tissue. However, the original lipidomic study only 
used GC-MS to investigate the composition of total fatty acids and free fatty acids in these 
tissues. This approach ignores what lipid species these fatty acids are associated with and hence 
provide a poor picture of overall lipid metabolism. As discussed in Chapter one, to truly 
understand how the lipidome changes one needs to profile intact lipids directly. Moreover, 
brown adipose tissue (BAT) which contains a higher number of mitochondria than WAT and 
plays an important role in non-shivering thermogenesis, might be influenced by PPAR to a 
larger extent compared with WAT. This will be investigated in this Chapter. 
6.2 Aims and objectives 
In this Chapter I aim to: 
i. Profile the lipid changes in BAT and WAT of PPAR null mice and compared with wild-
type controls. 
ii. Compare and contrast the influence of PPAR on lipid metabolism in BAT and WAT. 
 
 
 
6.3 Materials and Methods 
6.3.1 Animals and diets 
Tissues from 10 male wild-type SVEV/129 mice and 10 male PPARα-null mice were obtained 
from Dr. Andrew Murray, Department of Physiology, Development and Neuroscience, University 
of Cambridge. Mice were fed standard laboratory chow ad libitum (Special Diet Services, Essex, 
UK) and were sacrificed at the age of 8-10 months. The age range was sort of wide because the 
focus was not about the age and not many PPARα-null mice were available in our lab. Animals 
were killed by CO2 asphyxiation after overnight fasting. Interscapular brown adipose tissue 
(BAT), epididymal white adipose tissues (EPI-WAT) and inguinal white adipose tissues (ING- 
WAT) were rapidly dissected (<60 s post-mortem time prior to freezing), frozen in liquid nitrogen 
and stored at -80°C. All animal procedures were approved by the UK Home Office and the 
University of Cambridge and carried out under the supervision of a personal license holder. 
Only aged male mice were chosen because the PPAR null mice have been reported to exhibit 
spontaneous late-onset obesity even with a stable caloric intake and a marked sexual 
dimorphism [426] as discussed in Section 6.1. The females have higher serum triglycerides 
and gain more fat than the males, while the males show a delayed occurrence of obesity and 
original centrilobular-restricted steatosis [reference 426?]. The male-specific steatosis in 
PPAR null mice indicated discrepancies between the sexes toward lipid metabolism.  
 
6.3.2 Lipid Extraction 
Lipid extraction from mouse adipose tissue was performed according to Chapter 2 (section 2.3).  
 
6.3.3 GC-MS analysis for total Fatty Acids 
GC-MS analysis for total fatty acids from mouse adipose tissue was performed according to 
Chapter 2 (section 2.4). 
 
6.3.4 DI-MS/MS analysis for neutral lipids 
DI-MS/MS analysis for neutral lipids from mouse adipose tissue was performed according to 
Chapter 2 (section 2.5). 
 
6.3.5 UPLC-MS analysis for phospholipids 
UPLC-MS analysis for phospholipids from mouse adipose tissue was performed according to 
Chapter 2 (section 2.6). 
 
 6.4 Results 
6.4.1 Overview of the lipid changes in brown and white adipose tissues from PPARα null 
mice 
GC-MS and DI-MS/MS were used to profile the total FAs and TGs changes in BAT, EPI-WAT, 
representing visceral WAT, and inguinal (ING)-WAT, representing subcutaneous WAT, from 
PPARα null and wild-type (WT) mice. As the TGs occupied the majority of lipids content in 
adipose tissue, polar lipids (PLs) were determined by UPLC-MS after an SPE separation 
method detailed in Chapter 2. In total, 26 fatty acids, 108 TGs, and 175 PLs were detected 
including ceramides (Cers), lysophosphatidylcholines (lysoPCs), phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs), phosphatidylserines (PSs), and sphingomyelins (SMs).  
 
Robust PCA models were built using the three types of lipids (FA, R2=0.84, Q2=0.314, TGs, 
R2=0.919, Q2=0.834, PLs, R2=0.821, Q2=0.696) as shown in Fig 6.1. In all three models by 
different types of lipids, the ING-WAT was closer to the BAT compared with the EPI-WAT. 
Interestingly, ING-WAT reportedly expresses significantly higher levels of brite characteristic 
markers compared to EPI-WAT upon induction by cold [616-618]. The difference between 
PPARα null mice and wild-type controls was not clear in the PCA models. Thus, OPLS-DA 
models (of which parameters are shown in Table 6.1) were built for BAT, EPI-WAT and ING-
WAT in PPARα null mice compared with wild-type mice using FAs, TGs, and PLs models, 
respectively. 
  
Fig 6.1 PCA models of brown adipose tissues (BAT), epididymal adipose tissues (EPI) and 
inguinal adipose tissues (ING) from PPARα null (PA) and wild-type (WT) mice using 
(A) fatty acids, (B) triacylglycerides and (C) polar lipids including ceramides, 
lysophosphatidylcholines, phosphatidylcholines, phosphatidylethanolamines, 
phosphatidylserines, sphingomyelins (10 samples in each group). 
 
The OPLS models built using FAs and TGs separated PPARα null mice well from wild-type 
mice only for ING-WAT (FAs, Q2=0.712, TGs, Q2=0.397), while all three PL models were 
very robust (in BAT, Q2=0.683, in EPI-WAT, Q2=0.727, in ING-WAT, Q2=0.713). These five 
OPLS-DA models were further investigated (Fig 6.3-6.5) to identify individual metabolites 
responsible for the separation across the two genotypes. 
(A)
(B)
(C)
 
Table 6.1 Parameters of OPLS-DA models of brown adipose tissues (BAT), epididymal 
adipose tissues (EPI) and inguinal adipose tissues (ING) in PPARα null mice 
compared with wild-type mice using fatty acids (FAs), triacylglycerides (TGs) and  
polar lipids (PLs) including ceramides, lysophosphatidylcholines, 
phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, 
sphingomyelins (10 samples in each group). 
 
6.4.2 Palmitoleic acid, oleic acid, and linoleic acid decreased in inguinal adipose tissues 
from PPARα null mice compared with wild-type controls 
As shown in Fig 6.2, palmitic acid (C16:0), oleic acid (C18:1ω9) and -6 linoleic acid 
(C18:2ω6) dominated all three adipose tissues in either PPARα null or wild-type mice. The 
major products from DNL, C16:0 and C18:1, were increased in BAT compared with WAT, 
while the essential FAs originated from food, C18:2ω6 and C18:2ω3, were decreased in BAT 
compared with the WAT. This suggests that FAs from DNL, rather than those from food, are 
more stored in BAT compared with WAT, while WAT is better suited for the control of 
systemic lipid composition through regulating in vivo enzymes. As shown in the loading plot 
of Fig 6.3B, most of the FA species were increased in ING-WAT of PPARα null mice except 
palmitoleic acid (C16:1n7), oleic acid (C18:1ω9) and linoleic acid (C18:2ω6) compared with 
the wild-type controls. This may result from decreased FA oxidation in the liver and muscle of 
PPARα null mice. Another reason may be the metabolic perturbations associated with 
increased expression of PPARγ in adipose tissues of PPARα null mice as reported by Li et al. 
[428] and its influence on SREBP-1c and SCD which will be discussed below.  
Parameters BAT EPI ING
R2X(Cum)% 21.9 31.4 80.0
R2Y(Cum)% 49.1 73.6 78.7
Q2(Cum)% 15.1 31.4 71.2
Parameters BAT EPI ING
R2X(Cum)% 39.9 36.0 45.0
R2Y(Cum)% 38.2 29.1 69.8
Q2(Cum)% 23.0 2.9 39.7
Parameters BAT EPI ING
R2X(Cum)% 67.9 89.5 68.4
R2Y(Cum)% 97.8 100.0 94.0
Q2(Cum)% 68.3 72.7 71.3
FAs
TGs
PLs
  
 
 P-value by 2-way ANOVA C14:0 C16:0 C16:1ω7 C18:1ω9 C18:2ω6 C18:3ω3 C20:1ω9 
Interaction 0.0172 0.7130 0.3760 0.0315 0.4249 0.4446 0.3050 
Genotype <0.0001 <0.0001 0.1221 0.0878 0.0005 0.8772 0.9784 
Adipose type <0.0001 <0.0001 0.0134 0.0110 <0.0001 <0.0001 0.0623 
 
Fig 6.2 Total fatty acid composition in brown adipose tissues (BAT), epididymal adipose tissues (EPI) 
and inguinal adipose tissues (ING) from PPARα null (PA) and wild-type (WT) mice (10 
samples in each group). 
 
 
C14:0 C16:0 C16:1 C18:1 C18:2n6 C18:3n3 C20:1
BAT-PA 2.17% 25.62% 6.17% 32.52% 27.94% 1.55% 1.41%
BAT-WT 2.02% 22.89% 6.91% 31.55% 30.89% 1.65% 1.55%
EPI-PA 1.34% 17.49% 8.15% 29.90% 36.34% 2.70% 1.30%
EPI-WT 1.06% 15.19% 7.67% 30.00% 35.76% 2.48% 1.29%
ING-PA 2.16% 22.40% 6.99% 28.93% 29.97% 1.97% 1.76%
ING-WT 1.58% 19.43% 8.39% 31.27% 33.71% 1.93% 1.54%
                   
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                   
0.06%   0.89% 0.43%   0.72%   0.99% 0.08% 0.16%
0.06%   0.53% 0.61%   0.69%   0.40% 0.07% 0.11%
0.07%   0.57% 0.56%   0.49%   0.69% 0.11% 0.17%
0.03%   0.81% 0.60%   1.35%   2.08% 0.12% 0.10%
0.12%   0.85% 0.56%   0.78%   1.69% 0.16% 0.14%
0.07%   0.80% 0.41%   0.46%   0.60% 0.08% 0.11%
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Fig 6.3 OPLS-DA model (A) score plot and (B) loading plot of total fatty acids detected by 
GC-MS in inguinal adipose tissues (ING) from PPARα null (PA) and wild-type (WT) 
mice (10 samples in each group), and (C) identified individual metabolites responsible 
for the separation across the two genotypes. 
 
6.4.3 Short and unsaturated triacylglycerides are increased in inguinal adipose tissues 
from PPARα null mice 
As mentioned above, the OPLS-DA model of TGs was only moderately robust for ING-WAT 
in terms of comparing the two genotypes across the two WAT depots and BAT. Similar to the 
FA profile, most of the TG species were increased in ING-WAT of PPARα null mice as shown 
(A)
WTPA
(B)
(C)
WTPA
Fatty acids increased in PPARα
null model relative to control
Fatty acids decreased in PPARα
null model relative to control
C14:0 C16:1n7
C16:0 C18:1n9
C15:0 C18:2n6
C20:3n6
C18:3n6
C20:2n9
C17:0
C10:0
in the loading plot of the OPLS-DA model (Fig 6.4B). The loading plot identified some 
saturated and short TGs were particularly increased in ING-WAT of PPARα null mice, 
compared with wild-type controls (Fig 6.4C). It suggested that most of the TGs decreased in 
ING-WAT of PPARα null mice were constituted by the FAs listed in Fig 6.3C (C16:1n7, 
C18:1ω9 and C18:2ω6).  
 
 
Fig 6.4 OPLS-DA model (A) score plot and (B) loading plot of triacylglycerides in inguinal 
adipose tissues (ING) from PPARα null (PA) and wild-type (WT) mice (10 samples 
WTPA
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in each group), and (C) identified individual metabolites responsible for the separation 
between the two genotypes. 
 
6.4.4 Polar lipids were changed significantly in both brown and white adipose tissues from 
PPARα null mice 
There had been only a few lipidomic studies focused on adipose tissues from PPARα null mice 
[619-624], and none of them have investigated the composition of polar lipids as far as I know, 
maybe because the spectra of LC-MS data is dominated by TGs in the adipose tissues. This 
study used an SPE method to selectively remove most of the TGs in the adipose tissue and 
detected 175 PLs including six lipids classes (Cer, lysoPC, PC, PE, PS, and SM). As shown in 
Fig 6.5, the OPLS-DA models of PLs separated BAT, EPI-WAT, and ING-WAT of PPARα 
null mice from those of wild-type mice. Interrogation of the corresponding loadings plots and 
the variable influence on projection (VIP) plots for these OPLS-DA models identified many 
polar lipids significantly increased or decreased in BAT, EPI-WAT and ING-WAT of PPARα 
null mice (top 20 changed PLs in each group are summarized in Table 6.2 according to the 
lipid types). Similar changes to those detected in FAs and TGs were detected in PLs in that 
more PLs were increased in PPARα null mice, in particular PCs, the major plasma membrane 
lipids. The increased PCs may be a response mechanism for decreased FA oxidation and 
increased glycolysis in PPARα null mice. Interestingly, most of the decreased PLs are SMs 
which typically make up 10-20 mol % of plasma membrane lipids. The metabolic perturbations 
of SMs may influence signal transduction [625]: the synthesis of SMs at the plasma membrane 
can produce diacylglycerol, an important second messenger, while the degradation of SMs 
produces ceramides which are involved in the apoptotic signaling pathway. Moreover, most of 
the PLs (including all the six lipid classes) increased in PPARα null mice have shorter and 
more saturated side chains compared with those decreased in PPARα null mice. This change 
may lead to decreased fluidity of cell membranes.  
 
  
Fig 6.5 OPLS-DA model (A) score plot and (D) loading plot of polar lipids in brown adipose 
tissues from PPARα null (PA) and wild-type (WT) mice (10 samples in each group); 
OPLS-DA model (B) score plot and (E) loading plot of polar lipids in epididymal 
adipose tissues from PPARα null (PA) and wild-type (WT) mice (10 samples in each 
group); OPLS-DA model (C) score plot and (F) loading plot of polar lipids in inguinal 
adipose tissues from PPARα null (PA) and wild-type (WT) mice (10 samples in each 
group). Cer, ceramide, LysoPC, lysophosphatidylcholine, PC, phosphatidylcholine, PE, 
phosphatidylethanolamine, PS, phosphatidylserines, SM, sphingomyelins. 
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SM
(A)
(B)
(C)
(D)
(E)
(F)
BAT EPI ING 
Increased Decreased Increased Decreased Increased Decreased 
Cer(38:1) Cer(32:3) Cer(29:0) Cer(32:3) Cer(36:1) Cer(42:8) 
Cer(40:1) Cer(39:5) Cer(30:4) Cer(32:4) Cer(38:1)  
Cer(40:2) Cer(40:2) Cer(31:0) Cer(33:1) Cer(40:1)  
Cer(41:1) Cer(42:8)  Cer(35:5) Cer(41:1)  
Cer(41:2)   Cer(39:5) Cer(41:3)  
Cer(42:1)   Cer(40:2) Cer(42:1)  
Cer(42:2)   Cer(42:8) Cer(42:2)  
Cer(42:3)      
      
LysoPC(18:2) LysoPC(20:3)  LysoPC(20:3) LysoPC(20:4) LysoPC(22:5) 
LysoPC(20:4) LysoPC(22:5)  LysoPC(22:5)   
      
PC(36:4) PC(41:1) PC(33:0) PC(34:5) PC(36:0) PC(36:5) 
PC(37:3) PC(42:8) PC(35:1) PC(40:0) PC(36:1) PC(40:2) 
PC(38:1)  PC(35:2) PC(41:1) PC(36:2) PC(40:7) 
PC(38:4)  PC(36:2)  PC(37:3) PC(41:1) 
PC(38:5)  PC(36:5)  PC(38:4) PC(42:8) 
PC(40:3)  PC(37:3)  PC(38:5)  
  PC(38:1)    
  PC(38:4)    
  PC(38:5)    
      
PE(41:2)  PE(41:2)  PE(41:2)  
      
PS(30:3) PS(42:2) PS(30:3) PS(25:0) PS(30:3) PS(39:3) 
PS(41:5)  PS(35:1)  PS(35:1) PS(42:2) 
  PS(37:0)  PS(41:5)  
  PS(43:6)  PS(46:1)  
      
SM(34:1) SM(27:0) SM(34:1) SM(27:0) SM(31:1) SM(27:0) 
 SM(30:0) SM(35:2) SM(30:0)  SM(34:1) 
 SM(34:1) SM(38:1) SM(34:2)  SM(40:0) 
 SM(34:2)  SM(35:3)  SM(40:1) 
 SM(36:0)  SM(37:6)  SM(40:5) 
 SM(37:1)  SM(43:5)  SM(40:6) 
 SM(40:0)  SM(46:1)  SM(41:1) 
 SM(40:5)    SM(42:1) 
 SM(43:5)    SM(43:5) 
 SM(43:6)    SM(43:6) 
  SM(46:1)       SM(46:1) 
 
Table 6.2 Top 20 identified individual metabolites in brown adipose tissues (BAT), epididymal 
adipose tissues (EPI) and inguinal adipose tissues (ING) of PPARα null mice 
compared with wild-type mice by interrogation of the corresponding loadings plots 
and the variable influence on projection (VIP) for the OPLS-DA models in Fig 6.4. 
Cer, ceramide, LysoPC, lysophosphatidylcholine, PC, phosphatidylcholine, PE, 
phosphatidylethanolamine, PS, phosphatidylserines, SM, sphingomyelins. 
 
6.5 Discussion 
As reviewed by Mandard et al. [626], PPARα target genes are mostly associated with 
mitochondrial and peroxisomal FA oxidation, microsomal FA hydroxylation, and are involved 
in glucose and amino acid metabolism. Studies on the mouse have reported an obvious 
phenotype when fasted during which decreased FA oxidation led to increased FFA, 
hypoglycemia, hypoketonaemia, and hypothermia [627-629], or when fed on HFD which 
caused reduced myocardial FA oxidation and some evidence of cardiomyopathy emerged [630]. 
Hypoglycemia [627, 628, 631] is thought to result from impaired FA oxidation [627, 632] and 
failure in producing ketone bodies to spare glucose metabolism in PPARα null mice. Atherton 
et al. [431, 633] have conducted a comprehensive metabolomic study of the aqueous tissue 
extracts of PPARα null mutant mouse fed ad libitum using a combined 1H-NMR spectroscopy-, 
magic angle spinning 1H-NMR spectroscopy- and a gas chromatography-mass spectrometry-
based method. Interestingly, increased glycolysis and decreased gluconeogenesis were 
reported across heart, liver, skeletal muscle and adipose tissues of PPARα null mice without 
dietary intervention such as fasting or HFD-feeding. The Cori cycle and some amino acid 
metabolic pathways such as the alanine-glucose cycle were also decreased in activity. The 
increase of lactate and amino acids such as alanine which is important hepatic gluconeogenic 
substrates demonstrated limited gluconeogenesis in PPARα null mice and a failure by the liver 
to supply peripheral organs with ketone bodies from fatty acid oxidation. The failure in 
gluconeogenesis may result from reduced expression of glucose-6-phosphatase (G6pc), 
phosphoenolpyruvate carboxykinase 1 (Pck1), PGC1α and/or 6-phosphofructo-2-
kinase/fructose-2, 6-biphosphatase (Pfkf3b) which are partly regulated by PPARα [431]. 
Moreover, the expression of a gluconeogenic enzyme such as phosphoenolpyruvate 
carboxykinase (PEPCK) has been reported to be decreased in the liver of PPARα null mice 
[631]. Deletion of PPARα reduces the expression of pyruvate dehydrogenase kinase-4 (PDK4), 
which in turn inhibits pyruvate dehydrogenase and limits glycolysis across the body, 
particularly when fatty acids are in excess [626, 634]. The heart, diaphragm, WAT and soleus 
muscle tissues from the PPARα null mice also demonstrated decreased glucose and increased 
lactate too, which suggested limited gluconeogenesis and increased glycolysis, and in addition, 
the supply of ketone bodies was reduced along with decreased β-hydroxybutyrate in the heart 
[635, 636]. 
 
Considering lipid changes, according to the GC-MS analysis of the total lipid extracts 
conducted by Atherton et al. [431, 633], oleate (C18:1), linoleate (C18:2) and di-homo-γ-
linoleate (C20:3) and arachidonic acid (C20:4) were largely increased in the liver of PPARα 
null mice, and it was hypothesized this was because of decreased β-oxidation and ketogenic 
pathways mediated by PPARα. Oleate (C18:1) and linoleic acid (C18:2) were increased in the 
heart tissue from the null mice, while palmitic acid (16:0), docosahexaenoic acid (22:0), 
tetracosanoic acid (24:0) and arachidonic acid (20:4) decreased. This may be the result of the 
elongases and desaturase which are in part controlled by PPARα [637]. WAT from the PPARα 
null mice exhibited increased eicosanoic acid (20:0), eicosadienoic acid (20:2), di-homo-g-
linolenic acid (20:3), tridecanoic acid (13:0), docosadienoic acid (22:2) and hexadecadienoic 
acid (16:2), and decreased concentrations of octadecanoic acid (18:0), heptadecanoic acid 
(17:0), hexadecenoic acid (16:1) and tetradecanoic acid (14:1).  
 
In the present study, most of the FA species were increased in ING-WAT of PPARα null mice 
except palmitoleic acid (C16:1n7), oleic acid (C18:1ω9) and 6-linoleic acid (C18:2ω6). The 
difference may result from the age of mice (Atherton used 1 month-old mouse but we used 
animals at the age of 8-10 months in the present study) or the position of adipose tissues 
(Atherton used abdominal WAT). The increase of long-chain (10-16 carbons, LCFAs) and 
very-long-chain fatty acids (17-26 carbons, VLCFAs) may be due to lack of peroxisome 
proliferation because LCFAs and VLCFAs are preferentially oxidized in peroxisomes. 
Moreover, an eightfold increase in the expression of hepatic SCD activity has been reported by 
PPARα activation in wild-type mice [638]. On the other hand, if SCD activity cannot be 
activated in PPARα null mice, it seems reasonable that palmitoleic acid and oleic acid were 
decreased in the WAT of PPARα null mice. The activity of the desaturase SCD is partly 
controlled by PPARα [637], but another reason for changes in lipid composition may be the 
influence of PPARγ [639]. PPARγ is much more abundantly expressed in WAT than PPARα 
[429]. Interestingly, Li et al. [428] demonstrated that the expression of PPARγ increased 
significantly in PPARα null mice along with a profound perturbation in metabolism in adipose 
tissues where PPARα is weakly expressed. This compensatory upregulation may account for 
some of the metabolic changes detected. What’s more, as PPARα is important for peroxisome 
proliferation and β-oxidation [67-70], the dysfunctional peroxisome proliferation may be the 
reason there are less long and unsaturated FAs in adipose tissues of PPARα null mice. 
 
Our study not only profiled the FA changes in WAT of PPARα null mice but also examined 
intact lipids across a range of lipid classes. In total, 26 fatty acids, 108 TGs and 175 PLs 
including six lipid classes were detected using a combination of GC-MS, DI-MS/MS and SPE-
UPLC-MS methods, and used to build PCA and OPLS-DA models to investigate the influence 
of PPARα on BAT, EPI-WAT, and ING-WAT. ING-WAT was similar to the BAT in terms of 
the types of lipids compared with EPI-WAT, as ING-WAT reportedly expresses significantly 
higher levels of brite characteristic markers compared to EPI-WAT upon induction by cold 
[616-618]. Interestingly, neutral lipids (FAs and TGs) in ING-WAT seem to be more 
influenced by the knock-out of PPARα compared with those in BAT and EPI-WAT. Moreover, 
both neutral and polar lipids were more saturated and shorter in adipose tissues of PPARα null 
mice, all of which seem to be in accordance with the decrease in palmitoleic acid (C16:1n7), 
oleic acid (C18:1ω9) and 6-linoleic acid (C18:2ω6) detected. Knight et al. [638] reported that 
inclusion of the PPARα activator WY 14,643 in the diet stimulated the hepatic expression of 
not only genes of the FA oxidation pathway, but also those of the DNL pathways and 
cholesterol synthesis by increasing the cleavage of the SREBP-1c protein to the active form, 
accompanied by a rise in SCD mRNA expression. It is possible that a lack of the active form 
of SREBP-1c and SCD expression may explain the decreased unsaturated lipids in adipose 
tissues of PPARα null mice. 
 
Moreover, most of the PLs (including all six lipid classes) increased in PPARα null mice have 
shorter and more saturated side chains compared with those decreased in PPARα null mice. 
This change may lead to decreased fluidity of the membrane. Generally, saturated fatty acids 
make the membrane bilayer less fluid and inactive, which in turn has consequences for protein 
function and membrane transport [168], whereas unsaturated fatty acids result in a more plastic 
membrane and improve the function of membrane receptors and sensitivity to hormones [169, 
170]. The geometry of the cis-double bond induces a bend in the molecule, thereby precluding 
rigid lipid bilayers. One process of high relevance to T2DM is glucose transport across the 
membrane which may be influenced by membrane fluidity [171]. There have been studies 
reporting the relationship between membrane fluidity of erythrocytes and insulin sensitivity in 
hypertensive subjects [172], and also changes in the composition of membrane lipids associated 
with increased insulin sensitivity in skeletal muscles after physical training [173]. 
 
Interestingly, in Atherton’s research, the aging process was also characterized by decreased 
glucose and glycogen in the liver, heart, diaphragm, WAT, soleus, and gastrocnemius muscle 
tissues. In the liver, aging was associated with decreases in leucine and isoleucine and increases 
in lactate and alanine, aspartate and glutamate, suggesting decreased gluconeogenesis. 
However, the decrease in lactate, alanine, and glutamate suggested that glycolysis was inhibited 
in an age-dependent manner in heart, diaphragm and muscle tissues [431]. In the liver, FAs, 
taurine, and choline/phosphocholine were increased and cholesterol synthesis was decreased 
with age. Palmitic acid (C16:0) arachidonic acid (20:4) increased, while oleate (C18:1) and 
cholesterol decreased associated with the aging trend in the liver. In muscle and adipose tissues, 
the aging process was characterized by increases in a number of saturated fatty acids including 
palmitic acid (16:0), stearic acid (18:0), tetradecanoic acid (14:0) and heptadecanoic acid (17:0), 
as well as a decrease in docosahexaenoic acid (22:6), the β-oxidation product of 
tetracosahexaenoic acid (24:6). Thus, there should be an age-dependent study of the BAT and 
WAT of PPARα null mice in the future to characterize these changes further and understand 
better how aging interacts with this process. 
  
6.6 Conclusions 
This Chapter profiled total FA composition and different type of intact lipids (TG, Cer, lysoPC, 
PC, PE, PS, and SM) changes in BAT and WAT of PPARα null mice compared with wild-type 
controls. The inguinal WAT was found to be a mixed lipid profile of BAT and EPI-WAT, but 
it exhibited the most significant FA and TG changes in PPARα null mice. The differences 
might result from that the ING-WAT is at superficial depots while the EPI-WAT is one of the 
largest visceral fat depots with lower volatility. Polar lipids were found to be good in building 
OPLS-DA models to explain the differences between the two genotypes in both BAT and WAT. 
Most of the lipids were increased and became more saturated and shorter in PPARα null mice, 
which may result from a lack of active form of SREBP-1c and subsequent decreased of SCD 
expression, or associated with the change in expression of PPARγ induced in PPARα null mice. 
  
Chapter 7 Summary and Future Directions 
7.1 General discussion and summaries 
Obesity is a complex disorder where the genome of an organism interacts with diet and other 
environmental factors to influence ultimate body mass, composition, and shape, with 
characteristic excess fat storage in adipose tissue. Numerous studies have investigated how 
bulk lipid metabolism is influenced by obesity [640-643] but membrane component lipids such 
as PCs and PEs have been seldom investigated. Cell membrane components contribute to a 
variety of cellular processes including maintaining organelle functionality, providing an 
optimized environment for numerous proteins and providing important pools for metabolites, 
such as choline for one-carbon metabolism (e.g for methylation of DNA). This suggests a 
possible link between lipid metabolism, one-carbon cycle, DNA/histone methylation, and 
expression of genes involved in physiological and pathophysiological processes such as obesity 
and aging. 
 
The first part (Chapter 3) of this thesis is a comprehensive lipidomic study of white adipose 
tissue in mice that become obese either through genetic modification (ob/ob genotype), diet 
(high-fat diet) or a combination of the two across the life-course. In this chapter, I demonstrated 
that FA de novo synthesis is activated in ob/ob mice by leptin deficiency, possibly via an 
increase in food intake. In contrast to the shorter and more saturated TGs from DNL, more 
unsaturated PCs are synthesized in ob/ob mice to maintain the fluidity and normal function of 
cell membrane against increased de novo synthesis. However, this protective mechanism can 
be impaired by the long-term administration of an HFD, presumably through oxidative damage. 
Moreover, most of the lipids stored in the adipose tissue of HFD-fed mice are assembled 
directly using dietary fatty acids, which dramatically decreased the diversity of lipid 
composition. Longer TGs and saturated PCs accumulated in adipose tissue of aged mice, which 
increases susceptibility to metabolic diseases. These characteristic changes nicely complement 
previous lipidomic studies only focused on FAs and TGs in adipose tissue, and depict a more 
comprehensive metabolic network profile in adipose tissue.  
 
Secondly, the correlation between transcriptomic patterns of obesity and aging was 
investigated (Chapter 4). The two obesity models exhibited differently featured expression 
patterns but both had some changes in common with aging. Inflammation and immune system- 
related pathways were activated not only in the two models of obesity but also in white adipose 
tissue of aged mice. On the contrary, metabolic pathways, in particular, those related to lipid 
metabolism, were activated by leptin deficiency in the initiation of obesity of ob/ob mice, but 
inhibited to a large extent in white adipose tissue of aged ob/ob mice, compared to both the 
wild-type controls and the younger controls. The GO and KEGG enrichment analysis of these 
genes suggested that peroxisome and AMPK and PPARγ signaling pathways may act at the 
forefront in the progression of obesity and aging, as a protective mechanism in the initiation of 
oxidative damage, but then accumulated damage results in insulin resistance, the metabolic 
syndrome and T2DM. 
 
The third part (Chapter 5) linked lipidomic and transcriptomic changes through 1-C cycles and 
methylation donors. In ob/ob mice, the 1-C cycle was heavily activated and produced an 
abundance of SAMs for DNA and/or histone methylation. The produced SAM was used to 
methylate different genes with high selectivity. Lipid metabolism, 1-C metabolism, and 
epigenetic changes form a good combination for a better understanding of the extremely 
sophisticated role of adipose tissue in regulating energy homeostasis with the potential to be a 
barometer for pathophysiological processes of obesity and aging. Whether the activated 1-
carbon and methylation pathways are consequences or adaptive protective mechanism along 
with obesity and aging need to be further validated. This could be tested through analysis of 
genotype/diet-induced obese animal models in which the 1-carbon or methylation pathways 
were blocked by knock-out of certain genes of key enzymes, such as serine/betaine 
hydroxymethyltransferase (SHMT/BHMT) or some other kinds of methyltransferases. 
 
As found in Chapter 4, the peroxisome and PPARγ signaling pathways seem to play a key role 
in the progression of obesity and aging. It has been reported that the expression of PPARγ 
increased significantly in PPARα null mice [428], and only PPARα reportedly activates 
proliferation of peroxisomes [416]. PPAR is thought to have a profound effect on systemic 
metabolism and in particular the handling of lipids across the organism. So the last Chapter 
profiled total FA composition and different type of intact lipids (TG, Cer, lysoPC, PC, PE, PS, 
and SM) changes in BAT and WAT of PPARα null mice compared with wild-type controls. 
The inguinal WAT was found to be a mixed lipid profile of BAT and EPI-WAT, but it exhibited 
the most significant FA and TG changes in PPARα null mice. The differences might result 
from that the ING-WAT is at superficial depots while the EPI-WAT is one of the largest 
visceral fat depots with lower volatility. Polar lipids were found to be good in building OPLS-
DA models to explain the differences between the two genotypes in both BAT and WAT. Most 
of the lipids were increased and became more saturated and shorter in PPARα null mice, which 
may result from a lack of active form of SREBP-1c and subsequent decreased of SCD 
expression, or associated with the change in expression of PPARγ induced in PPARα null mice. 
 
In summary, my work using different rodent models (ob/ob, HFD-fed, and PPARα-null) and 
multi-omics techniques (lipidomics, metabolomics, and transcriptomics) demonstrated a 
protective metabolic mechanism activated in the initiation but impaired at the end of the 
processes of obesity and aging. This may explain the similarity of obesity and aging in terms 
of the high incidence of metabolic syndrome and related diseases. First, although there were 
more short and saturated neutral lipids in the adipose tissue of ob/ob mice due to increased de 
novo synthesis, phospholipids became more unsaturated to maintain the fluidity and normal 
function of the membrane. Interestingly, this protective mechanism was found to be impaired 
by long-term administration of an HFD, presumably through oxidative damage. Similarly, 
saturated PCs were found to be accumulated in adipose tissue of aged mice, increasing the 
susceptibility to metabolic diseases. Secondly, the transcriptomic study also demonstrated the 
correlation between obesity and aging in the firstly activated but then inhibited lipid metabolic 
pathways regulated by peroxisome, AMPK, insulin, and PPARγ signaling in the progress of 
obesity and aging, along with the up-regulation of inflammation in the whole process. Thirdly, 
phospholipids correlate better with transcriptional changes and one-carbon/choline/S-
adenosylmethionine metabolism within the adipose cells, suggesting that while triglycerides 
within the adipose tissue may be a relatively inert store of lipids, the compositional changes 
occur in cell membranes with more far-reaching functional consequences (epigenetics). Finally, 
another rodent model, knock-out of the PPAR which has a profound effect on both 
peroxisome and PPARγ signaling, demonstrated more saturated and short polar lipids, which 
is in good accordance with the former aspects of this thesis that advance our understanding of 
metabolic alternations implicated in the obesity and aging process. 
 
7.2 Limitations of the study 
Animal models have the advantage of ease of selective genetic manipulation and drug 
interventions and better tissue and organ availability over human tissue studies. This study 
utilized genetically modified mice and diet manipulation to expand our understanding of the 
underlying mechanism of both obesity and the aging process. However, there are a vast number 
of differences between the animal models and humans, and when some variables are not 
controlled for, such as food intake, wrong conclusions may be drawn.  
 
Firstly, it has been reported that ob/ob mice tend to eat more food compared with the wild-type 
controls [387, 394, 398]. On the contrary, rodents fed an HFD diet may regulate their food 
intake to compensate for the increased calorie content of the diets [644]. The differences 
observed in either lipidomics, transcriptomics or DNA methylation might be owing to the 
modified food consumption and thereby differential uptake of other nutrients such as protein, 
vitamin, minerals, rather than the lipids per se. In particular, the methyl groups of SAMs are 
derived from one-carbon metabolites (folate, choline, betaine, methionine, etc., as illustrated 
in Figure 1.1) which can be obtained from the diet. Food intake can affect the results to some 
extent. For example, low folate diets have been reported to lower methylation of some genes 
such as p53 in rat liver [645], and folate supplementation increased methylation in the promoter 
regions of glucocorticoid receptor and insulin receptor, PPAR, during the juvenile-pubertal 
period of the rat [646]. The methylation status of these genes can have an effect on the 
transcription and expression of other genes and can alter energy metabolism as a result. 
Deficiency or redundancy of choline [647-649] and betaine [650, 651], which are crucial for 
the one-carbon metabolism, can also influence gene methylation and expression in many 
tissues. While food intake was not measured in the current study, this could be addressed in 
future studies so that the intake of different nutrients can be calculated, and the effects of them 
on lipid and one-carbon metabolism and DNA methylation can be taken into account.  
 
Another limitation of the animal experiment design is that only male mice were studied. 
Pubertal parameters, such as cycling, estrus and vaginal opening, have all been reported [432] 
to be influenced by leptin signaling, which may add uncertainty to my metabolism study. In 
the second animal study in Chapter 6, only old male mice were chosen because the PPAR 
null mice have been reported to exhibit spontaneous late-onset obesity even with a stable 
caloric intake and a marked sexual dimorphism [426]. Female PPARα mice may be shown to 
have higher serum triglycerides and gain more fat than males, while males show a delayed 
occurrence of obesity and original centrilobular-restricted steatosis [reference 426?]. The male-
specific steatosis in PPAR null mice indicated discrepancies between the sexes toward lipid 
metabolism. There have been many variables (PPAR null or wild-type, BAT/EPI/ING 
adipose tissue) contributing to the statistical complexity, so only male animals, which have 
more steatosis compared with the female mice, were studied to reduce the complexity of 
multivariate statistics. In the future, the influence of sex on the lipid/one-carbon/methylation 
mechanism could be addressed.  
 
In the present study, white adipose tissue (WAT) from paired gonadal depots within the 
abdominal cavity in male mice was primarily examined, due to the abundance and availability 
of this tissue and previous reports demonstrating the signaling functions of the WAT (e.g. 
through producing leptin and adipokines) while the BAT seems to mainly response to signals 
and generates body heat [174, 235, 442]. Further, the visceral adipose tissue is linked to insulin 
resistance [443], type 2 diabetes [444], inflammatory diseases [445], and other obesity-related 
diseases[446]. In future studies, different fat depots as those examined in Chapter 6 could be 
examined. 
 
7.3 Future directions 
First, polyunsaturated fatty acids (PUFA) have been reported to prevent insulin resistance [10, 
11], and improve cardiovascular and metabolic health when combined with regular exercise 
[12]. These fatty acids are also able to increase adipose tissue fatty acid oxidation and reduce 
lipogenesis [13], modulate adipose tissue inflammation [14] and regulate adipokine secretion 
[15]. One proposal is to design an animal experiment to examine the epigenetic and metabolic 
effects of PUFA supplementation to further understand the mechanism by which improvements 
in insulin sensitivity and other metabolic conditions occur. A custom-produced diet with or 
without these micronutrients would be used to feed mice (n=10 /genotype/age group) for 
similar lengths of time and be sacrificed at similar ages as the high-fat diet group in Chapter 
2.2 to study the interaction between diet and epigenetic and metabolic modifications in WAT. 
To further understand the influence of diet on adipose tissue metabolism and epigenetics, I 
proposed to examine a combination of two or more diets including the following groups: (1) 
regular chow diet (no supplementation); (2) regular chow diet + 
methionine/choline/folate/other micronutrients; (3) high-fat diet (no supplementation); (4) 
high-fat diet + methionine/choline/folate/other micronutrients; (5) high-fat diet + 
polyunsaturated fatty acid (~50%); (6) high-fat diet switched to regular chow diet again (to 
examine the dynamic processes of epigenetic marking and metabolism); (7) other nutritional 
models, such as mice fed a high fructose or cholesterol diet.  
 
Other interventions not related to the diet could also be utilized to investigate the role of adipose 
tissues in obesity and aging. For example, the beneficial role of exercise in remodeling adipose 
tissues has been reported in animal models including inducing adaptive changes of lipolysis in 
the WAT [652, 653], activation of the BAT and beiging of the WAT [652, 653], regulating 
inflammation [654, 655] and metabolic dysfunction and adipokines [656-658]. 
 
Although ob/ob mice and obese human share a lot of similar metabolic phenotypes, leptin 
deficiency may result in differences in the severity of metabolic syndrome and diabetes. For 
example, unlike the ob/ob mice, there have been only a few diabetic humans reported without 
enough leptin [659-663]. Combination models could be utilized in future studies including but 
not limited to: db/db mice, PPARα knockout mice, SREBP-1c transgenic mice, and acyl-
coenzyme A oxidase (AOX) null mice. In humans, obesity is commonly caused by excessive 
food intake along with a lack of physical activity and genetic susceptibility. Therefore, a 
combination of genetic and diet interventions will offer a better model for metabolic diseases. 
Moreover, tissue-dependent metabolic effects are more complicated due to systemic changes. 
Some tissue-specific genetic models have been developed in which activation, overexpression, 
and ablation of genes can be limited in only one type of tissue such as the rodent models of 
overexpression of PPARδ in the adipose tissue [610] which have been developed under the 
control of the enhancer-promoter region of the adipocyte fatty acid binding protein (aP2) gene. 
In addition, RNAi techniques [664] can be used to inhibit expression of selected genes and test 
the control points of the pathways discussed in Chapter 4 with high selectivity and versatility 
as opposed to knock-out and metabolic inhibitors. 
 
Ideally, it would be best to obtain human adipose tissue to see if the same metabolic and 
epigenetic changes occur as those observed in the animal models utilized in this thesis. 
However, to make the analysis more statistically robust, large sample size is required, which is 
technically very difficult to achieve. Therefore, breeding studies in other animals to examine 
the interaction of diet with epigenetic modifications could be a consideration for further 
analysis. Small animals such as using Caenorhabditis elegans (C.elegans) or fruit flies 
(Drosophila) are easier to manipulate and take a much shorter time to observe the interactions 
of diet, obesity, and aging. However, these small animals are more difficult to mimic human’s 
pathophysiological responses and to test the tissue-specific changes. Large animal models 
recapitulate the anatomy, physiology, and function of human’s organs and tissues, making them 
a better link in the translation of basic research to clinical practice [665]. The research can also 
be expanded by the development of cell lines derived from the adipose tissue. The cell lines 
would be good tissue-specific models and are easy to manipulate and determine. But it should 
be cautious because all immortalized cell lines do not behave identically to their in vivo 
counterparts. Primary cells would be better to surmount the disadvantages even though they 
can suffer from a lack of homogeneity, a rarity of supply, mortality, and intransigence to growth 
in culture [666].  
 
I have examined the methylation status of four genes known to be implicated in metabolic 
diseases as mentioned above. It was assumed that the global DNA methylation status and the 
methyl donors involved in epigenetic modifications will help us to develop a further 
understanding of the mechanism of obesity, metabolic syndromes, and the aging process. 
However, only four genes cannot fully explain the regulating network involving metabolic and 
epigenetic pathways. Future studies could use bisulfite sequencing to monitor the methylation 
status of the whole genome of adipose tissue samples in the processes of obesity and aging. 
Not only markers of obesity, but also those of senescence such as telomeres [667, 668], 
plasminogen activator inhibitor-1 [669], and senescence marker protein-30 (SMP30) [670]. 
Moreover, the polar, aqueous soluble metabolites other than one-carbon metabolites, such as 
the intermediates in the TCA cycle, protein, and glucose metabolism, could be determined by 
LC-MS to further define the role of adipose tissue in obesity and aging. The turnover of the 
metabolites could be determined by using 13C labeled substrate studies to provide more than a 
“snapshot” of the metabolic status in the adipose tissue. Through the use of a selection of the 
cell lines/primary cells/animal models discussed above and the application of different 
intervention methods, metabolomic techniques (DI-MS/GC-MS/LC-MS with SPE separation 
and 13C labelled substrate), transcriptomics and bisulphite sequencing methods, it would be 
possible to improve our understanding and further characterise the complex interactions 
between metabolites and genes involving in the systematic biological networks and their 
perturbation in the adipose tissue during the processes of obesity and aging. 
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